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ABSTRACT 
 
Mechanisms of Hormonal Activation of Cdc25A and Coactivation of Estrogen  
Receptor α by Protein Inhibitor of Activated STAT3 (PIAS3). (December 2006) 
Wan-Ru Lee, B.S., National Taiwan University; 
M.S., National Taiwan University 
Chair of Advisory Committee: Dr. Stephen H. Safe 
 
The estrogen receptor (ER) is a ligand-activated transcription factor that regulates 
gene expression. The classical mechanisms of nuclear ER action include ligand-induced 
dimerization of ER which binds estrogen responsive elements (EREs) in promoters of 
target genes. In addition, non-genomic pathways of ER action have also been identified 
in breast cancer cells. 
Cdc25A is a tyrosine phosphatase that catalyzes dephosphorylation of 
cyclin/cyclin-dependent kinase complexes to regulate G1- to S-phase cell cycle 
progression. Cdc25A mRNA levels are induced by 17β-estradiol (E2) in ZR-75 breast 
cancer cells, and deletion analysis of the Cdc25A promoter identified the -151 to -12 
region as the minimal E2-responsive sequence. Subsequent mutation/deletion analysis 
showed that at least three different cis-elements were involved in activation of Cdc25A 
by E2, namely, GC-rich Sp1 binding sites, CCAAT motifs, and E2F sites. Studies with 
inhibitors and dominant negative expression plasmids show that E2 activates Cdc25A 
expression through activation of genomic ERα/Sp1 and E2F1 and cAMP-dependent 
activation of NF-YA. Thus, both genomic and non-genomic pathways of estrogen action 
are involved in induction of Cdc25A in breast cancer cells. 
The PIAS family was initially identified as cytokine-induced inhibitors of STATs 
which contain several conserved domains involved in binding to other nuclear 
coactivators. In this study we have investigated coactivation of ERα by PIAS3 in breast 
cancer cell lines transiently cotransfected with the pERE3 constructs which contain three 
tandem EREs linked to a luciferase reporter gene. PIAS3 coactivated ERα-mediated 
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transactivation in cells cotransfected with pERE3 and wild-type ERα. In contrast to many 
other coactivators, PIAS3 also enhanced transactivation of ERα when cells were 
cotransfected with the TAF1 ERα mutant. In addition, PIAS3 does not interact with 
activation function 2 (AF2) domain of ERα in a mammalian two-hybrid assay. These 
data indicate that coactivation of ERα by PIAS3 was AF2-domain independent. Analysis 
of several PIAS3 deletion mutants showed that the region containing amino acids 274 to 
416 of PIAS3 are required for coactivation suggesting that the RING finger domain and 
acidic region of PIAS3 are important for interactions with wild-type ERα. These results 
demonstrate that PIAS3 coactivated ERα and this represents a non-classical 
LXXLL-independent coactivation pathway. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Cancer 
1.1.1 What is cancer? 
Normal cells grow, divide, and die in an orderly fashion. During the early years of a 
person's life, cells in many tissues divide more rapidly until the individual becomes an 
adult. After that, cells in most parts of the body divide only to replace worn-out or dying 
cells and to repair cell damage. Cancer is a group of diseases characterized by 
uncontrolled growth and spread of abnormal cells. Cancer develops when cells in 
specific tissues exhibit uncontrolled or dysregulaated growth. Even though cancer is 
often regarded as a single condition, it consists of more than 100 different diseases 
depending on its tissue origin. Compared to the physiology of normal cells, cancer cells 
exhibit deregulated homeostasis, uncontrolled growth, and invasiveness that are caused 
by cellular genetic or epigenetic alterations. 
Cancer is the second leading cause of death in the United States. Half of all men 
and one third of all women in the United States will develop cancer during their lifetimes. 
About 1.4 million new cases of cancer will be diagnosed in 2006 and approximately 0.56 
million people will die from this disease. Approximately, 1 out of 4 deaths are due to 
cancer. The 5-year survival rate from all cancers combined after first diagnosis is 
approximately 65%, whether in remission, under treatment, or disease-free (1). 
 
1.1.2 Breast cancer 
Breast cancer is the leading cancer among white and African American women and 
an estimated 211,240 new cases of invasive breast cancer will be diagnosed in women in 
the United States during 2005. In addition to invasive breast cancer, 58,490 new cases of  
 
_________________ 
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in situ breast cancer are expected to occur among women during 2005 (2). While its 
incidence continues to rise, the mortality rate from breast cancer has remained almost 
unchanged in the past 5 decades, occupying first place as a cause of cancer-related 
deaths in nonsmoking women (3).  
 
1.1.2.1 Development of the mammary gland 
The mammary gland comprises stromal and epithelial cells that communicate with 
each other through the extracellular matrix (ECM). The major functional units of the 
mammary gland are the lobular structures comprising several small blind-ended ductules 
situated at the end of the terminal ducts and known as terminal ductal lobular units 
(TDLUs). The entire ductal system is lined by a continuous layer of luminal epithelial 
cells that are, in turn, surrounded by a layer of myoepithelial cells as shown in Figure 
1-1. These myoepithelial cells are in direct contact with the basement membrane. The 
TDLUs are surrounded by delimiting fibroblasts and embedded in a specialized 
intralobular stroma. The luminal epithelial cells are the major proliferating cell type, 
whereas cell division or expression of antigens associated with proliferation is 
exceedingly rare in the myoepithelial cell type (4). 
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Figure 1-1 Two distinct mechanisms of branching morphogenesis in the pubertal 
mouse mammary gland (5). 
 
Unlike most vertebrate organs, breast tissue continually changes in structure 
throughout the lifetime of reproductively-active females. Development of the mammary 
gland can be divided into 5 distinct stages which include the embryonic and prepubertal 
stage, puberty, pregnancy, lactation, and involution. Between birth and puberty, the 
growth of this structure is isometric in relation to the rest of the body, but at puberty, 
under the influence of ovarian and pituitary hormones, the gland undergoes the first 
phase of allometric growth. In early puberty, the primitive ductal structures begin to 
rapidly divide and multiply to form a treelike structure composed of many ducts. Once 
ovulatory menstrual cycles have begun, there is a cyclical increase in proliferation 
associated with the luteal phase, and the TDLUs become more elaborate in terms of the 
number of alveoli they contain during each successive ovulatory cycle (6).  
This progressive development of the epithelium continues until approximately 35 
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years of age. The second phase of allometric growth in the mammary gland occurs 
during pregnancy. During early pregnancy, there is another burst of activity in which the 
ductal trees expand further and the number of ductules within the TDLUs greatly 
increase. These ductules differentiate to synthesise and secrete milk and lactate in late 
pregnancy, and in the postnatal period. Once weaning has occurred, the mammary gland 
involutes; the secretory luminal epithelial cells apoptose, the alveoli collapse and both 
epithelial and stromal components are remodeled to resemble the prepregnant state. 
Interestingly, the developing mammary gland displays many of the properties 
associated with tumor progression. For example, the terminal end bud (TEB) is a rapidly 
proliferating mass of epithelial cells that invades into stromal tissue, much like a solid 
tumor. Moreover, many of the vital factors required for mammary development are also 
involved in breast cancer. 
 
1.1.2.2 Risk factors for development of breast cancer 
A risk factor is anything that increases your probability of developing a disease, 
such as cancer. Different cancers have different risk factors and these risk factors can be 
divided into several categories. Based on epidemiological studies conducted in different 
populations, several well-established risk factors for breast cancer have been identified 
and these include: age, geographic location and socioeconomic status, reproductive 
events (menarche, menopause, pregnancy, breastfeeding), exogenous hormones 
(hormone replacement therapy and oral contraceptives), lifestyle risk factors (alcohol, 
diet, obesity and physical activity), mammographic density, history of benign breast 
disease, ionizing radiation, bone density, height, IGF-1 and prolactin levels, exposure to 
chemopreventive agents, as well as genetic factors (high- and low-penetrance breast 
cancer susceptibility genes) (Table 1-1). 
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Table 1-1 Summary of breast cancer risk factors (7). 
 Breast Cancer Risk Factors Magnitude of Risk 
 Factors that increase breast cancer risk  
 Increasing age ++ 
 Geographical region (USA and western countries) ++ 
 Family history of breast cancer ++ 
 Mutations in BRCA1 and BRCA2 genes ++ 
 Mutations in other high-penetrance genes (p53, ATM, NBS1, LKB1) ++ 
 Ionizing radiation exposure (in childhood) ++ 
Well-confirmed History of benign breast disease ++ 
factors Late age of menopause (>54) ++ 
 Early age of menarche (<12) ++ 
 Nulliparity and older age at first birth ++ 
 High mammography breast density ++ 
 Hormonal replacement therapy + 
 Oral contraceptives recent use + 
 Obesity in postmenopausal women + 
 Tall stature + 
 Alcohol consumption (~1 drink/day) + 
 High insulin-like growth factor I (IGF-I) levels ++ 
Probable High prolactin levels + 
factors High saturated fat and well-done meat intake + 
 Polymorphisms in low-penetrance genes + 
 High socioeconomic status + 
 Factors that decrease breast cancer risk  
 Geographical region (Asia and Africa) -- 
 Early age of first full-term pregnancy -- 
 Higher parity -- 
Well-confirmed Breast feeding (longer duration) -- 
factors Obesity in premenopausal women - 
 Fruit and vegetables consumption - 
 Physical activity - 
 Chemopreventive agents - 
Probable  Non-steroidal anti-inflammatory drugs - 
factors Polymorphisms in low-penetrance genes - 
++ (moderate to high increase in risk) -- (moderate to high decrease in risk);  
+ (low to moderate increase in risk)  - (low to moderate decrease in risk) 
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Reproductive risk factors 
Several reproductive factors such as nulliparity (having no children), late age at first 
birth, early age at menarche, and late age at menopause all have been associated with an 
increase in breast cancer risk.(8-11). For each of these factors, breast cancer risk tends to 
increase throughout the range of the variables. For example, risk is enhanced with 
increasing age at menopause from before 40 years of age to after 50 years of age.  
Women who have a first birth after age 30 years have a 50% to 100% higher risk of 
breast cancer relative to those who had their first child by age 20. Women who reached 
menarche by age 12 have only a 20 to 30 percent higher breast cancer risk compared 
with women who reached menarche at age 14 years. 
The relationship between parity and breast cancer risk is more complex. Relative to 
nulliparous women, breast cancer risk actually is increased for one to two decades after 
giving birth, perhaps because of the increased exposure to circulating steroid hormones 
during pregnancy (12). After this time, however, breast cancer risk is lower in parous 
women compared with nulliparous women. This delayed (but long-lasting) reduction in 
risk may be related to hormone-induced changes in the cells of the breast, which result in 
their decreased susceptibility to carcinogens (12). Overall, the reduction in risk 
associated with parity outweighs the initial increase in risk, as the reduction occurs later 
in life when a woman's absolute breast cancer risk is much higher. 
The duration of lifetime exposure to ovarian hormones is closely related to breast 
cancer risk. Early age at menarche (less than 12 years of age versus more than 14 years 
of age) has been associated with a 10~20% increase in breast cancer risk (13,14) and a 
1-year delay in the onset of menarche is associated with a 5% reduction in risk for 
developing breast cancer in later life (15). Similarly, delayed menopause maximizing the 
number of ovulatory cycles leads to an increased breast cancer risk and each 1-year 
delay in the onset of menopause is associated with a 3% increase in risk (16). In contrast, 
surgically induced menopause before the age of 35 results in a decreased breast cancer 
risk. These women have only 40% of the risk of women experiencing natural menopause. 
It has been demonstrated that mammary epithelial cell proliferation, which is linked to 
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breast cancer development, can be correlated with serum ovarian hormonal levels. 
Proliferation rates are low in the follicular phase of the menstrual cycle, when estradiol 
and progesterone levels are also low, whereas during the luteal phase proliferation rates 
are two-fold higher and correlate with the significantly increased ovarian hormone levels 
(17). The higher cellular proliferative activity confers a higher susceptibility of the 
mammary gland to be transformed by chemical carcinogens (18). After menopause, 
ovarian hormone levels drop and this correlates with a substantial decrease in mammary 
epithelial cell proliferation (19). Numerous prospective epidemiological studies also 
provide strong evidence for this mechanism. Accordingly, postmenopausal women who 
develop breast cancer have on average 15% higher levels of circulating estradiol than 
other postmenopausal women (19). 
Prolonged lactation has been demonstrated to be protective (20). There is a 4.3% 
decrease in the relative risk of breast cancer for every 12 months of breastfeeding, in 
addition to a decrease of 7.0% for each birth (21). The decrease of breast cancer risk due 
to prolonged lactation may be explained in part by the reduction of total number of 
ovulatory menstrual cycles and consequently cumulative ovarian hormone exposure 
(19). 
 
Genetic risk factors 
The most important risk factor for breast cancer is age. After controlling for age, the 
greatest increase in risk has been associated with a family history of breast cancer, with 
the number, type and age at onset of affected relatives being important determinants of 
risk. Family history of breast cancer especially combined with mutations in 
high-penetrance breast cancer susceptibility genes, such as BRCA1 and BRCA2, p53, 
PTEN, ATM, NBS1 or LKB1, which are responsible for a large proportion of the 
hereditary breast cancer greatly increases risk for this disease.  
Over the last decade, two breast cancer susceptibility genes have been identified: 
BRCA 1 and BRCA 2. Women who carry deleterious mutations in BRCA1 or BRCA2 
have a considerably increased lifetime risk of breast cancer (~ 80%), that is roughly ten 
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times greater than that of the general population (22). BRCA1 is a tumor suppressor 
gene whose primary function is maintaining genomic integrity (23). Germline mutations 
in BRCA1 are associated with approximatively 42% of breast cancer families and 81% 
of families with both ovarian and breast cancer (24). Loss of heterozygosity (LOH) in 
BRCA1 gene is frequently observed in hereditary breast cancers and it is one of the most 
common mechanisms by which the normal allele is inactivated (25). Germline mutations 
in BRCA2 are linked with approximately 76% of breast cancer families in which both 
females and males are affected. This percentage decreases to 32% in families where only 
the women have breast cancer, and this is further increased to 14% in breast-ovarian 
cancer families (24). Similar to BRCA1, LOH  plays an important role in the 
development of BRCA2-induced breast cancers (26). 
p53 is found mutated in all of the major histogenetic groups, including cancers of 
the colon, stomach, breast, ovary, lung, brain, and esophagus (27). Among 
high-penetrance genes, p53 was the first tumor suppressor gene linked to hereditary 
breast cancer (28). Women with germline mutation in p53 have an 18-fold higher risk for 
developing breast cancer before age of 45 compared to the general population, and the 
risk declines with age (maximum is before the age of 20) (29). 
There are also low penetrance genes (but present in a high percentage of individuals) 
that enhance breast cancer risk in combination with exogenous (e.g. diet, pollution) and 
endogenous (e.g. hormones) factors (30). These genes include phase I metabolic enzyme 
which metabolically activate carcinogens (e.g. the cytochrome P450 family proteins) and 
phase II enzymes which inactivate carcinogens (e.g. N-acetyl transferase and GST 
family proteins). Polymorphisms in both phase I and II enzymes involved in xenobiotic 
and endobiotic metabolism therefore may modulate the relative risk of breast cancer for 
an individual (31).  
 
Lifestyle risk factors 
Other than aging and genetic risk factors, lifestyle-related risk factors, such as 
alcohol, obesity and high-fat diet, breast-feeding and pregnancy as well as oral 
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contraceptive use, are risk factors by choice. 
Several major reviews of epidemiologic data confirm a statistically significant 
association between moderate to heavy alcohol intake and subsequent risk of developing 
breast cancer (32,33). There is evidence of a dose-response relationship. One combined 
analysis of data from 53 studies around the world estimated that the risk factor for breast 
cancer increased 7% for each additional 10 g of alcohol consumed daily (34). The 
association between alcohol intake and greater breast cancer risk has been observed 
regardless of the type of alcohol consumed, and alcohol intake is associated with a 
higher risk for both premenopausal and postmenopausal breast cancer (33). Furthermore, 
alcohol causes alterations of the immune system and nutritional deficiencies, including 
but not limited to folate, pyridoxal phosphate, vitamin B12, vitamin D, vitamin A and 
retinoids, vitamin E, zinc and selenium, all of which impair the ability of the human 
body to repair or in inhibit tumor development (35).    
Adult weight gain has been consistently associated with a greater risk for 
postmenopausal breast cancer (36,37). Findings from two of the largest cohort studies 
suggest that there is a doubling of risk associated with a weight gain >20 kg and this was 
limited to women who had never used postmenopausal hormone replacement therapy 
(36,37). In those studies, a 20% greater risk was observed for weight gains of 2-20 kg.  
The human diet contains a great variety of natural and chemical carcinogens and 
anti-carcinogens (38). Some of these compounds may act through the generation of 
oxygen free radicals, which can lead to DNA damage, or other deleterious components. 
Well-done meat consumption has been associated with increased breast cancer risk (39), 
probably due to production of heterocyclic aromatic amines (HAAs) and other harmful 
compounds in the process of cooking. A high intake of fat, especially unsaturated fatty 
acids, may be weakly associated with an increased breast cancer risk (40), while a 
particular type of polyunsaturated fatty acids (PUFAs), omega-3 PUFAs, seem to be 
protective (41,42).  
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1.1.2.3 Treatment of breast cancer 
Breast cancer prognosis is dependent on the stage of disease at diagnosis. Five-year 
survival rates range from 84% for early breast cancer (EBC) to 18% for advanced breast 
cancers (ABC) (43). The chance of recovery and choice of treatment depend on the stage 
of the patient’s cancer, the type of breast cancer, certain characteristics of the cancer cells, 
the patient’s age and general state of health.  
There are treatments for all patients with breast cancer. Four types of treatment are 
used: surgery, radiation therapy, chemotherapy and endocrine therapy. In addition, 
biological therapy, using the patient’s immune system to fight cancer, and bone marrow 
transplantation are also being investigated in clinical trials. Among these treatments, 
surgery has been applied to most patients with breast cancer.  
 
Surgery and radiation therapy 
Surgical treatment of breast cancer in the early days of radical mastectomy was 
aimed at curing the disease by cutting it out. This included surgically removing a very 
large surrounding area of normal tissue in an attempt to remove microscopic traces of the 
cancer spreading beyond a more obvious mass. For women with early-stage invasive 
breast cancer, surgery is usually followed by radiation therapy (RT) (44,45). 
Radiotherapy was used to destroy any cancer that could not be removed by surgery. In 
patients with early breast cancer who undergo breast-conserving surgery and receive 50 
Gy of radiation to the whole breast, an additional dose of 16 Gy of radiation to the tumor 
bed reduces the risk of local recurrence, especially in patients younger than 50 years of 
age (46). 
 
Chemotherapy 
Chemotherapy is generally reserved for patients with hormone-sensitive disease 
who have failed one or more hormonal treatments or those with who have symptomatic 
disease that requires prompt symptom relief. Chemotherapy is called a systemic 
treatment because the drugs enter the bloodstream, travel through the body, and can kill 
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cancer cells outside the breast area. Population- and hospital-based studies evaluating 
survival during the pre- and postchemotherapy era suggests that cytotoxic chemotherapy 
prolongs survival by an average of about 9 to 12 months (47). The cytotoxic agents most 
commonly used for the treatment of metastatic breast cancer and having substantial 
single-agent activity include combinations of alkylating agents and antimetabolites such 
as cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) used in the 1970s. 
Anthracyclin-based combinations including 5-fluorouracil, doxorubicin and 
cyclophosphamide (FAC); 5-fluorouracil, epirubicin and cyclophosphamide (FEC) were 
extensively used in the 1980s-1990s (48). 
For patients with estrogen receptor (ER) - positive and progesterone receptors (PR) 
- positive breast cancer are normally treated with hormone therapy using drugs that 
change the way hormones work or by surgery that removes organs that make hormones, 
such as the ovaries.  
 
Hormone therapy 
In 1896, Beatson found that some premenopausal women with breast cancer 
benefited from removal of their ovaries (49). In 1936, Professor Antoine Lacassagne 
showed that the agent in the ovaries that caused mammary cancer was estrogen (50). 
After ER α was discovered, the link between ERα expression and response to hormone 
or endocrine therapy was established.   
Selective estrogen receptor modulators (SERM) including both steroidal and 
nonsteroidal antiestrogens (51) were initially evaluated in rodent models and shown to 
exhibit antiestrogenic activity in mammary tumors. The compounds were then 
successfully translated into the clinic (52). Although targeting the ER with the 
nonsteroidal antiestrogen tamoxifen has increased survival of breast cancer patients (53), 
the strategic application of long-term antihormonal treatments (54) has created an 
important increase in disease-free and overall survival (55). However, tamoxifen is not a 
pure antiestrogen, and this drug exhibits partial estrogen-like actions that produce a 
suboptimal blockade of estrogen-stimulated breast tumor growth. In addition, 30% of 
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women treated with tamoxifen complain of side-effects including hot flashes, vaginal 
discharge, and vaginal bleeding (56,57). Tamoxifen treatment is also associated with a 
higher risk of less common long-term side-effects; studies have found a two to four 
times higher relative risk of developing endometrial cancer in women taking tamoxifen 
than in agematched populations (58,59). Due to the imitations of tamoxifen, other 
hormone therapies have been developed for treatment of hormone-sensitive breast cancer. 
Currently, aromatase inhibitors are used to produce an estrogen-free environment and 
these compounds are effective inhibitors of ER-positive breast cancer growth (60). 
Aromatase inhibitors inhibit the enzymatic conversion of adrenal androgens into 
estrogens in peripheral tissues, the major source of estrogens in postmenopausal women. 
Most importantly, the use of aromatase inhibitors for treatment of breast cancer avoids 
some of the estrogen-like side effects observed in patients treated with tamoxifen. One of 
the improved new SERMs is raloxifene, which was originally a discarded breast cancer 
drug named keoxifene. Raloxifene maintains bone density in overiectomized rats (61) 
and prevents carcinogen-induced rat mammary carcinogenesis (62). Raloxifene is 
currently available for the prevention of osteoporosis but with breast and endometrial 
safety.  
 
1.1.3 The role of estrogen in breast cancer 
Estrogens are ovarian steroid hormones required for establishment and maintenance 
of the female reproductive tract. They also play important roles in development of the 
male reproductive tract, in bone formation, lipid metabolism and maintenance of the 
cardiovascular and nervous systems (63,64). The naturally occurring estrogens 
17β-estradiol (E2), estrone (E1) and estriol (E3) are C18 steroids derived from 
cholesterol (Figure 1-2). The most biologically active estrogen in breast tissue is E2. 
Circulating estrogens primarily originate from ovarian steroidogenesis in premenopausal 
women and peripheral aromatization of ovarian and adrenal androgens in 
postmenopausal women (65). Estrogens play a major role in promoting the proliferation 
of both the normal and neoplastic breast epithelium (66,67). Estradiol acts locally in the 
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mammary gland, stimulating DNA synthesis and promoting bud formation, through an 
ER-mediated mechanism. 
 
 
Figure 1-2 Steroidogenic pathways leading to the biosynthesis of estrogens. 
 
 
1.1.3.1 Estrogens in human breast carcinogenesis  
As described earlier, an association between the risk of breast cancer and 
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persistently elevated blood levels of estrogen has been consistently observed in many 
studies. There are three mechanisms that are responsible for the carcinogenicity of 
estrogens: receptor-mediated hormonal activity (68), a cytochrome P450-mediated 
metabolic activation and redoxcycling (69) and the induction of aneuploidy by estrogen 
(70,71). There is also evidence that estrogen may compromise the DNA repair system 
and allows accumulation of lesions in the genome essential for estrogen-induced 
tumorigenesis (72).  
 
Receptor-mediated pathway 
The receptor-mediated activity of estrogen is generally related to induction of 
expression of the genes involved in the control of cell cycle progression and growth of 
human breast epithelium. The classical mechanism of estrogen action involves binding 
of the hormone to nuclear ER, which then forms a dimer that interacts with 
estrogen-response elements (EREs) in regulatory regions of estrogen-responsive genes. 
The DNA-bound ER complex associates with basal transcription factors, coactivators 
and corepressors to alter gene expression. The presence of ERα-positive and 
ERα-negative cells with different proliferative activity in the normal human breast may 
help to elucidate the genesis of ERα-positive and ERα-negative breast cancers. It has 
been postulated that either ERα-negative breast cancers result from the loss of the ability 
of the cells to synthesize ERα during clinical evolution of ERα-positive cancers, or that 
ERα-positive and ERα-negative cancers are different entities (73). The newly discovered 
ERβ opens another possibility that those cells traditionally considered negative for ERα 
might be positive for ERβ (74). ERα and ERβ are encoded by separate genes. The DNA 
binding domains (DBDs) of ERα and ERβ are highly homologous (75) and thus they 
bind to the same EREs. The ligand-binding domain of these two ERs also share a high 
degree of homology and it is not surprising that many compounds tested so far bind to 
both receptors with similar affinities (76). However, estrogen responses mediated by 
ERα and ERβ may vary with tissue-specific expression of their coactivators that transmit 
the effect of ER-ligand complex to the transcription factor complex at the promoter of 
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target genes. 
     
Estrogen metabolism 
Studies in rodents have demonstrated that estrogens or their catechol metabolites 
are carcinogens in various tissues, including the kidney, liver, uterus, and mammary 
glands (77-80). E2 and estrone are the two major endogenous estrogens and these 
compounds undergo cytochrome p450-dependent oxidation of catecholestrogen to give 
2-hydroxycatechol or 4-hydroxycatechol estrogen (81,82). Further oxidation gives the  
estrogen 3,4-quinone which can form unstable adducts with adenine and guanine in 
DNA, leading to depurination and mutations in vitro and in vivo (77,83). Reduction of 
estrogen quinones back to hydroquinones (catechols) activates redox cycling and 
produces reactive oxygen species. This may account for the oxidative damage to lipids 
and DNA that is associated with estrogen treatment (84,85). In addition to preventing 
metabolism of catechol estrogen to quinones, the 2-methoxy catechol may be a 
protective metabolite (86,87). 
There are two lines of evidence that support a role for estrogen metabolites as 
causative factors for human breast cancer. In postmenopausal women, estrogen levels in 
breast tissue are 10 to 50 times the levels in blood (88), and concentrations of estradiol 
are higher in malignant tissues compared to nonmalignant tissues (81). Furthermore, 
levels of estrogen metabolites and conjugates detected in breast tissue range from 3 to 13 
pmol per gram of tissue (89), demonstrating that oxidative pathways are active in the 
breast. The second line of evidence supporting a role for estrogen metabolites in human 
breast cancer comes from studies of associations of breast-cancer risk and 
polymorphisms in genes encoding enzymes involved in estrogen synthesis and 
metabolism. For example, breast cancer patients have a higher percentage of CYP19 
tetranucleotide repeat polymorphisms than controls and this correlates with the 
decreased activity of phase II enzymes in breast cancer patients and a possible increase 
in the more genotoxic phase I catecholestrogen metabolites (90). 
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1.2 Cancer and the cell cycle 
1.2.1 An overview of cell cycle regulation 
Early embryonic cells can proceed through continuous cycles of DNA replication 
and nuclear division (Figure 1-3). However, as embryogenesis continues, a new 
regulatory system is introduced to regulate cell cycle progression. A gap called G1 phase 
is incorporated between nuclear division (M phase) and DNA synthesis (S phase); and 
another gap called G2 phase occurs between S and M (Figure 1-3). These gaps allow for  
 
 
M
(mitosis)
S phase
(DNA synthesis)
G2
(Gap 2)
G1
(Gap 1)
Cells that 
cease 
division  
 
 
Figure 1-3 Stages of the cell cycle. 
 
 
the repair of DNA damage and replication error.  
The transition from one cell cycle phase to another occurs in an orderly fashion and 
is regulated by different cellular proteins. Key regulatory proteins are the 
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cyclin-dependent kinases (CDK), a family of serine/threonine protein kinases that are 
activated at specific points of the cell cycle. Nine CDKs have been identified and five of 
them are active during the cell cycle (Table 1-2). When activated, CDKs induce 
downstream processes by phosphorylation of selected proteins (91,92). CDK protein 
levels remain stable during the cell cycle, in contrast to their activating proteins, the 
cyclins. The cyclins perform multiple regulatory functions. In addition to the appropriate 
phosphorylation state of CDKs, binding to a cyclin is necessary for CDK activation. 
Cyclins not only interact with CDKs but also target these complexes into the nucleus; 
since CDKs lack nuclear localization signals (93). Some CDKs bind more than one 
cyclin (92,94). The cyclin bound by a given CDK probably provides some substrate 
specificity. The cyclins were so named because of their cyclic expression during the cell 
cycle (Figure 1-2) (92,95). Because of this cyclic expression, CDK complexes are 
activated only at specific times during the cell cycle. Part of the cyclic expression of 
cyclin proteins is due to their regulated degradation. Cyclins contain protein motifs rich 
in proline (P), glutamate (E), serine (S), and threonine (T) (PEST sequences), which 
target them for degradation by ubiquitination at specific times (95-98). Thus, a cycling 
cell enters and exits cell cycle phases in parallel with the synthesis and degradation of 
specific cyclins (Figure 1-4, Table 1-2). In general, before a cell can enter the next phase 
of the cell cycle, the appropriate cyclin from the previous phase is degraded, and the 
cyclin for the next phase is synthesized.  
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Figure 1-4 Schematic drawing of cell cycle-dependent levels of cyclins. Thickness of 
hashed bars indicates relative intracellular cyclin concentration. 
 
 
 
Table 1-2 Cyclin-CDK complexes are activated at specific points of the cell cycle. 
CDK Cyclin Cell cycle phase activity 
CDK4 Cyclin D1, D2, D3 G1 phase 
CDK6 Cyclin D1, D2, D3 G1 phase 
CDK2 Cyclin E G1/S phase transition 
CDK2 Cyclin A S pahse 
CDK1 Cyclin A G2/M phase transition 
CDK1 Cyclin B Mitosis 
CDK7 Cyclin H All cell cycle phases 
 
 
 
1.2.1.1 G1/S phase transition and regulation 
G1 is a period when many signals intervene to influence cell division and 
differentiation. Diverse metabolic stress and environmental signals are integrated and 
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interpreted during this period. On the basis of these inputs, the cells decide whether to 
enter S phase or arrest at G1 phase. In higher eukaryotes, Cdk2 combines with E-type 
cyclines (E1, E2) and cyclin A (99,100). Cyclin E levels are constantly high in early 
embryonic cells, allowing Cdk2 to intiate S phase as soon as M phase is complete (100). 
There are various mechanisms to enforce the existence of G1 phase by keeping Cdk2 
inactive until mitogenic signals intervene. One of these mechanisms is based on limiting 
the supply of cyclin E expression which is dependent on E2F transcription factors 
(101,102). In mitotically resting cells, and in cells that have just emerged from M phase, 
E2F factors are bound to the retinoblastoma protein (Rb) or its family members, p107 
and p130 (103). Rb binding turns E2Fs into repressor complexes (like E2F4 and E2F5) 
or inactive transactivators (like E2F1, -2 and -3) (102). The hypophosphorylated form of 
the pRB prevents premature entry into S phase by binding to E2Fs which regulate 
expression of S phase genes. Phosphorylation of pRB at serine and threonine residues in 
mid-to-late G1 phase by mitogen-induced cyclin D-dependent kinases removes the 
growth-inhibitory effects of pRB thereby allowing activation of cell cycle regulatory 
genes including cyclins E and A.  
The c-myc protooncogene is a transcription factor and member of the 
helix-loop-helix/leucine zipper protein family, whose endogeneous expression is rapidly 
induced by mitogens and whose ectopic expression can induce entry of quiescent cells 
into S phase (104). c-Myc activates several genes important for G1/S control and these 
include cyclins D1, D2 and E, and the Cdc25A phosphatase, an essential regulator of S 
phase entry which catalyzes removal of the inhibitory phosphates (Tyr15/Tyr14) on 
Cdk2 (105-107). In terms of the key activities, c-Myc has been implicated at least three 
distinct programs: regulation of cyclinE-Cdk2 activity, E2F-dependent transcription, and 
cell growth (104,108,109). Both RB-E2F and Myc-regulated programs convergently 
control the abundance and activity of cyclinE-Cdk2 (110,111). Cdk2 activity appears to 
complete and maintain the neutralizing phosphorylation of pRB, a process initiated by 
cyclinD-dependent kinase in G1, thereby preventing unscheduled activation of pRB in S 
phase, and feeding a regulatory loop which amplifies both E2F and cyclinE-Cdk2 ativity. 
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p27kip1 is another target of the cyclinE-cdk2 kinase. The phosphorylation and subsequent 
degradation of p27kip1 allows the timely elevation of Cdk2 activity necessary for S phase 
initiation and progression.  
 
1.2.1.2 G2/M phase transition and regulation 
A number of different cyclin/CDK complexes involved in cell cycle regulation have 
been identified. Cyclin A is induced shortly after cyclin E and binds Cdk2 in S phase and 
Cdk1 (cdc2) in G2 and M phases. The entry into mitosis is under the control of B-type 
cyclins, which also associate with Cdk1 (112,113). Regulation of cyclin B/Cdk1 
complexes at multiple levels ensures the precise timing of mitotic entry. In human cells, 
cyclin B is synthesized from the end of S phase, mainly due to cell cycle-regulated 
transcription (114,115). In addition, cyclin B1 mRNA is thought to be more stable in G2 
phase as compared to G1 phase, and becomes more unstable after DNA damage (116). 
These data suggest that cyclin B levels are also controlled by regulation of mRNA 
stability. After association of a specific cyclin with its appropriate CDK, the cyclin/CDK 
complex is regulated by a number of phosphorylation events. Phosphorylation of the 
conserved threonine (Thr161) in the T-loop of Cdk1 is required for activation of the 
cyclin B/Cdk1 complex and is mediated by the CDK activating kinase (CAK). CAK was 
found to be a cyclin/CDK complex itself, composed of cyclin H and Cdk7. A third 
component, MAT1, is thought to function in stabilizing the cyclin H/Cdk7 interactions 
(117-119). CDK regulation occurs through distinct mechanisms in different species. 
During G2, mammalian cyclin B/Cdk1 complexes are held in an inactive state by 
phosphorylation of Cdk1 at the two negative regulatory sites, Thr 14 and Tyr15. 
Inactivation of Cdk1 via Tyr15 phosphorylation plays a very important role in the 
control of initiation of mitosis in both fission yeast and animal cells (120,121). 
Phosphorylation of Cdk1-Tyr15 is carried out by the Wee1/Mik1 family of protein 
kinases (122,123). The distinct locations of these Cdk1 inhibitory kinases may 
co-operate to guarantee inactivation of multiple Cdk1 subpopulations before the onset of 
mitosis. Genetic studies identified Cdc25 as a positive regulator of Cdk1, by 
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counteracting Wee1 activity (124). Dephosphorylation of Thr14 and Tyr15 by Cdc25C in 
late G2 activates the cyclin B/Cdk1 complex and triggers the initiation of mitosis (125). 
Cyclin B/cdc2 complexes in turn are thought to phosphorylate Cdc25C, which further 
activates Cdc25C, including the full activation of cyclin B/Cdk1 by forming an 
autocatalytic feedback loop (126,127) 
Another mechanism for regulating cyclin/CDK complexes is to localize these 
complexes and their regulators into particular subcellular compartments. Like most 
cyclins, cyclin A appears in the nucleus upon its synthesis (S phase) and remains nuclear 
until its degradation (M phase). In contrast, cyclin B1 is initially localized in the 
cytoplasm during S phase and G2 phase, and is translocated into the nucleus at the 
beginning of mitosis (128). Deletion studies revealed the existence of a cytoplasmic 
retention signal (CRS) in the N-terminal part of cyclin B1, since deletion of this 
sequence caused cyclin B1 to become nuclear (129). Phosphorylation of cyclin B1 
within the CRS is required to allow nuclear import of the protein. Thereafter, it was 
shown that the cytoplasmic localization of cyclin B1 is the result of continuous export 
from the nucleus during interphase. The nuclear export was shown to be mediated by a 
hydrophobic nuclear export signal (NES) within the CRS of cyclin B and was blocked 
by leptomycin B, a specific inhibitor of the nuclear export factor CRM1 (130-132). 
Phosphorylation of cyclin B1 functions to promote nuclear import as well as to inhibit 
nuclear export (130). Therefore, it is thought that phosphorylation of cyclin B1 at the 
G2/M transition blocks complex formation with CRM1 and prevents its return to the 
cytoplasm. Induction of p21 expression resulted in an accumulation of cells in both G1 
and G2 phases of the cell cycle and in inhibition of cyclin E-, cyclin A- and cyclin 
B-associated kinase activity (133,134). p21 inhibits cyclin/CDK complexes by blocking 
CAK-mediated activation (134-136). As cells enter mitosis, phosphorylation of key 
components of the subcellular structures results in complete reorganization of the 
architecture of the cell. This phosphorylation is mainly due to the activation of the 
cyclinB/Cdk1 complexes. Besides regulating the activity of itself by phosphorylating 
Cdc25C, cyclin B/Cdk1-mediated phosphorylation also induces changes in the 
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microtubule network, the actin microfilaments and the nuclear lamina (137-139). Finally, 
downregulation of transcription during mitosis is thought to be mediated by cyclin 
B/Cdk1, since cyclin B/Cdk1 directly inhibits pol III-mediated transcription by TFIIIB 
(140). 
 
1.2.1.3 The role of Cdc25 in cell cycle 
The mammalian Cdc25 family consists of three members, Cdc25A, Cdc25B and 
Cdc25C, which appear to have specificity for different cyclin/CDK complexes. Whereas 
Cdc25A promotes entry into S phase by acting on cyclinA/Cdk2 and cyclinE/Cdk2 (141), 
both Cdc25B and Cdc25C play a role in the onset of mitosis. Cdc25B is thought to 
regulate centrosomal microtubule nucleation during mitosis (142). Cdc25C is the 
phosphatase responsible for triggering activation of cyclinB/cdc2 complexes by 
dephosphorylating the inhibitory Cdk1 sites Thr14 and Tyr15 (143-148). Cdc25C is 
localized in the cytoplasm during interphase, and enters the nucleus just prior to mitosis 
(149,150). The cytoplasmic localization was shown to require a 58 amino acid region in 
Cdc25C, which contain a 14-3-3 binding site. Ogg et al showed that Ser216 within this 
region is the major phosphorylation site of Cdc25C during interphase, and this serine is 
not phosphorylated during mitosis (151). Subcellular localization may contribute to 
negative regulation of Cdc25A activity during interphase. Cdc25B is localized in both 
the cytoplasm and the nucleus and this localization is thought to be dependent on the 
combined effects of an NLS, an NES and on the interaction with 14-3-3 proteins (152). 
A positive feedback loop between cdc2 and Cdc25C in necessary for the full activation 
of cyclin B/cdc2 complexes at the onset of mitosis. There are indications that kinases 
other than cyclinB/cdc2 may provide the initial trigger for activating Cdc25C, which was 
found to be phosporylated and activated by cyclinE/Cdk2 and cyclinA/Cdk2 in vitro 
(153). In conclusion, although cyclinB/cdc2 complexes contribute to activation of 
Cdc25C, an upstream kinase is probably required for the initial Cdc25C activation.  
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1.2.2 Checkpoints in cell cycle 
When the genetic material is damaged, a delay in cell cycle progression facilitates 
DNA repair, thereby avoiding the replication and subsequent propagation of potentially 
hazardous mutations. Highly conserved DNA-repair and cell-cycle checkpoint pathways 
allow cells to deal with both endogenous and exogenous sources of DNA damage. How 
much an individual is exposed to these agents and how their cells respond to DNA 
damage are critical determinants of whether that individual will develop cancer.  
 
1.2.2.1 G1 and G1/S checkpoint responses 
The ability of the cell cycle checkpoints, signaling pathways which monitor the 
integrity and replication status of the genome, to inhibit entry into S phase is associated 
with the function of the p53 tumor suppressor (154). The p53 protein is a transcription 
factor which becomes stabilized and active upon DNA damage, and in turn regulates 
transcription of a large number of genes, among them the p21WAF1/CIP1 Cdk inhibitor 
(CKI) capable of silencing the Cdks which are essential for S phase entry (111,154). 
Recent research on the molecular mechanisms of p53 pathways indicate an early 
activation of ataxia telangiectasia mutated (ATM) or ataxia telangiectasia related (ATR), 
two large kinases from the PI-3 kinase superfamily (155,156). ATM/ATR directly 
phosphorylate the p53 transcription factor in its amino-terminal transactivation domain, 
particularly on Ser15. Thr 18 and Ser 20 are also targeted by CHK1/CHK2 (157-161). In 
addition, the ubiquitin ligase MDM2 that normally binds p53 and ensures rapid p53 
turnover, is targeted after DNA damage by ATM/ATR (162), as well as by CHK2/CHK1. 
These modifications of p53 and MDM2 contribute to the stabilization and acculmulation 
of the p53 protein and the subsequent induction of p21CIP1/WAF1, the key transcriptional 
target of p53, which silences the cyclinE/Cdk2 kinase and casues G1 arrest. Cyclins E 
and A, and the activator of the cyclinE/Cdk2 kinase, the Cdc25A phosphatase, are also 
induced in late G1. In response to genotoxic stress, this physiologically operating 
mechanism is enhanced through increased activity of CHK1 and CHk2, leading to 
downregulation of Cdc25A and consequently to inhibition of the cyclinE/Cdk2 
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complexes (159,163,164). The CHK1/CHK2-Cdc25A checkpoint is implemented rapidly, 
independent of p53, and this delays the G1/S transition for only a few hours, unless the 
sustained p53-dependent mechanism prolongs the G1 arrest. 
 
1.2.2.2 S-phase checkpoint pathways 
There are at least two parallel branches of this checkpoint that decrease ongoing 
DNA synthesis, both of which are controlled by the ATM/ATR signaling machinery. One 
of these effector mechanisms operates through the Cdc25A-degradation cascade. The 
inhibition of Cdk2 activity downstream of this pathway blocks the loading of Cdc45 
onto chromatin. Cdc45 is a protein required for the recruitment of DNA polymerase α 
into assembled pre-replication complexes, so the inhibition of Cdk2 activity prevents the 
initiation of new origin firing (159,163). The other branch of the intra-S-phase 
checkpoint reflects the impact of ATM-mediated phosphorylation of NBS1 on several 
sites. The concept of the two parallel effector branches of the intra-S-phase checkpoint 
has been documented for responses to both ionizing radiation (165) and to ultraviolet 
light (166). Apart from the inhibition of replication-origin firing, another critical function 
provided by S-phase checkpoints is to protect the integrity of the stalled replication forks. 
It helps prevent the conversion of primary lesions into DNA breaks and facilitates the 
subsequent recovery of DNA replication (163,167). 
 
1.2.2.3 The G2 checkpoint 
The G2 checkpoint prevents cells from initiating mitosis when they experience 
DNA damage during G2, or when they progress into G2 with some unrepaired damage 
inflicted during previous S or G1 phases (168,169). The critical target of the G2 
checkpoint is the mitosis-promoting activity of the cyclinB/Cdk1 kinase, whose 
activation after various stresses is inhibited by ATM/ATR, CHK1/CHK2 and/or 
p38-kinase-mediated subcellular sequestration, degradation and /or inhibition of the 
Cdc25 family of phosphatases that normally activate Cdk1 at the G2/M boundary 
(164,169-172). p53 activates several genes that interfere with the Cdk1 activity (173). It 
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strongly induces p21 (174), the CDK inhibitor, which inhibits the Cdk1 kinase activity. 
p53 also activates the GADD45 gene, which dissociates the cyclinB/Cdk2 complex 
(175,176), and the 14-3-3 sigma gene (177). The 14-3-3 sigma protein binds Cdk1 and 
anchors the Cdk1/cyclinB complex in the cytoplasm (173,178), preventing its nuclear 
translocation and arresting the cell in G2. An additional mechanism through which p53 
induce G2 arrest is by direct repression of cyclin B1 and Cdk1 gene transcription.  
 
1.2.3 Cell cycle and cancer 
Aberrant activation of the cell cycle can be achieved by upregulation of cell-cycle 
activators (often encoded by protooncogenes) or downregulation of cell-cycle inhibitors 
(often encoded by tumor suppressor genes). Abnormal regulation of these genes is 
involved in promoting the transformation of a normal cell into a continuously 
proliferating cell, which is independent of growth-promoting and resistant to 
growth-inhibiting signals. This cell transformation is supported by other mechanisms, 
such as angiogenesis as well as evasion of apoptosis and immune surveillance, and will 
create the clonogenic malignant cell. 
 
1.2.3.1 Oncogene 
The well-studied upregulated cell-cycle activators in cancer include cyclin D, cyclin 
E, cyclin A, Cdc25B, c-Myc. Overexpression of cyclin D1 caused by gene amplification 
or aberrant activation of protein synthesis is frequently found in several human tumors 
(179,180). Aberrant activation of the cyclin D1 gene can be induced by chromosomal 
rearrangement which brings this gene under the influence of a strong promoter or 
enhancer (179,181). Cyclin E overexpression has also been associated with different 
tumors and elevated cyclin E levels in a tumor predict decreased survival of breast 
cancer patients (182). Deregulated expression of cyclin E also induces chromosomal 
instability and thereby contributes to tumorigenesis. (183). Increased expression of 
cyclin A has also been detected in many types of human cancers. For example, , higher 
expression of cyclin A has been found in up to 80% of hepatocellular carcinomas (184). 
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Elevated c-Myc expression due to translocation juxtaposing the c-myc gene with the 
immunoglobulin gene enhancer results in B-cell tumors (181). Overexpression of the 
c-Myc protein can also be achieved by gene amplification, an alteration frequently seen 
in breast cancer (185).  
 
1.2.3.2 Tumor suppressor gene  
Similar to the activation of cell-cycle, defects in cell-cycle checkpoints lead to 
uncontrolled proliferation and can result in malignancy. Genes involved in the negative 
regulation of the cell cycle are called tumor suppressor genes. In general, two major 
pathways are involved in the negative regulation of the cell cycle: namely the “Rb 
pathway” and the “p53 pathway”. Rb is mutated in several human tumors (186) and 
mutated or deleted Rb is unable to repress the function of E2F. The Rb gene is most 
often implicated in adult cancers, such as small cell carcinomas and inherited allelic loss 
of Rb confers increased susceptibility to tumor formation. (187). Inactivation of the Rb 
pathway is also accomplished by mutations of other regulatory factors. Loss-of-function 
mutations in the INK4a family members, particularly p16INK4a, occur frequently in 
human cancers (188). For example, in melanomas, one copy of mutant p16INK4a is 
inherited and the second copy is lost in the tumor cell. Unlike regulators of the Rb 
pathway, p53 is not required for cell cycle progression. Its role is to arrest the cycle only 
when the cell is damaged, by either G1 arrest or by inducing apoptosis (189). The p53 
gene is mutated in more than 50% of human cancers and is the most frequent genetic 
alteration associated with malignancy (190). Furthermore, inactivation of the p53 
pathway can occur via defects in upstream or downstream regulators which have been 
observed in several human cancers. In general, tumors with an intact wild-type p53 have 
a better prognosis and a better response to therapy compared to tumors with defective 
p53 (191). Overexpression of MDM2, the negative regulatgor of p53, by gene 
amplification or other mechanisms has been reported in leukemia and lymphoma, breast 
carcinoma, sarcoma and glioma and may represent an alternative mechanism for 
escaping p53-mediated growth arrest (192-194). 
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1.3 Gene regulation 
Control of gene expression is achieved through the coordinated action of various 
cis- and trans-acting factors including matrix attachment regions (MARs), locus control 
regions (LCR), nucleosome remodeling, histone modifications, gene methylation, 
transcription factors, enhancers and silencers, and promoters (195-197). 
 
1.3.1 Promoter organization  
In general, the promoter is an integral part of the gene and often makes sense only 
in the context of its own gene. Promoter regions comprise the genomic DNA sequences 
found upstream from the transcribed sequence but often overlap with, or include, the 
first exon of a gene. Promoters are the central processors of transcriptional control, as 
the regulatory information contributed by the other elements must be integrated within 
the context of a promoter in order to influence gene expression (195).  
 
1.3.1.1 Architecture of the core promoter  
Recognition of the core promoter by the transcription machinery is essential for 
correct positioning and assembly of RNA Pol II and the general transcription factors. 
Sequence elements found in core promoters include the TATA element (TBP-binding 
site), BRE (TFIIB-recognition element), Inr (initiator element) and DPE (downstream 
promoter element) (198). Most promoters contain one or more of these elements, but no 
one element is absolutely essential for promoter function. The TATA box was the first 
identified core promoter element. In most RNA polymerase II-transcribed genes 
examined, the TATAAA sequence was present 25 to 30 bp upstream of the transcription 
start site (199). At TATA-containing promoters, formation of the TBP/TATA complex is 
the initial step in assembly of the transcription machinery. The TFIIB recognition 
element (BRE) is the only well-characterized element in the core promoters. 
Protein-DNA crosslinking studies confirmed that TFIIB is in close proximity to the 
upstream sequences (200). A study with human TFIIB established the existence of a 
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eukaryotic BRE that prefers a 7-bp sequence: G/C G/C G/ACGCC (201). Recognition of 
the BRE was found to be mediated by a helix-turn-helix motif at the C-terminus of 
TFIIB (202). Interestingly, this motif is missing in yeast and plants, suggesting that the 
BRE may not contribute to gene regulation in these organisms. The TFIIB and BRE 
interaction was originally reported to stimulate RNA polymerase II transcription in an in 
vitro assay reconstituted with purified basal factors (201). However, it was also observed 
that the BRE is a repressor of basal transcription in vitro with crude nuclear extracts as 
well as in vivo in transfection assays (203). Repression associated with TFIIB-BRE 
interactions can be relieved when transcriptional activators were bound to distal sites, 
which resulted in an increased amplitude of transcriptional activation. The Inr was 
defined as a discrete core promoter element that is functionally similar to the TATA box 
and can function independently of a TATA box in an analysis of the lymphocyte-specific 
terminal transferase (TdT) promoter (204). TATA box and Inr function synergistically 
with one another when separated by 25-30 bp but act independently when separated by 
more than 30 bp. The DPE was identified as a downstream core promoter motif that is 
required for the binding of purified TFIID to a subset of TATA-less promoters (205). The 
DPE is conserved from Drosophila to humans and is typically but not exclusively found 
in TATA-less promoters. The DPE functions cooperatively with the Inr, and the core 
sequence of the DPE is located at precisely +28 to +32 relative to the A+1 nucleotide in 
the Inr motif (206). 
 
1.3.1.2 RNA polymerase II transcription machinery 
Regulation of transcription is one of the most important steps in control of cell 
growth and differentiation. Transcription is carried out by the enzyme RNA polymerase 
(Pol) along with other factors termed general transcription factors (GTFs). The GTFs 
include TBP, TFIIB, TFIIE, TFIIF, and TFIIH and were identified biochemically as 
factors required for accurate transcription initiation by RNA pol II from doublestranded 
DNA templates in vitro (207). The GTFs are involved in recognition of promoter 
sequences, the response to regulatory factors and conformational changes essential to the 
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activity of Pol II during the transcription cycle (Table 1-3) (208). Pol II transcription 
typically begins with the binding of gene-specific regulatory factors near the site of 
transcription initiation. These factors can act indirectly on the transcription machinery by 
recruiting factors that modify chromatin structure, or directly by interacting with 
components of the transcription machinery. Both the direct and indirect mechanisms 
result in recruitment of the transcription machinery to a core promoter (described in the 
previous section) (209). Pol II and the general factors are all bound to the promoter 
forming the preinitiation complex (PIC) (Figure 1-5). Order-of-addition experiments 
demonstrated that PIC assembly is nucleated in vitro by TBP binding to the TATA 
element followed by binding of TFIIB, RNA pol II-TFIIF, TFIIE, and TFIIH (210). Next, 
a conformational change occurs in which 11-15 bp of DNA surrounding the transcription 
site are melted and the template strand of the promoter is positioned within the active 
site cleft of Pol II to form the open complex (211). Initiation of transcription begins with 
synthesis of the first phosphodiester bond of RNA. After synthesis of about 30 bases of 
RNA, Pol II releases its contacts with the core promoter and the rest of the transcription 
machinery and enter the stage of transcription elongation (212).  
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Table 1-3 Yeast general transcription factors (213). 
 
Factora Mass (kDa) Gene(s) Essential Charateristics 
TBP (factor d)  
 
27 SPT15 Yes Binds TATA element; nucleates PIC 
assembly; recruits TFIIB 
TFIIB (factor e)  
 
38 SUA7 Yes Stabilizes TATA-TBP interaction; recruits 
RNA pol II-TFIIF; affects start site 
selection; zinc ribbon 
TFIIF (factor g)  
 
82 TFG1, 
SSU71 
Yes Facilitates RNA pol II promoter targeting; 
stimulates elongation; functional 
interaction with TFIIB 
 47 TFG2 Yes σ factor homology; destabilizes 
nonspecific RNA pol II-DNA 
interactions 
 27 TFG3, 
ANC1, 
SWP29, 
TAF30 
No Common subunit of TFIID, TFIIF, and 
the SWI/SNF complex  
TFIIE (factor a)  66 TFA1 Yes Recruits TFIIH; stimulates TFIIH 
catalytic activities; functions in promoter 
melting and clearance; zinc binding 
domain  
 43 TFA2 Yes  
TFIIHb (factor b)  
 
95 SSL2, 
RAD25 
Yes Functions in promoter melting and 
clearance; ATPdependent DNA helicase 
(39 3 59); DNA-dependent ATPase; 
ATPase/helicase required for both 
transcription and NER 
 85 RAD3 Yes ATP-dependent DNA helicase (59 3 39); 
DNA-dependent ATPase; ATPase/helicase 
required for NER but not transcription 
 73 TFB1 Yes Required for NER 
 59 TFB2 Yes Required for NER 
 50 SSL1 Yes Required for NER; zinc binding domain 
 47, 45 CCL1 Yes TFIIK subcomplex with Kin28 
 37 TFB3 Yes Zinc RING finger; links core-TFIIH with 
TFIIK; unlike Mat1, not a subunit of 
kinase/cyclin subcomplex 
 33 KIN28 Yes TFIIK subcomplex with Ccl1 
 
a The initial designations of the yeast general transcription factors by Kornberg’s laboratory are denoted in arentheses. 
b TFIIH is composed of core-TFIIH (Rad3, Ssl1, Tfb1 to Tfb4), plus Ssl2/Rad25 and the TFIIK kinase/cyclin ubcomplex (Kin28, Ccl1). 
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Figure 1-5 Schematic depiction of the transcription PIC. PIC assembly is nucleated 
by TBP binding to the TATA box, inducing a sharp bend in the DNA template, followed 
by association of TFIIB, RNA pol II/TFIIF, TFIIE, and TFIIH. Each pattern denotes a 
distinct general transcription factor. Subunit composition is indicated, except for TFIIH 
(9 subunits) and RNA pol II (12 subunits). Although PIC assembly can occur by 
stepwise addition of the general transcription factors (GTFs) in vitro, the discovery of 
RNA pol II holoenzyme complexes that include GTFs suggests that stepwise assembly 
might not occur in vivo (213). 
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Pol II is especially equipped to cooperate with processing factors and other nuclear 
proteins, mostly through interactions with a unique domain from the large subunit of the 
enzyme (214). This carboxy-terminal domain (CTD) of Pol II is composed of tandem 
repeats of a heptad with the conserved consensus sequence YSPTSPS. The CTD can 
allosterically regulate capping enzymes and regulate transcriptional elongation and 
termination (215).  
 
1.3.2 Transcriptional coregulators 
Transcriptional regulation is dependent not only on transcription factor activation 
and chromatin remodeling, but also on a group of transcription factor coregulators – 
coactivators and corepressors. In addition to transcription factor activation and 
chromatin changes, there is an expanding array of additional modifications involved in 
transcriptional regulation. 
 
1.3.2.1 Transcriptional coactivators 
In general, coactivators do not bind to DNA, but interact indirectly through 
association with other DNA-binding proteins (e.g., nuclear receptors). Once recruited to 
the promoter, coactivators enhance transcriptional activity through a combination of 
mechanisms, including efficient recruitment of basal transcription factors such as 
template-activating factors and TATA-binding protein. In addition, coactivators possess 
themselves, or recruit other nuclear proteins that possess, enzymatic activities crucial for 
efficient gene expression including the histone acetyltransferase (HAT) (e.g., CBP/p300, 
p160s), methyltransferases (e.g., CARM1), ubiquitin ligases (e.g., E6-AP) and ATPase 
(e.g., SWI/SNF). 
The p160/steroid receptor coactivator (SRC) family is a well-studied group of 
transcriptional coregulatory proteins that function through histone tail modifications, 
altering chromatin structure, and facilitating transcription initiation. The members 
include SRC1, glucocorticoid receptor interacting protein (GRIP1) and P/CIP (SRC3). 
The p160/SRC family share a common structure that includes an N-terminal basic 
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helix-loop-helix domain, a PAS domain, a C-terminal transcriptional activation domain 
and a central region containing three nuclear receptor interacting LXXLL motifs (216). 
SRC1 and SRC3 exhibit HAT activity, which is necessary for the formation of an open 
chromatin structure (217). SRC coactivators can also interact with general coactivators 
such as the CREB binding protein (CBP) and p300 (218).  
In addition to HAT activity, coactivator-mediated methylation of proteins in the 
transcription machinery may also contribute to transcriptional regulation by NRs . For 
example, coactivator-associated arginine methyltransferase 1 (CARM1) binds to the 
C-terminal domain of GRIP1, methylates histone H3, and enhances transcriptional 
activation by NRs (219). 
Another coactivator related to chromatin modification is SWI/SNF, a complex with 
ATPase activity, which alters nucleosomal structure and is involved in the transcriptional 
regulation of NRs (220). The ATP-dependent chromatin-remodeling complexes use 
energy from ATP hydrolysis to increase the mobility of nucleosomal DNA, thereby 
regulating a variety of cellular processes, including transcription, DNA replication, and 
DNA repair and recombination. The targeting of SWI/SNF is thought to be achieved 
through the interaction of DNA-binding transcription factors, coactivators, or general 
transcription machinery. Different SWI/SNF components have been shown to mediate 
critical interactions between ER and mammalian SWI/SNF (221,222). In the context of 
NR-coactivator complexes, multiple interactions are probably involved in the recruiting 
and stabilization of SWI/SNF on NR target-gene promoters. 
Another NR binding protein, the steroid receptor activator (SRA), is unique among 
coactivators. It functions as an RNA transcript rather than as a protein (223). SRA is 
selective for steroid hormone receptors and mediates transactivation via their N-terminal 
activation function. In addition, the E6-associated-protein (E6-AP), an ubiquitin ligase, 
has been identified as a coactivator of progesterone receptor (PR) (224). E6-AP also 
coactivates the hormone-dependent transcriptional activities of other nuclear hormone 
receptors.  
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1.3.2.2 General transcriptional repressors 
In general, corepressor proteins coordinate the inactivation of transcriptionally 
active complexes through their direct interactions with DNA-binding transcription 
factors and the coordinate rcruitment of chromatin modifying enzymes that may return 
the nucleosome to an inactive state. The first corepressors identified for nuclear 
receptors were SMRT (Silencing mediator of retinoid and tyroid hormone receptors) and 
NCoR (nuclear hormone receptor corepressor) (225). These two proteins share a 
common molecular architecture and approximately 45% amino acid homology (226). 
Both SMRT and NCoR can be divided into a N-terminal portion having three to four 
distinct transcriptional repression (or silencing) domains (RDs), and a C-terminal portion 
composed of two or three nuclear receptor interaction domains (NIDs) (227,228) Both 
proteins interact with NRs through a C-terminal region, and nucleate the multiprotein 
repressor complexes through N-terminal repression domains, which interact with 
chromatin remodeling enzymes such as histone deacetylase (HDAC). HDACs inhibit 
gene transcription by remove the acetyl group from histons, which allows histons to bind 
DNA. Nuclear receptor-SMRT/NCoR complexes can also be regulated by 
phosphorylation of the corepressor, which can occur even in the absence of receptor 
ligand. Phosphorylation of corepressors can either enhance or inhibit the interaction 
between receptors and corepressors. For example, phosphorylation of the C terminus of 
SMRT by casein kinase/CK2 stabilizes corepressor binding to T3Rs (229). In contrast, 
negative regulation of SMRT occurs in response to growth factor receptor-mediated 
phosphorylation through a Ras-MEKK1-MEK1 pathway (230). 
A new aspect of transcriptional regulation is related to oxidant signals, reactive 
oxygen intermediates, and cellular redox state on cell physiology, function, and viability. 
Elements of this complex system can directly impact gene transcription. One example of 
this type of regulation involve nicotinamide adenine dinucleotide (NAD), a widespread 
small biological molecule that participates in numerous cellular reactions including 
transcriptional control (231). One of the NAD-dependent coregulatory proteins is the 
C-terminal binding protein (CtBP), an ubiquitious corepressor with numerous interacting 
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proteins (232). CtBP may mediate repression in an HDAC-dependent or -independent 
manner. NADH binding changes the CtBP three-dimensional confirmation, resulting in a 
shift in protein-protein interactions and increased corepressor activity (233). Another 
transcriptional regulator influenced by NAD is Sir2p, which is required for nucleolar 
silencing (234). Sir2p is critical for silencing of the telomere and rDNA loci and this 
activity requires NAD as a cofactor for its HDAC activity (234,235). 
 
1.4 Nuclear hormone receptor superfamily 
Members of the nuclear hormone receptor superfamily are ligand dependent 
transcription factors which modulate a large number of essential cellular activities. The 
superfamily consists of receptors for steroid hormones (e.g. estrogen, progestin and 
androgen), steroid derivatives (e.g. dihydroxyvitamin D3) and non-steroids (e.g. 
retinoids and thyroid hormone). In addition, there are members of this superfamily for 
which endogenous ligands have not yet been identified, namely the “orphan receptors”.  
Nuclear hormone receptors can be divided into two groups: type I and Type II 
receptors. Type I receptors include the classic steroid hormone receptors, such as 
glucocorticoid receptor (GR), which undergo nuclear translocation upon hormone 
binding and associate with their consensus sequences on DNA as homodimers. Type II 
receptors include retinoic acid receptor (RAR), retinoid X receptor (RXR), thyroid 
hormone receptor, and vitamin D3 receptor, which reside in the nucleus, regardless of 
the presence of ligand, and heterodimerize with RXR on their DNA binding sites.  
 
1.4.1 Structure and function of nuclear receptors 
Members of the nuclear hormone receptor superfamily were first cloned during the 
1980s and comparison of their cDNAs and protein sequences revealed common 
structural motifs (236). These common structural motifs between members of the nuclear 
hormone receptor superfamily suggest that they are evolutionarily linked.  
Based on the sequence homologues between nuclear hormone receptors, their 
general structure can be divided into six subregions, including the N-terminal half of the 
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receptor or A/B region and region C which includes the conserved DNA-binding motif. 
The C-terminus is subdivided into a short region D, called the “hinge-region”, region E 
which corresponds to the ligand binding domain and region F which is only present in 
some receptors (Figure 1-6). 
 
1.4.1.1 The A/B domain 
The A/B region is the most poorly conserved region within the NR family in terms 
of length and amino acid sequence. The A/B domain contains a transcription activation 
function-1 (AF1) that synergistically interacts with ligand dependent AF2 located at the 
C-terminal region of the receptor. AF1 is responsible for promoter context and cell type 
receptor activity. For example, glucocorticoid receptor (GR) and other steroid hormone 
receptor mutants that only express their A/B and C domains (DNA binding domain) were 
constitutively active and stimulated transcription from simple promoters containing their 
cognate binding sites (237,238). The A/B domain appears to directly or indirectly contact 
a variety of coactivator and corepressor proteins as well as other transcription factors 
(239-241) suggesting that A/B domains interact with tissue-specific cofactors. The 
functions of many proteins depend upon their structures, however, the AFs in A/B 
domains when expressed as peptides exhibit a random coil configuration (242,243). The 
N-terminal AFs of some nuclear hormone receptors may contain helical structures (242). 
There are two hypothesized models for AF1 folding. The first hypothesis is that the AF1 
does not have to be well-structured, but must present a cluster of charges, sufficient to 
activate the transactivation function (244,245). The second hypothesis states that the act 
of binding one or more of its cognate partners induces the appropriate folding of the A/B 
domain. Two models are consistent with the second hypothesis, namely, the induced-fit 
and selected-subset models. The induced-fit model assumes that nonspecific initial 
binding due to random interactions between the binding partner (BP) and the AF domain 
induces a rapid shift in structure of the AF, leading to collapse of the molecule into the 
correct functional shape resulting in enhanced, specific AF1-BP binding. When sufficient 
quantities of BP are in proximity to the properly folded subpopulation of AF, they bind  
 37
 
 
 
 
 
 
 
Figure 1-6 Schematic illustration of the structural and functional organization of 
NRs. The evolutionary conserved regions C and E are indicated as boxes and a black bar 
represents the divergent regions A/B, D, and F. Note that region F may be absent in some 
receptors. Domain functions are depicted below and above the scheme. Two 
transcription activation functions (AFs) have been described in several nuclear receptors, 
a constitutively active AF1 in region A/B and a ligand-inducible AF2 in region E. Within 
these activation functions, autonomous transactivation domains (ADs) have been defined 
in the estrogen (ER) and progesterone receptor (PR) N-terminal regions. In the case of 
the estrogen, retinoid and thyroid hormone receptors an autonomous activation domain 
(AF2 AD) encompassing helix H12 has been detected at the C-terminal end of the ligand 
binding domain E (246). 
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with high affinity and shift the remainder of the AF1 into the fully formed functional 
AF-BP structure. In addition to the binding of coactivators and corepressors, 
posttranslational modifications of receptors may contribute to the structure of the 
N-terminal AFs. Phosphorylation is well known to affect activity of certain steroid 
hormone receptors, and many of the phosphorylated amino acids are in the A/B domain 
(247). A recent study proposed that binding of the ER to its response element can 
regulate the structure and biological activity of the receptor and influence recruitment of 
coactivators to the ER at target gene promoters (248). This suggests that the DBD-RE 
binding represents an active event in which intramolecular forces induce folding to give 
functional receptors.  
 
1.4.1.2 The DNA-binding domain (DBD)  
The most conserved domains in nuclear receptors is within 66 amino acids located 
in region C. Deletion analysis and single amino acid mutations indicates that this region 
contains the DNA-binding motif which is required for sequence specific recognition and 
binding of the receptor to hormone responsive elements (HREs). The DNA-binding 
motif contains highly conserved cysteine residues which are required for coordinating 
Zn2+ ion. Each of the two Zn2+ ions is bound by four cysteines forming a C2-C2 
zinc-finger (Figure 1-7). Although the 66 amino acid fragment is necessary for the 
receptor to bind DNA, the flanking amino acid sequences are also important for ERα 
(249). DNA binding of the C domain of ERα was weak and was only observed on 
perfect ERE palindromic sequences, however the addition of amino acids from region D 
greatly enhanced the receptor binding to consensus and nonconsensus EREs (249).  
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Figure 1-7 Sequence of amino acid residues of the human glucocorticoid receptor, 
showing two zinc finger motifs. The three highlighted amino acids around the first zinc 
finger (P-box) are those essential for discrimination between GRE and ERE, whereas the 
highlighted amino acids around the second zinc finger, known as D-box, are important 
for protein:protein interactions in the dimeric DBD:GRE complex (250). 
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The two zinc-fingers have different structures and functions. The helix of the first 
zinc-finger is primarily involved in site-specific recognition based on its interaction with 
certain bases in the cognate response element hexamer. Also within this helix are the 
amino acids responsible for site-specific discrimination of binding. These 3-4 amino 
acids have been termed the P box (250,251). A loop formed in the second zinc-finger 
provides the DBD homodimerization interface and the helical region, and some 
non-specific DNA interactions.  
In general, nuclear hormone receptors bind to DNA as dimers. Type I steroid 
hormone receptors bind as homodimers, whereas type II receptors bind preferentially as 
heterodimers. For type I receptors, it was shown that two receptors cooperatively bind to 
their palindromic response element, and the DBD is sufficient to provide this 
cooperative binding. Replacement of four amino acids in region C (the D-box) of ER 
with the homologous amino acids of the retinoic acid receptor (RAR) abolished 
cooperative binding (252). Thus, the DBD of a receptor contains information which 
specifies dimerization and cooperative DNA-binding functions as well as the DNA 
sequence to specificity. 
In order to further understand the DNA-binding properties of nuclear hormone 
receptors, x-ray crystal structures of the DBD of GR, ER, and RXR bound to their 
response elements have been solved (250,251,253). The central feature of the secondary 
structure elements within the GR DBD is found in three helical regions. Helices I and III 
are oriented perpendicular to each other and form the base of a hydrophobic core. NMR 
studies indicate that helices I and III are both regular α-helices, whereas helix II is 
somewhat distorted (254). The crystal structures show that helix I fits into the major 
groove of the DNA helix and provides critical contacts between three amino acids in the 
protein helix and certain bases in the major groove (250). The dimer interface, a loop of 
five amino acids that is also called the D box, lies between the first two cysteines of the 
second zinc finger. 
The relative orientation of the two DBDs in the homodimeric complex is 
determined not only by the response element sites, but also by monomer interactions 
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critical for recognition of spacing and orientation of hexameric half-sites (250). The 
crystal structures of the DBD homodimer: DNA complex of the GR and ER shows that 
each DBD exposes an α-helix to the bases in the major groove of the DNA, and the 
recognition surfaces of these complexes are supported in the major groove. Each 
monomer contacts the sugar phosphate backbone on either side of the major groove. 
Interestingly, the structure of the RXR DBD has an additional helix immediately after 
the second zinc finger. This additional helix presumably facilitates both protein:DNA 
and protein:protein interactions required for high affinity binding of the RXR DBD to its 
cognate response element. The amino acids in this third helix are conserved in the 
isoforms of RXR found in different species; suggesting that the third helix may be a 
general feature of the receptor. There are indications that the third helix in the RXR DBD 
functions not only in RXR homodimerization, but may also function in the well known 
interactions of RXR with other members of the nuclear receptor superfamily (251,255).  
Functional analysis in gene expression assays showed that the DBD of PR and GR 
can activate gene transcription in vitro and in vivo (256-258) and deletion analysis 
defined one nuclear localization signal within the DBD of PR (259). 
In summary, The DBD of nuclear hormone receptors is multifunctional. It contains 
sequence specific DNA-binding activity, information for homo- and hetero-dimerization, 
cooperative binding to other receptor molecules, a weak transcriptional activation 
function and a nuclear localization signal. 
 
1.4.1.3 Functional domains in the C-terminus  
The ligand binding domain (LBD) localized in the C-terminal E region is the 
second most conserved domain of the nuclear receptors (NRs). All LBDs are composed 
of a series of 11~12 α-helices (H1~H12) closely folded in a similar manner. The 
unliganded LBD of RXR-α was the first of these structures to be solved (260). Although 
the secondary structure in the unliganded and liganded RXR-α and RAR-γ are similar, 
the latter structure is more compact suggesting that ligand binding may function to 
stabilize the conformation of a large portion of the LBD. 
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The ERα LBD is the first structure of Type I NRs which compare the binding of an 
agonist and an antagonist (261). The agonist (E2) and antagonist (raloxifene) bind at the 
same site but induce different conformations due to major alterations in the position of 
helix 12. When antagonist is bound, H12 appears to be in a position that blocks the 
LBD-binding site for coactivators via their cognate LXXLL motif.  
The C-terminal part of the LBDs of the RAR, the TR, and the ER have a ligand- 
inducible activation function, termed AF2 (262,263). In the unliganded RXR-α LBD 
structure, the region is essential for AF2 function and adopts a helical structure, which 
corresponds to the C-terminal helix H11. The helix is often known as the AF2 activation 
helix. Both deletion and mutation studies have shown that AF2 is essential for ligand 
induced transcriptional activation. It appears that activation of AF2 upon ligand binding 
corresponds to major conformational changes, which create the proper surface required 
for efficient interaction with transcriptional coregulatory factors, which are the putative 
mediators of AF2 function (264,265). The amphipathic C-terminal activation helix, even 
in the absence of ligand, constitutes an active conformation, which has been observed in 
the structures of the ligand-bound RAR-α and TR (266). This may explain 
ligand-independent activation of this receptor. An approach in defining the LBD 
suggests that at least part of the D-region is required for hormone binding (267). Also, 
deletion of eight amino acids from the C-terminus of TR abolishes hormone binding 
completely. Thus, the minimal hormone binding domain comprises the entire E-region 
and part of the D-region.  
Steroid hormone receptors bind to their response elements as dimers and the 
existence of two dimerization signals within the coding sequence of nuclear hormone 
receptors has been described (268). One is localized in the DBD and is considered to be 
weak; the other is stronger and dependent on hormone (269). The sequences in the 
dimerization domain reveal a heptate repeat of hydrophobic residues which are 
conserved in all members of the nuclear hormone receptor superfamily. This suggests 
that nuclear hormone receptors have a leucine-zipper type dimerization interface (270). 
Taken together, the C-terminus of nuclear receptor contains sites for ligand binding, 
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homo- and/or hetero-dimerization, and transcriptional activation. 
 
1.4.2 Nuclear receptor-mediated gene regulation 
Transcriptional regulation by NRs is a complex process. It requires recruitment of 
specific classes of coactivators and other transcription-related factors being recruited to 
the target promoter by the DNA-bound receptor in the chromatin environment of the 
nucleus. Each factor in the collection contributes one or more distinct activities, such as 
chromatin remodeling, histone modification, cofactor complex assembly and recruitment 
of the basal transcription machinery. The ultimate goal is to stimulate the transcription of 
target genes by RNA polymerase II (RNA pol II). 
 
1.4.2.1 DNA recognition by nuclear receptors 
The initial step in transactivation is the binding of receptor dimers to their HRE 
within the regulatory region of hormone responsive genes. Several in vitro studies have 
demonstrated that tight binding of both type I and II NRs to their cognate HREs occurs 
in a ligand-independent manner (271) although under certain cellular conditions, NR 
occupancy of HREs is ligand-dependent (272). However, in the case of the ER, ligand 
binding does not change the affinity of the receptor homodimer for its specific RE (273) 
indicating that binding of the receptor to the template may be influenced by other factors 
within the cell. 
The identity of HREs is due to three features: the nucleotide sequence of the two 
core motif half-sites, the number of base pairs separating them and the relative 
orientation of the motifs. According to the type of interaction with HREs, the nuclear 
receptor superfamily has been divided into four classes. The DNA-binding sites for 
nuclear receptors exist as one or two copies of hexamer sequences. The class I receptors 
all recognize a 5’-AGAACA-3’ core while the class II receptors recognize a 
5’-AGGTCA-3’ core (274). Steroid hormone receptors only bind inverted repeats with a 
three-nucleotide spacer, except for the androgen receptor which also binds direct repeats 
(Figure 1-8). Among the best-characterized non-palindromic arrangements are the direct 
 44
repeats of 5’-AGGTCA-3’, which are targets for the nuclear receptors that form 
heterodimers with RXR (275). The repeats vary in the length of the spacer that separates 
the two hexameric half-sites. The number of spacing nucleotides restricts the species of 
receptor dimers that can activate these HREs (276).  
Analysis of all natural steroid-response elements revealed that one half-site is more 
likely a consensus sequence while the other can show divergence from the consensus 
sequence (274). The consensus half-site is initially recognized bound with high affinity 
and binding of the first DBD results in a conformational change in the protein that 
supports the formation of the proper dimerization interface, that enables a second 
monomer to bind co-operatively to the second half-site in the HRE.  
 
 
 
GRE 
 
5’ AGAACA (N)3 TGTTCT 3’ 
3’ TCTTGT (N)3 ACAAGA 5’ 
 
ERE 
 
5’ AGGTCA (N)3 TGACCT 3’ 
3’ TCCAGT (N)3 ACTGGA 5’ 
VDRE 
 
5’ AGGTCA (N)3 AGGTCA 3’ 
3’ TCCAGT (N)3 TCCAGT 5’ 
 
TRE 
 
5’ AGGTCA (N)4 AGGTCA 3’ 
3’ TCCAGT (N)4 TCCAGT 5’ 
 
RARE 
 
5’ AGGTCA (N)5 AGGTCA 3’ 
3’ TCCAGT (N)5 TCCAGT 5’ 
 
 
 
Figure 1-8 Consensus sequences of hormone response elements. Consensus 
sequences of DNA sites that bind the glucocorticoid receptor (GRE), estrogen receptor 
(ERE), vitamin D3 receptor (VDRE), thyroid hormone receptor (TRE), and retinoic acid 
receptor (RARE). 
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1.4.2.2 Nuclear receptor-directed initiation of gene expression 
The initiation of mRNA synthesis by RNA polII involves the direct binding of core 
promoter DNA elements by a collection of “basal” transcription factors. Direct 
interactions between the p160 proteins and AF2 domains of some NRs have been clearly 
demonstrated (277,278). Once bound to the NR, p160 proteins facilitate recruitment of 
p300/CBP to the regulatory region. After p300/CBP is bound to DNA via the NR (Figure 
1-9), it may increase the number of productive preinitiation complexes present within the 
promoter (279). Furthermore, p300/CBP can interact with Pol II through the 
intermediate of RNA helicase A and recruit the Pol II holoenzyme complex to the 
promoter region (280). The acetyltransferase activity of p300/CBP is also essential for 
mediating transactivation by both ER (281) and TR/RXR (282) from repressive 
chromatin. The arigine methyltransferase CARM1 coactivator can synergize with p160 
and p300 proteins to enhance ligand-dependent transcriptional activation by NRs, 
possibly through to methylation of  histone H3 (283). The next step involved is 
recruitment of TRAP220/SMCC/mediator complex. The DNA tethered SMCC complex 
can also recruit the Pol II holoenyzme to the proximal promoter. NRs also facilitate 
recruitment of SWI/SNF to the promoter region. SWI/SNF can induce remodeling of the 
proximal promoter region and facilitates binding of the basal transcriptional machinery 
to the DNA template and association between TBP and TATA box.  
In general, the binding of ligand-activated NRs to DNA-response elements in the 
promoter region of a hormone-responsive gene stimulates the assembly of a stable basal 
transcription factor/RNA pol II transcription PIC at the promoter, with recognition of the 
TATA box and other core promoter elements by a complex called TFIID being a critical 
initial step of NR-mediated transcriptional activation.  
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Figure 1-9  Coactivator and corepressor complexes for regulation of nuclear 
receptor-mediated transcription (284). 
 
 
 
1.4.2.3 Role of coregulators in NR-mediated transactivation 
Nuclear receptors carry out many different transcriptional functions through the 
recruitment of a group of positive and negative regulatory proteins, referred to as 
coactivators or corepressors, respectively (216). Alternatively, coregulators can also be 
classified into two main groups according to their functions. The first group contains 
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factors that covalently modify histones (ie. acetylation, methylation, phosphorylation, 
ubiquitylation). The second group includes ATP-dependent chromatin remodeling factors 
that modulate promoter accessibility to transcription factors and to the basal 
transcriptional machinery. These coregulators are not exclusive to NRs, and are used in a 
similar way by numerous other DNA-bound transcription factors. For a detailed 
description of coregulators please refers to Section 1.3.2. 
Ligand binding is the crucial molecular event that switches the function of nuclear 
receptors from active repression to transcriptional activation. Structural and molecular 
studies of the interactions between nuclear receptors and coregulators has provided 
evidence that hormone binding induces a conformational change in the ligand-binding 
domain of the receptor, which results in reduced affinity for corepressors and enhanced 
affinity for coactivators. Similarly, agonist binding to steroid hormone receptors also 
induces specific conformations that favors coactivator binding, whereas antagonist 
binding promotes interactions with corepressors. However, in some cases, recruitment of 
ubiquitylation machinery and proteasome-dependent degradation of the repressors are 
required to fully promote the release of the corepressors in response to ligand binding 
(285).  
Recent studies using chromatin immunoprecipitation (ChiP) analysis have revealed 
detailed and coordinated patterns of cofactor recruitment and preferential selectivity for 
factors that have similar enzymatic activities (286,287). In the case of the E2-responsive 
pS2 promoter, recruitment of different classes of cofactors occurs in a precise temporal 
and sequential fashion (209,286). Interestingly, some coregulators seemed to be 
redundant, and different family members were equally capable of being recruited 
alternatively to the promoter (286). By contrast, preferential interactions between a 
nuclear receptor and a specific HAT-containing enzyme or a specific member of the 
NCoA family of coactivators have also been observed (288,289). 
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1.5 Estrogen receptor (ER) 
The estrogen receptors (ERα and ERβ) are Class I members of the nuclear receptor 
superfamily of ligand-inducible transcription factors (290). ERα and ERβ possess the 
hallmark modular structure characteristic of other NRs (Figure 1-10). Because ERα and 
ERβ display a high degree of sequence similarity in the DNA- and ligand-binding 
domains (DBD, 96% and LBD, 53%, respectively), it is not surprising that these 
receptors interact with identical response elements and exhibit similar ligand binding 
affinity profiles (291). ERα is widely expressed and is the predominant ER subtype in 
the breast, uterus, and bone. On the other hand, ERβ is expressed primarily in the ovary, 
prostate, testis, lung, thymus, spleen and in localized areas of the brain (292).   
 
 
 
 
 
 
Figure 1-10  Structure and homology between human ERα and the long form of 
ERβ (293). 
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1.5.1 Biological roles of estrogen receptors 
In the late 1960s and early 1970s, the ER was initially used as a predictor of breast 
cancer response to endocrine ablation. Tumors that were ER rich were more likely to 
respond to endocrine therapy than if the tumor was ER poor (294). From the 1970s to the 
present day, the ER has evolved to be the most effective target for breast cancer therapy. 
The present challenge is to dissect the individual roles of ERα and ERβ as transcription 
factors that participate in normal and aberrant physiological processes. 
Estrogen has multiple physiological functions and is a central modulator at the 
molecular, cellular, and behavioral level. It regulates the growth, differentiation, and 
physiology of the reproductive process through the ER. Estrogen plays a critical role in 
sexual differentiation and maturation as well as growth of female secondary sexual 
organs. Estrogen has multiple effects on the gene expression in both the vagina and the 
uterus and in the mammary gland where estrogen together with progesterone regulate 
lactogenesis. E2 also affects other tissues, such as bone, liver, brain and the 
cardiovascular system. Because of the functional diversity displayed by estrogens which 
act through the ER, understanding the basis of ER actions at the molecular level can 
identify molecular targets that are the basis for therapeutic intervention and treatment of 
hormone-related disease such as breast cancer (295).  
 
1.5.1.1 The role of ERα and ERβ in breast cancer 
The ERα is an important target for development of drugs for treatment and 
prevention of breast cancer (53). The interaction of estrogen with the ERα can result in 
increased proliferation of breast cancer cells and some forms of endocrine therapy block 
the interactions of estrogen with ERα. This can be accomplished by inhibiting the 
production of estrogen by ovariectomy, or be inhibiting conversion of steroidal 
precursors to estrogen using aromatase inhibitors. The ERα can also be targeted directly 
using SERMs such as tamoxifen and raloxifene as competitive inhibitors of ERα-E2 
interactions (296), or by the removal and degradation of ERα by “pure” antiestrogens 
such as ICI 182,780 (297). Endocrine manipulation is one of the least toxic and most 
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effective therapies for treatment of hormone responsive breast cancers. Current studies 
have shown that 5 years of adjuvant tamoxifen treatment is beneficial in pre- and 
postmenopausal women with ER-positive tumors (59). In addition, tamoxifen can be 
used for the prevention of breast cancer in high risk patients (298). 
The role of ERβ in breast cancer growth and development is not as clear as the role 
of ERα (299). ERβ modulate estrogenic activity in breast cancer because it is expressed 
in normal and malignant breast tissue, binds E2 and can heterodimerize with ERα 
(300,301). One problem is that although ERβ mRNA level expression has been 
determined using PCR based techniques, ERβ antibodies are not well characterized or 
effective for detecting this protein and this has led to inconsistencies in the literature. For 
example, one study reported that ERβ is a good prognostic indicator for breast cancer 
and expression of ERβ was associated with better survival in patients receiving adjuvant 
tamoxifen (302). Another study showed that ERβ is associated with negative axillary 
node status and low grade tumors (303). In addition, ERβ patients had a better disease 
free survival rate (304) and levels of ERβ were decreased in proliferative preinvasive 
tumors (305). These studies suggest a protective role for ERβ in breast cancer. In 
contrast, there is evidence suggesting that ERβ is a poor prognostic indicator. For 
example, tumors that expressed both ERα and ERβ were node positive and of a higher 
grade (306) and ERβ mRNA levels were also elevated in tumors that displayed 
tamoxifen resistance (307). 
Overall, the majority of studies suggest that the presence of ERβ is a good 
prognostic marker for breast cancer. However, the relative amounts of ERα and ERβ 
must be considered. As normal breast tissue becomes tumorigenic, the amount of ERα 
increases whereas the amount of ERβ decreases (308). The majority of ER present in 
breast tumors is ERα and therefore the biological relevance of ERβ expression in breast 
cancer remains a topic of debate.  
 
1.5.2 Molecular mechanisms of ER actions 
The biological effects of estrogens are mediated through ERα and ERβ. There are 
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two models for the ER actions namely the genomic and non-genomic pathways. 
 
1.5.2.1 Gene regulation through genomic pathway 
Estrogen diffuse passively in and out of cells (309) and the classical mechanism of 
ER action involves binding of E2 to ER in the nucleus; the receptors form dimers and 
bind to specific response elements known as estrogen response elements (EREs) located 
in promoters of target genes (Figure 1-11) (64). Hormone binding also induces a 
conformational change within the ligand binding domain of the receptors, and this 
allows coactivator proteins to be recruited (310). This leads to alteration of chromatin, 
histone unwinding, interactions with components of the basal transcription machinery 
complex, and subsequent mRNA expression. 
There are several human genes that are regulated by ERs and do not contain 
ERE-like sequences (Figure 1-11) (311). The receptors in such cases are tethered 
through protein-protein interactions to a transcription factor complex that contacts the 
DNA (312). Several genes are activated by E2 through the interaction of ERs with Fos 
and Jun proteins at AP-1 binding sites (313). An E2-responsive AP-1 element was 
initially identified in the proximal promoter of the ovalbumin gene (314). Fos and Jun 
family proteins bind AP-1 elements as homo- or heterodimers. These proteins contain 
leucine zipper domain that mediates DNA binding and are typically associated with 
genes that rapidly respond to various extracellular stimuli (315).  
Mechanistic studies of ER/AP-1 actions have shown that the requirement for ER 
structural domains is dependent on the receptor subtype and on ligand structure. For 
example, E2-dependent activation of ERα/AP-1 complexes require the AF2 domain of 
the receptor, which binds p160 coactivators and stabilizes the formation of a multiprotein 
complex containing c-Jun, ERα, and transcriptional coactivators at the promoter. 
However, the ER DBD is required for tamoxifen-activated ERα/AP-1 dependent activity 
(316). Furthermore, ICI, 182,780, an antiestrogen that inhibits ER dimerization and ER 
DNA (ERE) binding, activates an AP-1 reporter construct (317). Interestingly, full length 
ERα containing mutations in AF1 also compromised E2-mediated AP-1 activity,  
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Figure 1-11 Genomic and nongenomic actions of ER on a target gene promoter 
(359).
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indicating that ERα/AP-1 action requires both AF1 and AF2 (318).  
ERβ also activates transcription from an AP-1 element. However, the effects of 
estrogen and antiestrogens on ERβ/AP-1 contrasts to those observations for ERα/AP-1. 
E2, ICI, 182,780, tamoxifen, and raloxifene all activate AP-1 reporter construct in cells 
cotransfected with ERα whereas, in the presence of ERβ, E2 not only acts as antagonist 
but also inhibits the activity of tamoxifen and raloxifene dependent induction of 
ERβ/AP-1. Moreover, tamoxifen or raloxifene alone behave as full ERβ/AP-1 agonists 
(319). 
Genes that contain GC-rich promoter sequences are regulated in a similar manner 
through the interaction of ERs with the Sp transcription factor (316,320-323).  
E2-responsive GC-rich elements were initially identified in the c-myc gene promoter 
(324). This site contains a nonconsensus ERE-half site (ERE½) and a Sp1 binding site 
that was required for estrogen-mediated induction. Similar ERE½/Sp1 elements have 
been subsequently characterized in the cathepsin D (325), heat shock protein 27 (Hsp27) 
(326) and TGF α gene promoters. However, mutation of the ERE1/2 in the Hsp27 
promoter did not result in the loss of E2 responsiveness, and the E2-dependent ERα/Sp1 
action is also observed in cells transfected with a DBD deletion ERα mutant. The data 
suggested that GC-rich site alone was sufficient for E2-responsiveness and ERα binding 
to DNA was not required for activation of genes through GC-rich sites. The 
ERE-independent ERα/Sp1 action has also been observed for several genes including 
retinoic acid receptor α (327), c-Fos (328), insulin-like growth factor-binding protein-4 
(329), bcl-2 (330), adenosine deaminase (331), thymidylate synthase (332), cyclin D1 
(333), cad (334), E2F-1 (335). 
Although both ERα and ERβ forms complexes with Sp1 protein, only ERα induces 
consensus Sp1 element-linked reporter gene activity whereas ERβ, exhibits minimal or 
decreased the basal reporter gene activity and these responses are ligand- and cell 
type-specific. Interestingly, it was recently reported that both ERα and ERβ regulate 
EGF receptor gene expression through GC-rich elements and, depending on the ligand, 
ERβ exerts full agonist activity on this promoter, indicating that promoter context is also 
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an important factor in ERβ/Sp1 action (336). 
ERα/Sp1 protein-protein interactions were investigated in vitro using GST pull- 
down assays, which showed interactions between the C-terminal end of Sp1 with 
multiple regions of ERα (337). Additionally, it has been shown using a series of ER α 
deletion mutants and ERα/ERβ chimeric mutants that the AF1 domain of ERα is critical 
for ERα/Sp1-mediated transactivation. Recent studies also indicated that E2-dependent 
activation of ERα/Sp1 required the C-terminal F domain of ERα, which was not 
required for antiestrogen activation of ERα/Sp1 (338). 
ERα not only interacts with Sp1 but also with Sp3 protein, another member of Sp 
protein family. It was found that vascular endothelial growth factor (VEGF) gene 
expression is regulated by ERα/Sp1 or ERα/Sp3 either positively or negatively and the 
Sp1/Sp3 ratio is critical for VEGF gene regulation. By using Sp protein deficient SL2 
cells, upregulation of the VEGF promoter activity with E2 treatment was observed in 
cells cotransfected with ERα and Sp1 expression plasmid whereas downregulation of the 
same promoter activity was observed when cells cotransfected with ERα and Sp3 
expression plasmid (339,340). 
Even though the ERE-independent genomic actions are not involved with direct 
binding of ER to DNA, the DBD of the receptors is frequently required (316,320-323). 
Mutation analysis has revealed specific residues within the second zinc finger structure 
of the ERβ DBD that discriminate between the classical mechanism of ER action and the 
modulation of AP-1 and STAT5 activities through tethering (341). The data suggests that 
the DBD may be required for proper protein-protein interactions or it may be involved in 
recruiting additional coregulator proteins to the promoter region. 
 
1.5.2.2 Non-transcriptional mechanisms of signal transduction through ER 
The genomic pathway is complex and tissue-specific and many induced genes and 
estrogenic responses are only observed several hours after treatment with E2. This 
pathway fails to explain certain rapid estrogen-induced actions, such as those occurring 
in the vasculature and nerve cells, which are often observed within seconds after 
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exposure to E2. The rapid estrogen signaling is linked to non-genomic pathways where 
estrogen activates cell membrane or intracellular (cytosolic) forms of the ER or other 
proteins to alter the transmembranous flux of the sodium, potassium and calcium ions 
that rapidly modulate the internal state of cells (342,343). Alternative hypotheses related 
to plasma membrane-ER have also been reported and involve regulation of cell 
membrane-ion channels (344), G-protein-coupled receptors (345), and tyrosine kinases - 
many of these are related to membrane/cytosolic ER or GPR30. 
Activation of various protein-kinase cascades had been associated with the 
nongenomic actions of the steroid hormones. Hormone-induced non-genomic pathways 
in various cells include the mobilization of intracellular calcium (346), stimulation of 
adenylate cyclase activity and cAMP production (347,348). E2 activates MAPK 
signaling in several cell types, including breast cancer (349), endothelial (350), bone 
(351), and neuroblastoma (345) cells. E2 also activates the phosphatidylinositol-3-kinase 
(PI3-K) signaling pathway in endothelial (350), breast cancer (352), and liver (353) cells. 
ER-activated nongenomic pathways modify ER and its coactivators by phosphorylation, 
resulting in an altered topology of these proteins that can result in ligand-independent 
activation of the ER or differential responsiveness to selective ER modulators (Figure 
1-11) (354). Specific binding sites for estrogen at the outer surface of isolated 
endometrial cells were first reported during the 1970s (355). Membrane localization of 
ERα has been reported by several groups (356,357) and a serine in the E domain of ERα 
is required for the localization and function of membrane ERα (358). Mutation of S522 
to alanine (S522A) results in a form of ERα that is poorly localized in the membrane 
after expression in CHO cells and membrane ER decrease by 62% compared to cells 
transfected with wild-type ERα. In addition, there is decreased co-localization of ERα 
S522A with caveolin-1, a protein that facilitates ER transport to the membrane. 
Furthermore, expression ERα S522A in MCF-7 significantly decreased membrane ERα 
since this ERα mutant binds and sequesters endogenous membrane ERα (358). In 
contrast, S522A did not affect nuclear localization or function of endogenous ERα.  
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1.5.3 Regulation of estrogen receptor activity 
Cellular responses to E2 are highly controlled, involving regulation of the ERα 
levels through transcriptional, posttranscriptional, and posttranslational mechanisms 
(360). Binding of E2 to ERα induced proteasome-dependent degradation of the receptor 
and the half-life of bound ERα protein decreased from around 5 days to 3–4 h (361). ER 
activity is also regulated through the posttranslational modification and interactions with 
different coregulators which mediate transcriptional activation or repression by multiple 
mechanisms. Interactions of ERα with coregulators results in recruitment of the 
transcriptional machinery to the promoter by remodeling chromatin, or through 
activation of coregulatory protein dependent enzymatic activities, including histone 
acetyltransferase, deacetylase, ATPase, protease, kinase, ubiquitin ligase, and histone 
methyl transferaseactivities (219,220,224). The activity of the ER can involve 
ligand-independent or non-genomic effects.  
 
1.5.3.1 Phosphorylation of ERα 
The ligand-independent activity of the ER is a result of kinase-dependent 
phosphorylation of primarily serine residues in the AF1 domain of ERα. E2, 4-OHT and 
ICI 164,384 induce ERα phosphorylation at S118 in ERα-positive MCF-7 cells and both 
E2 and phorbol ester (TPA) induced S118 phosphorylation of ERα in COS-1 cells 
transfected with ERα (362). Treatment of SK-Br-3 cells with EGF also induced 
MAPK-dependent phosphorylation of S118 and that S118 is required for epidermal 
growth factor (EGF) activation of the ER via MAP kinase (363) . In response to E2, 
S167 is another phosphorylation site in MCF-7 cells transfected with recombinant ER 
and phosphorylation was casein kinase II-dependent (364). PI3-K-dependent 
phosphorylation of S167 has also been observed (365) and phosphorylation of S104 and 
S106 is mediated by the cyclinA-CDK2 complex in U-2 OS human osteosarcoma cells 
(366). S236 in the DNA binding domain, is phosphorylated by protein kinase A and 
phosphorylation of this site plays a role in ERα dimerization (367). 
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In general, phosphorylation of Ser residues in the AF1 domain influences the 
recruitment of coactivators, resulting in enhanced ER-mediated transcription (368,369). 
The importance of Ser-118 phosphorylation has been studied by a number of 
different groups and there are discrepancies in the literature concerning the 
transcriptional activity of the mutant ERα, in which Ser-118 has been mutated to 
Ala(ERα S118A), compared to wild type ERα. In cell lines of either fibroblast or 
epithelial origin ERα S118 exhibited decreased E2-dependent transactivation compared 
to wild type ERα (363,370,371), whereas mutation of Ser-118 to an acidic residue 
enhanced the transcriptional response (370). In contrast, Le Goff et al. (372) found that 
ERα S118 and ERα exhibit similar activies in mediating hormone-induced gene 
expression, however, an ERα mutant in which Ser-104, Ser-106 and Ser-118 were all 
mutated to Ala exhibited decreased activity.  
Tyrosine phosphorylation of ERα has been detected at Y537 in MCF-7 cells (373) 
and p60c-src and p56lck mediate this phosphorylation E2 does not induce. Y537 
phosphorylation indicating that it is associated with basal activity of ERα. The AF2 
region plays an important role in mediating transcriptional activation by cAMP (374), 
however, mutagenesis of putative PKA phosphorylation sites did not prevent activation 
of ERα-mediated transcription by cAMP (375). Thus PKA may regulate coactivator 
function rather than the phosphorylation of ERα.  
 
1.5.3.2 Ubiquitination of ERα 
Treatment of cultured breast epithelial cells with E2 significantly decreases levels 
of ERα in cultured breast epithelial cells (376) and this is due to a activation of 
ubiquitin-proteasome pathway (224,377-379). In addition to E2, the pure ER antagonist 
ICI 182,780 inhibits ERα-dependent activity by inducing rapid downregulation of the 
receptor (380) and the selective ER modulator (SERM) GW5638 also induces ERα 
degradation (379). 
The Ub-proteasome system consists of the 26S proteasome complex which is 
composed of a 20S catalytic core for protein proteolysis and two ATPase-containing 19S 
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regulatory particles that recognize polyubiquitin- tagged substrates (381). Like many 
other transcription factors, stimulation of ERα transcriptional activation appears to be 
associated with receptor ubiquitination and proteasomal degradation (379,382). Several 
proteins possessing Ub ligase activity (e.g. E6AP, p300, BRCA1, and MDM2), as well 
as SUG1, a component of the 19S proteasome, associate with ERα and modulate 
receptor signaling (224,383-386). These observations suggest that proteasome- mediated 
receptor degradation is important for ER function. 
Blocking ERα turnover by a proteasome- specific inhibitor such as MG132, 
decreased expression of an ERα-responsive luciferase reporter, suggesting that 
proteasomal degradation of ERα is required for its transactivation function (287,387). 
However, it has recently been shown that MG132, and other proteasome inhibitors 
decrease production of a functional firefly luciferase enzyme (388), and this may also 
contribute to decreased activity of ERα-responsive constructs expressing luciferase. This 
complements other reports shown that proteasomal degradation is not essential for ERα 
transcriptional activity but functions to limit E2-induced transcriptional output (389).In 
the absence of estrogen, ERα is also ubiquitinated and degraded via an ubiquitin- 
proteasome pathway (390). However, estrogen-dependent ubiquitination of the receptor 
required the E domain within the ERα LBD, whereas this domain was not required for 
ubiquitination of the unliganded receptor. Tateishi et al (390) reported that ERα is 
regulated by two independent ubiquitin-proteasome pathways, which are switched by 
ligand binding to ERα. One pathway is necessary for the transactivation of the receptor 
and the other is involved in quality control of the receptor. 
 
1.6 Research objectives 
1.6.1 Objective 1 
Cdc25A phosphatase is expressed in all eukaryotes and, mammals and the Cdc25A, 
Cdc25B, and Cdc25c forms are encoded by distinct genes (391-393). Cdc25 
phosphatases play a critical role in cell cycle progression by regulating phosphorylation 
of cyclin-dependent kinase (cdk)/cyclin complexes at specific phases of the cell cycle 
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(141,148,391-400). Cdc25 phosphatases are dual-specific protein tyrosine phosphatases 
and catalyze rapid dephosphorylation of cyclin/cdk complexes on threonine14 and 
tyrosine15 (144,148,392,401). Regulation of G1 to S-phase progression in the cell cycle 
is primarily by Cdc25A associated with dephosphorylation and activation of the 
cdk2/cyclin A and cdk2/cyclin E complexes (402-405). Cdc25 phosphatases are 
overexpressed in a wide variety of tumors, and overexpression of Cdc25A and Cdc25B 
in cooperation with ras immortalizes mouse embryo fibroblasts (402-405). 
Cdc25A plays an important role in cell cycle progression and in malignant 
transformation in breast cancer and this protein is also over-expressed in human 
mammary tumors (406). Mitogen activation of cells results in increased expression of 
Cdc25A in G1 for subsequent activation of cdk2 and progression of cells through 
S-phase. E2 induces Cdc25A protein and mRNA levels in MCF-7 breast cancer cells 
(407,408). Foster et al. (408) studied interactions of Cdc25A with multiple G1 to 
S-phase cell cycle regulators in breast cancer cells and showed that cdk2 activity is 
required for activation of Cdc25A which is a critical protein in hormone-dependent 
proliferation of MCF-7 breast cancer cells. The first objective of this study was to 
investigate the molecular mechanism of E2-dependent activation of Cdc25A in ZR75 
breast cancer cells and identify which cis-acting elements and trans-acting factors in the 
Cdc25A promoter are required for E2-induced transactivation.   
 
1.6.2 Objective 2 
The PIAS family, originally identified as cytokine-induced inhibitors of STATs, 
consists of five structurally related mammalian proteins, PIAS1/GBP, PIAS3, PIASxα, 
PIASxβ, and PIASy. These proteins contain several conserved domains. The conserved 
N-terminal region of PIAS proteins contains several well characterized domains. The 
SAF-A/B, Acinus, PIAS (SAP) domain binds A/T-rich DNA and may be involved in 
targeting PIAS proteins to the nuclear scaffold (409). The SAP domain encompasses an 
LXXLL motif that is required for transcriptional repression (410). The RING-finger-like 
zinc-binding domain (RLD) mediates the SUMO-E3-ligase activity of PIAS proteins and 
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binds directly to Ubc9, the SUMO E2 enzyme (411). Most PIAS proteins also contain a 
PINIT motif, which plays a role in nuclear retention (411). The C termini of PIAS 
proteins are more diverse; however, all contain an acidic domain preceded by several 
serines (Ser/Ac). Within the acidic domain, a SUMO-1 Interaction Motif (SIM) exists 
(412). Also, a serine- and threonine-rich region (S/T) is present in the C termini of all 
PIAS proteins except for PIASγ. The function of this region is unknown.  
Other than being the negative regulators of cytokine signaling which inhibit the 
activity of STAT-transcription factors, PIAS proteins also function as transcriptional 
coregulators in various important cellular pathways. It has been reported that PIAS 
proteins modulate the ligand-dependent transactivation potential of the steroid hormone 
receptors (413). Depending on the receptor type, the cell lines and promoters used in 
transactivation assays, both activating and repressing effects on transcription were 
observed upon expression of a distinct PIAS family member, indicating that PIAS 
proteins play a cell context-dependent dual role as activators or repressors in steroid 
hormone signaling. Jimenez-Lara and co-workers (412) identified PIAS3 as a binding 
partner of GRIP1/TIF2. PIAS3 also interacts with TBP in a yeast two-hybrid screening 
assay (414). The localization of SUMO E2-ligase activity and TBP-binding activity to 
opposite ends of PIAS proteins suggests that these proteins might “dock” at TBP and 
sumoylate transcription factors at the promoter. 
An important mechanism for controlling the activity of transcriptional regulators 
appears to be their targeting to specific subnuclear sites. Increasing evidence indicates 
that the PIAS/SUMO system is involved in this process. Sapetschnig and co-workers 
(415) demonstrated that the repressor function of Sp3 resides in a small inhibitory 
domain that serves as an interface for binding to PIAS1 and harbors a SUMO attachment 
site . PIAS1 promotes the modification of Sp3 by SUMO, which further enhances the 
interaction of PIAS1 and Sp3. SUMO triggers the targeting of Sp3 to PML 
(Promyelocytic leukemia) nuclear bodies, acting as a major regulatory switch that 
converts Sp3 from a transcriptional activator to a repressor (415). 
The SUMO E3-ligase activity of PIAS proteins often results in sumoylation of 
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transcription factors which interact with PIAS proteins. Unlike the ubiquitination process, 
the E3 ligase is dispensable and plays a role by enhancing sumoylation of target proteins. 
In addition to sumoylation, PIAS proteins can have SUMO-independent effects. Lee and 
co-workers (416) showed that PIAS1 binding to Msx1 homeodomain protein is required 
for localizing Msx1 to the nuclear periphery and the SUMO sites in Msx1 are not 
required for this localization to occur. It was concluded that the localization of Msx1 to 
the nuclear periphery by PIAS1 binding is the important determinant for the repressive 
activity of Msx1. In contrast, the SUMO ligase activity of PIAS1 toward Msx1 is 
apparently not important for this process.  
Several studies have reported that SUMO-1 regulates the hormone-induced 
transactivation of some nuclear receptors. This regulation can be achieved by 
sumoylation of either receptors or coregulators, indicating that sumoylation can be an 
integral part of nuclear hormone receptor function. In particular, a recent report showed 
that ERα-mediated transcription is stimulated by SUMO-1 expression. It has been 
speculated that enhanced ERα-dependent  transcription by SUMO-1 may be due to 
sumoylation of the coactivator steroid receptor coactivator 1 (SRC-1) (417). 
Over-expression of PIAS3 can induce apoptosis in prostate cancer cell lines both in 
vitro and in vivo. Wang and co-workers (418) checked 100 human cancer samples 
including 13 breast cancer samples and showed increased nuclear staining of PIAS3 in 
approximately 97% of these sample compared to staining in the corresponding normal 
tissues. The second objective of this study was to investigate coactivation of ER by 
PIAS3 and also identify the functional domains of PIAS3 required for this enhanced 
activity, and for interactions with ERα. 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Chemicals, cells, and antibodies 
MCF-7 and ZR-75 breast cancer cells, HeLa, and COS-7 cells were obtained from 
the American Type Culture Collection (ATCC, Manassas, VA). MCF-7 cells were 
routinely maintained in DME/F12 medium with phenol red and supplemented with 5% 
fetal bovine serum (FBS) plus antibiotic antimycotic solution (Sigma, St. Louis, MO). 
COS-7 and HeLa cells were maintained in Dulbecco’s Modified Eagle Media (DMEM) 
(Gibco Invitrogen Corporation, Carlsbad, CA) medium with phenol red and 
supplemented with 5% FBS plus antibiotic antimycotic solution. ZR-75 cells were 
maintained in RPMI 1640 media (Sigma) supplemented with 2.2 g/L sodium bicarbonate, 
2.38 g/L HEPES, 0.11 g/L sodium pyruvate, 4.5 g/L glucose, and 7.5 % FBS plus 
antibiotic antimycotic solution. Cells were cultured and grown in an air-carbon dioxide 
(95:5) atmosphere at 37°C. For transient transfection studies, cells were grown for 1 day 
in DME/F12 medium without phenol red and 2.5% FBS stripped with dextran-coated 
charcoal. ICI 182780 was kindly provided by Dr. Alan Wakeling (AstraZenaca 
Pharmaceuticals, Macclesfield, UK). The kinase inhibitors H8 and SQ22536 were 
purchased from Cal-Biochem (La Jolla, CA). Cdc25A, PIAS3, ERα and Sp1 antibodies 
were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Myc-tag 
antibodies was obtained from Cell Signaling Technology (Beverly, MA). GAPDH 
antibody was obtained from Ambion, Inc. (Austin, TX). SYBR® Green PCR master mix 
and dNTP mix were obtained from Applied Biosystems (Foster City, CA). 
SuperScript™ III reverse transcriptase and oligo (dT)20 were obtained from Invitrogen 
(Carlsbad, CA). All other chemicals and biochemicals were the highest quality available 
from commercial sources. 
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2.2 Cloning and plasmids  
2.2.1 Cdc25A experiment 
The pcdc25A-1 was kindly provided by Joan Massagué (Cell Biology Program and 
Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, 
NY). Wild-type human estrogen receptor α (hER ) expression plasmid was provided by 
Dr. Ming-Jer Tsai (Baylor College of Medicine, Houston, TX). The ER deletion mutant 
ER 11C was provided by Professor Pierre Chambon (Institut de Genitique et de 
Biologie Moleculaire et Cellulaire, Illkirch, France). The DP1 mutants DP1 Δ103-126 
and DP1 Δ 127-411 bind E2F-1 but not DNA (419) and were kindly provided by Dr. 
Harlow (Harvard Medical School, Boston, MA). E132 is an E2F-1 mutant that also does 
not bind DNA (420) and was provided by Dr. Nevins (Duke University, Durham, NC). 
The dominant negative Sp1 construct (pEBG-Sp) expresses the DNA binding domain 
(amino acids 592-758) but not the activation domain of Sp1 (421) and was provided by 
Dr. Thiel (University of Cologne, Cologne, Germany). The dominant negative NF-YA 
construct (Δ 4YA13m29) encodes for a dominant negative NF-YA (421) and was 
provided by Dr. Mantovani (University of Milan, Milan, Italy Cdc25A promoter variants, 
pcdc25A-2 (-209/+129), pcdc25A-3 (-184/+129), pcdc25A-4 (-31/+129), pcdc25A-5 
(-151/-12), and pcdc25A-6 (-184/-65), were made by PCR amplification using 
pcdc25A-1 as template (Table 2-1). The PCR products were purified and ligated into 
pGL2 basic vector (Promega Corp.) between XhoI and HindIII polylinker sites. 
Site-directed mutagenesis was performed using the two-step overlap extension PCR 
method (Table 2-1). PCR primers were synthesized by Genosys/Sigma (The Woodlands, 
TX). All ligation products were transformed into competent Escherichia coli cells. 
Plasmids were isolated, and clones were confirmed by DNA sequencing (Gene 
Technologies Laboratory, Texas A&M University). 
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Table 2-1 Summary of primers for generating variant constructs of pcdc25A 
 Primersa Template 
pcdc25A-2 Forward: 5 -GTA TCT CGA GCT CTT CTG CTC TGG GCT-3  pcdc25A-1 
Reverse: 5 -CTT TAT GTT TTT GGC GTC TTC CA-3   
pcdc25A-3 Forward: 5 -GTA GCT CGA GTT CTG AFGA GCC GAT GAC 
CTG-3  
pcdc25A-1 
Reverse: 5 -CTT TAT GTT TTT GGC GTC TTC CA-3   
pcdc25A-4 Forward: 5 -GTA TCT CGA GAG CAG CTG GCC CCA CTG A-3  pcdc25A-1 
 Reverse: 5 -CTT TAT GTT TTT GGC GTC TTC CA-3   
pcdc25A-5 Forward: 5 -GCT CGA GAG CCG CTT TCT TCT TCC CCT CT-3  pcdc25A-1 
 Reverse: 5 -GAT AAG CTT CTC AGT GGG GCC AGC TGC T-3   
pcdc25A-6 Forward: 5 -GTA GCT CGA GTT CTG AFGA GCC GAT GAC 
CTGm3  
pcdc25A-1 
 Reverse: 5 -CCG CAA GCT TGA ATC CAC CAA TCA GTA AGC-3  
pcdc25A-1m1 5 -CGC CCG GCT GGG TTC GAG GTA-3  pcdc25A-1 
pcdc25A-1m2 5 -CTG CTC TGG GCT CTT CCC CCT TC-3  pcdc25A-1 
pcdc25A-1m3 5 -CTA GGA AAG GGG TTC GGG GCA G-3  pcdc25A-1 
pcdc25A-1m12 5 -CTG CTC TGG GCT CTT CCC CCT TC-3  pcdc25A-1m1 
pcdc25A-1m13 5 -CTA GGA AAG GGG TTC GGG GCA G-3  pcdc25A-1m2 
pcdc25A-1m23 5 -CTA GGA AAG GGG TTC GGG GCA G-3  pcdc25A-1m2 
pcdc25A-1m123 5 -CGC CCG GCT GGG TTC GAG GTA-3  pcdc25A-1m23 
pcdc25A-5m1 5 -CTA GGA AAG GGG TTC GGG GCA G-3  pcdc25A-5 
pcdc25A-5m2 5 -GAT TCC GTA AGG CGC CAA C-3  pcdc25A-5 
pcdc25A-5m3 5 -GAT TCC GTA AGG CGC CAA C-3  pcdc25A-5m1 
pcdc25A-5m4 5 -GTT GCT TAC TGA TAC GTG GAT TCC-3  pcdc25A-5 
 5 -CCT CTC ATT GTA CCA GCC TAG CTG-3   
 a Mutations are underlined and substituted bases are indicated in bold. 
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2.2.2 PIAS3 experiment 
TAF1-ERα and Null-ERα expression plasmids were provided by Dr. D. McDonnell 
(Duke University, Durham, NC). The human ER deletion construct 19c-ERα was 
provided by Dr. Pierre Chambon (Institut de Genetique et de Biologie Moleculaire et 
Cellulaire, Illkirch, France). The pERE3 reporter containing three consensus ERE sites linked 
to a luciferase gene was created by cloning an oligonucleotide with three ERE elements into 
BamHI-HindIII cut pXP-2 plasmid (408). The wild-type mouse PIAS3 expression vector 
was originally provided by Dr. Olli A. Jänne (Institute of Biomedicine University of 
Helsinki FIN-00014 Helsinki, Finland) and used as the PCR template for further cloning. 
The PIAS3 expression plasmids used in the transfection assay including WT and 
deletion mutants (PAIS3#2~6) were generated by PCR amplification and ligated into 
pCDNA3.1/His/Myc vector (Invitrogen). For mammalian two-hybrid assay, the expression 
plasmids of GAL4-DBD-ERα chimeras including pM-ER, pM-ER (A/B) and pM-ER (C/F) were 
made by Dr. B. Saville in this lab as previously described (422). The VP-16-PIAS3 chimera 
expression plasmid was generated by PCR amplification and ligted into pACT vector 
(Promega). Oligonucleotide primers used for in this study are listed in Table 2-2.  
 66
Table 2-2 Summary of primers used for cloning the PIAS3 constructs 
Clones Primers 
WT (PIAS3#1) 
F, 5’-GTA CTG GTC GAC TCT AGA GTG ATG AGT TTC CGA GTG TCT-3’ 
R, 5'-GTA CTG GCG GCC GCG TCC AAG GAA ATG ACG TCT-3' 
PIAS3#2 
F, 5’-GTA CTG GTC GAC TCT AGA GTG ATG AGT TTC CGA GTG TCT-3’ 
R, 5'-GTA CTA CTG GCG GCC GCA GCC ACT TCA CTG TCG GGG T-3' 
PIAS3#3 
F, 5'-GTA CTG GTC GAC TCT AGA ACT ACA AGT CTC CGG GTG T-3' 
R, 5'-GTA CTG GCG GCC GCG TCC AAG GAA ATG ACG TCT-3' 
PIAS3#4 
F, 5'-GTA CTG GTC GAC TCT AGA ACT ACA AGT CTC CGG GTG T-3' 
R, 5’-GTA CTG GCG GCC GCT CCC TCC TGG ACT GCG CTG TAC T-3’ 
PIAS3#5 
F, 5’-GTA CTG GTC GAC TCT AGA ATT CAG CCA GAG AGT AAG AA-3’ 
R, 5'-GTA CTG GCG GCC GCG TCC AAG GAA ATG ACG TCT-3' 
PIAS3#6 
F’ 5’-GTA CTG GTC GAC TCT AGA TTG CCC CCC ACC AAG AA-3’ 
R, 5'-GTA CTG GCG GCC GCG TCC AAG GAA ATG ACG TCT-3' 
PIAS3#1 Δ393-416 
F, 5’-AGC GCA GTC CAG GAG GGA GTC GAC CCC AC-3’ 
R, 5’-GCA GTG CTT CTT GGT GGG GTC GAC TCC C-3’ 
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2.3 Transient transfection and luciferase assay  
2.3.1 Cdc25A experiment 
For transfection experiments, 2255,000 ZR-75 cells were initially seeded in 12-well 
plates. Twenty-four h after seeding, ZR-75 cells were transfected by the calcium 
phosphate method with Cdc25A promoter-luciferase reporter constructs, ERα 
expression vector and pCDNA3/His/lacZ (Invitrogen) that was used as a standard 
reference control plasmid for determining transfection efficiencies. After 5 h, cells were 
shocked with 25% glycerol and washed with PBS. Fresh DME/F12 without phenol red 
and charcoal-stripped FBS containing DMSO or 10 nM E2 in DMSO were added to the 
cells and incubated for 24 h.  
 
2.3.2 PIAS3 experiment 
MCF-7, HeLa, COS-7 and ZR-75 cells were seeded in DME/F-12 medium without 
phenol red containing 2.5 % dextran/charcoal-stripped FBS. After 24 h cells were 
transfected with GeneJuice transfection reagent (Novagen, Madison, WI) according to 
manufacture's recommendation. Five hours after transfection, cells were replaced with 
fresh DME/F12 without phenol red and treated with DMSO or 10 nM E2 for 36 h. 
For transient transfection of siRNA, MCF-7 cells were seeded in DME/F-12 
medium without phenol red containing 2.5 % dextran/charcoal-stripped FBS. At the 
same time, cells were transfected with siRNA of PIAS3 (5nM, final concentration) using 
siPORTTM NeoFxTM transfection reagent (Ambion). 
Cells from each experiment were then harvested in 100 μl of 1X Reporter lysis 
buffer (Promega). Luciferase assays were performed on 30 μl of the cell extract using 
the Luciferase assay system (Promega). Light emission was detected on a Lumicount 
luminometer (Packard, Meriden, CT). β-Galactosidase assays were performed on 20 μl 
of cell extract using the luminescent Galacton-Plus assay kit (Tropix, Bedford, MA). The 
luciferase activity observed in each treatment group was normalized to β-gal activity 
obtained from the same sample to correct for transfection efficiencies. Data are 
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expressed as fold induction (by E2 or other chemicals) compared to the solvent (DMSO) 
control.  
 
2.4 Western blot assay   
Cells were seeded into 60 mm tissue culture plates in DME/F-12 medium without 
phenol red containing 2.5% charcoal-stripped FBS. After 24 h, cells were treated with 10 
nM E2 and harvested at designated time points and lysed in ice-cold lysis buffer (50 mM 
HEPES [pH 7.5], 500 mM NaCl, 10% [vol/vol] glycerol, 1% Triton X-100, 1.5 mM 
MgCl2, 1 mM EGTA) supplemented with protease inhibitor cocktail (Sigma). Equal 
amounts of protein from each treatment group were boiled in 1x Laemmli buffer (50 mM 
Tris-HCl, 2% sodium dodecyl sulfate [SDS], 0.1% bromphenol blue, 175 mM 
β-mercaptoethenol), separated by SDS-10% polyacrylamide gel electrophoresis 
(SDS-PAGE), and transferred to polyvinylidene difluoride (PVDF) membrane. 
Membranes were blocked with Blotto (5% milk, Tris-buffered saline [10 mM Tris-HCl, 
pH 8.0, 150 mM NaCl], and 0.05% Tween 20) and probed with primary antibodies. 
Following incubation with peroxidase-conjugated secondary antibody, immunoglobulins 
were visualized using the ECL detection system (Perkin Elmer Foster City, CA). 
 
2.5 Nuclear extract preparation and EMSA 
Cells were seeded in 100 mm tissue culture plates using DME/F12 without phenol 
red, supplemented with 2.5% charcoal-stripped FBS. After 24 h, cells were treated for 1 
h with DMSO or 10 nM E2. Nuclear extracts were obtained using the NE-PER nuclear 
and cytoplasmic extraction kit (Pierce) according to the manufacturer's instructions. 
Nuclear extracts obtained from different treatment groups were incubated for 20 min in 
HEGD buffer with poly-(dI-dC), unlabeled oligonucleotides or antibodies for supershift 
assays. The mixture was then incubated for additional 20 min after addition of 
32P-labeled oligonucleotide. Reaction mixtures were separated on 5% polyacrylamide 
gels (acrylamide:bis-acrylamide 30:0.8) at 140 V in 1X TBE (0.09 M Tris-HCl, 0.09 M 
boric acid and 2 mM EDTA, pH 8.3). Gels were dried and protein-DNA complexes were 
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visualized using a Storm 860 instrument (Amersham Biosciences, Piscataway, NJ). 
Oligonucleotides used for EMSA in this study are summarized as follows (mutations are 
underlined and substituted bases are indicated in bold). 
Sp1  5 -ATT CGA TCG GGG CGG GGC GAG C-3  
Cdc25A 5 -ACT AGG AAA GGG GGG CGG GGC AGC A-3  
Cdc25A mutant -CTA GGA AAG GGG TTC GGG GCA G-3  
 
2.6 RT-PCR assay  
Total RNA was extracted using Nucleospin RNA purification kit (BD Biosciences 
Clontech), following the manufacturer’s instructions. An aliquot of 750 ng RNA was 
used as the template for cDNA synthesis by incubating with oligo-d(T) primer and 
multiscribe reverse transcriptase (Perkin Elmer) at 48°C for 40 min. PCR amplification 
was performed with Taq PCR Master Mix (Promega, Madison, WI). The following 
conditions were used for the PCR assays: one cycle of 2 min at 95°C; 34 cycles of 30 sec 
at 95°C; 30 sec at 57.5°C; 1 min at 72°C; one cycle of 5 min at 72°C. PCR products 
were analyzed by electrophoresis on 1.5% agarose gels containing ethidium bromide. 
Oligonucleotide primers used for PCR in this study include the following: 
 
Cdc25A 
F’ 5’-AGC CCC AAA GAG TCA ACT AAT CCA GA-3’ 
R’ 5’-CCG GTA GCT AGG GGG CTC ACA-3’ 
GSα 
F’ 5’-GTG ATC AAG CAG GCT GAC TAT-3’ 
R’ 5’-GCT GCT GGC CAC CAC GAA GAT GAT-3’ 
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2.7 Coimmunoprecipitation assay 
COS-7 cells were seeded into 60 mm tissue culture plates in phenol red-free 
DME/F-12 medium containing 2.5% charcoal-stripped FBS. After 24 h., transient 
transfections were performed by using GeneJuice transfection reagent (Novagen) 
according to the manufacturer's protocol. After 4-6 h., transfected cells were treated with 
10 nM E2 for 24h. Cells were harvested and lysed by using 1 ml of RIPA buffer (1x PBS, 
1% Nonidet P-40 or Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml 
PMSF in isopropanol, aprotinin, 100 mM sodium orthovanadate), and cellular debris 
was removed by centrifugation at 10,000xg for 10 min at 4ºC. The supernatant was 
transferred to a fresh microcentrifuge tube and precleared by adding 20 µl of protein 
A-agarose conjugate slurry (Sigma) and incubated at 4ºC for 1h. After centrifugation for 
1 min, the supernatant was transferred to another new microcentrifuge tube, and 2.5 µg 
of rabbit polyclonal anti-ERα antibody (Santa Cruz) was added and incubated at 4 ºC for 
1 hr. After incubation, 20 µl of protein A-agarose conjugate slurry (Sigma) was added 
and incubated at 4ºC for another 1 h. The immunoprecipitate was collected by 
centrifugation, gently washed with 500 µl RIPA buffer (3X), and resuspended and 
denatured in 50 µl of 2x Laemmli buffer. The immunoprecipitated sample was analyzed 
in a western blot assay.  
 
2.8 Chromatin immunoprecipitation assay (ChIP) 
ZR-75 cells (2 × 107 cells) were treated with DMSO (time 0) or 10 nM 17
-estradiol (E2) for varying times. Cells were then fixed with 1.5% formaldehyde, and the 
crosslinking reaction was stopped by addition of 0.125 M glycine. Nuclei were collected, 
and sonicated to desired length (500 1,000 bp) of chromatin. The chromatin was 
pre-cleared by addition of protein A-conjugated beads (Upstate), and incubation at 4°C 
for 1 h with gentle agitation. The pre-cleared chromatin was immunoprecipitated with 
antibodies (Santa Cruz Biotechnology) to Sp1, ER , NF-Y, and E2F1 at 4°C overnight, 
together with protein A-conjugated beads. The beads were then extensively washed, and 
protein-DNA crosslinks were reversed. PCR was performed with the purified DNA and 
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the following primers: (1) Cdc25A forward primers, 5 -CTT CTG AGA GCC GAT 
GAC CT-3 ; reverse primer, 5 -CAC CTC TTA CCC AGG CTG TC-3 ; amplifying a 
225 bp region of the human Cdc25A promoter from -186 to +39; (2) CNAP1 forward 
primers (Activemotif), 5 -ATG GTT GCC ACT GGG GAT CT-3 ; reverse primer, 5
-TGC CAA AGC CTA GGG GAA GA-3 ; amplifying a 174 bp region of the CNAP1 
exon; (3) glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward primers 
(Activemotif), 5 -TAC TAG CGG TTT TAC GGG CG-3 ; reverse primer, 5 -TCG AAC 
AGG AG GAG CAG AGA GCG A-3 ; amplifying a 167 bp region of human GAPDH 
promoter. PCR products were resolved on a 2% agarose gel. 
 
2.9 Real-time PCR. 
For experiments involving siRNA, pancreatic cancer cells were transfected as 
described previously. Total RNA was isolated using the RNeasy Protect Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s protocol. RNA was eluted with 
30 μL RNase-free water and stored at −80 °C. RNA was reverse transcribed using 
Superscript III reverse transcriptase (Invitrogen) according to the manufacturer’s 
protocol. PCR was carried out using SYBR Green PCR Master Mix from PE Applied 
Biosystems (Warrington, UK) on an ABI Prism 7700 Sequence Detection System (PE 
Applied Biosystems). The 20-μL final volume contained 0.5 μM of each primer and 
2 μL cDNA template. GAPDH was used as an exogenous control to compare the relative 
amount of target gene in different samples. The PCR profile was as follows: 1 cycle of 
95 °C for 10 min, then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. The comparative 
CT method was used for relative quantitation of samples. Primers (QuantiTect assays) 
were purchased from Qiagen (Valencia, CA). The following primers were used:  
 
pS2 (F): 5′- TTG GAG AAG GAA GCT GGA TGG -3′ 
pS2 (R): 5′- ACC ACA ATT CTG TCT TTC ACG G -3′ 
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2.10 Statistical analysis 
Statistical significance was determined by ANOVA and Student's t-test, and the 
levels of probability are noted. The results are expressed as means ± SD for at least three 
separate (replicate) experiments for each treatment.
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CHAPTER III 
RESULTS 
 
3.1 Cdc25A is activated by E2 in ZR-75 cells 
3.1.1 Deletion and mutational analysis of the Cdc25A gene promoter 
Previous studies show that E2 induced Cdc25A mRNA and protein levels in MCF-7 
cells and the antiestrogen ICI182780 inhibited the hormone-induced response (423,424). 
Results in Figure 3-1 show that E2 also induced Cdc25A mRNA levels in ZR-75 cells, 
and a two-fold or greater increase was observed from 6 to 24 h after treatment. The -460 
to +129 region of the Cdc25A promoter contains multiple GC-rich motifs, two CCAAT 
motifs, and two E2F-1 binding sites (Fig. 3-2A) (424). ZR-75 cells were transfected with 
pcdc25A-1 which contains the -460 to +129 promoter insert and E2 induced luciferase 
activity. The deletion constructs pcdc25A-2, pcdc25A-3, and pcdc25A-4 containing the 
-209 to +129, -184 to +129, and -31 to +129 region, respectively, of the Cdc25A 
promoter were also transfected into ZR-75 cells, and E2 induced activity in cells 
transfected with the former two constructs. The results show that basal activity was 
decreased approximately 40-50% after deletion of the upstream GC-rich site (#1), 
whereas deletion of GC-rich site #2 did not affect activity. Subsequent deletion of the 
-184 to -31 region of the promoter resulted in almost complete loss of basal and 
hormone-induced activity, suggesting that E2-responsiveness was associated with the 
GC-rich, CCAAT, and E2F-1 binding sites within this region of the Cdc25A promoter. 
pcdc25A-5 was also highly E2-responsive in transient transfection assays confirming that 
the 3  +129 to -11 region was not required for E2-induced transactivation. Thus, the -151 
to -12 region of the Cdc25A promoter was the minimal sequence required for 
E2-responsiveness, but this does not exclude hormone-responsiveness of other upstream 
(5 ) cis-elements. Results in Figure 3-2B show that E2 induces transactivation in cells 
transfected with pcdc25A-1 and pcdc25A-5, and the hormone-induced response was 
significantly inhibited by the antiestrogen ICI 182780. These data confirm the role of 
E2/ER in mediating activation of Cdc25A.  
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Figure 3-1 Hormone inducibility of Cdc25A in ZR-75 cells. Induction of mRNA 
levels. ZR-75 cells were treated with DMSO (solvent) or 10 nM E2 for different times, 
and mRNA levels were determined by RT-PCR analysis. 
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Figure 3-2 Deletion analysis of Cdc25A promoter-reporter (luciferase) constructs. 
(A)  ZR-75 cells were transfected with the various constructs, cells were treated with 
DMSO or 10 nM E2, and luciferase activity determined as described in the Materials 
and Methods. (B) Inhibition by ICI 182780. Cells were treated as described in (A); 
however, ICI 182780 and ICI 182780 plus E2 treatment groups were also added. 
Results in (A) and (B) are expressed as mean ± SE for at least three replicate 
determinations for each treatment group and significant (P < 0.05) induction by E2 (*) 
or inhibition by E2 plus ICI 182780 (**) are indicated.  
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Previous studies in the laboratory have characterized activation of E2-responsive 
genes through interactions of ER /Sp1 with GC-rich promoter sequences (420), and the 
Cdc25A promoter contains three consensus Sp1 binding sites. Results in Figure 3-3A 
illustrate that mutation of one or more of the three GC-rich motifs at -384, -191, and -39 
decreases hormone-responsiveness of several constructs compared to that observed in 
cells transfected with pcdc25A-1. These results suggest that hormone-dependent 
activation of ER /Sp1 plays a role in mediating induction of Cdc25A by E2, but other 
pathways also contribute to this response. Previous studies have demonstrated that ER
/Sp1-mediated transactivation, through interaction with GC-rich cis-elements, can also be 
observed for ER 11C/Sp1 in which the DNA binding domain of ER  has been deleted 
(335). Figure 3-3B compares hormone-induced transactivation in ZR-75 cells 
cotransfected with pcdc25A-1 plus wild-type human ER  or ER 11C, and the induction 
of luciferase activity by E2 in cells cotransfected with the ER  deletion constructs 
confirms that the ER /Sp1 pathway plays a role in hormonal regulation Cdc25A. Gel 
mobility shift assays comparing the binding of nuclear extracts from ZR-75 cells to 
32P-labeled consensus Sp1 and Cdc25A-Sp1 (-52 to -28) oligonucleotides show a similar 
pattern of protein-DNA interactions (Fig. 3-4). Radiolabeled GC-rich (Sp1) and Cdc25A 
oligonucleotides alone did not give retarded bands (lanes 1 and 8); incubation with 
nuclear extracts gave one major retarded band (lanes 2 and 9) which was supershifted 
with Sp1 antibody (lanes 3 and 10) and unaffected by non-specific IgG (lanes 4 and 11). 
Both retarded bands were decreased after competition with 100-fold excess unlabeled 
Sp1 (lanes 5 and 12) and Cdc25A (lanes 6 and 13) oligonucleotides but not by mutant 
Cdc25A oligonucleotide (lanes 7 and 14). The role of Sp1 in mediating hormone-induced 
luciferase activity in cells transfected with pcdc25A-5 was also confirmed by decreased 
inducibility after cotransfection with dominant negative Sp1 expression plasmid (Fig. 
3-5). Approximately 40% of hormone-induced transactivation was observed in replicate 
studies, thus confirming a role for ERα/Sp1 in mediating activation of Cdc25A. 
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Figure 3-3 Role of ER/Sp1 in mediating activation of Cdc25A. (A) Mutational analysis of 
GC-rich sites. ZR-75 cells were transfected with pcdc25A-1 or a series of mutant constructs, 
treated with DMSO or 10 nM E2, and luciferase activity determined as described in the Materials 
and Methods. (B) Inducibility by ER11C. Cells were treated as described in (A); however, both 
wild-type ER and ER11C were cotransfected. Results in (A) and (B) are expressed as mean ± SE 
for three replicate determinations for each treatment group. Significant (P < 0.05) induction by 
E2 (*) is indicated. 
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Figure 3-4 Gel mobility shift assay. Nuclear extracts from ZR-75 cells were incubated 
with 32P-labeled oligonucleotides and other antibodies/ oligonucleotides, and a gel 
mobility shift assay was carried out as described in the Materials and Methods. Sp1-DNA 
binding and antibody supershifted complexes are indicated by arrows. Lanes 1 and 8 
represent incubation of the free probe alone.  
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Figure 3-5 Effect of dominant negative Sp1 in ZR-75 cells. Cells were 
transfected with pcdc25A-5 (containing promoter region from -151 to -12), 
treated with DMSO or 10 nM E2, and cotransfected with various amount of 
dominant-negative Sp1 expression plasmid as described in Materials and Methods. 
dnSp1 (250~1000ng) resulted in significantly (**p < 0.05) decreased E2-induced 
luciferase activity.  
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Figure 3-6 Role of CCAAT sites in hormonal activation of Cdc25A. (A) Mutational 
analysis of -151 to -12 region of the Cdc25A promoter. ZR-75 cells were transfected 
with the various constructs, treated with DMSO or E2, and luciferase activity 
determined as described in the Materials and Methods. Results are mean ± SE for three 
replicate determinations for each treatment group, and significant induction by E2 (*)  
is indicated. 
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Mutation analysis of the -151 to -12 region of the promoter was also determined in 
ZR-75 cells transfected with pcdc25A-5 and four constructs containing mutations of the 
GC-rich (pcdc25A-5m1), E2F-1 (pcdc25A-5m2), GC-rich and E2F-1 (pcdc25A-5m3), 
and NFY (pcdc25A-5m4) motifs. E2 induced activity in cells transfected with wild-type 
and mutant constructs (Fig. 3-6); however, the fold-induction was lower in cells 
transfected with the mutant plasmids. These results demonstrate that multiple sites in the 
Cdc25A promoter region contribute to the E2-responsiveness of this gene.  
 
3.1.2 Role of NF-Y and E2F1 in activation of Cdc25A gene expression 
The role of NF-YA in mediating activation of Cdc25A by E2 was further 
investigated (Fig. 3-7) in cells transfected with constructs containing only the CCAAT 
sites (pcdc25A-6 and pcdc25A-5m3) and a dominant negative expression plasmid for 
NF-YA (Δ4YA13m29) (335,425). The results showed that dominant negative NF-YA 
significantly inhibited hormonal activation of both pcdc25A-6 and pcdc25A-5m3. 
Previous studies in this laboratory confirmed expression of NF-YA in ZR-75 cells and 
showed that hormonal activation of CCAAT motifs in the E2F-1 gene promoter were due 
to cAMP/PKA-dependent activation of NF-YA through non-genomic pathways (417,426). 
Results in Figure 3-8A show that the PKA inhibitor SQ22536 inhibited induction of 
luciferase activity by E2 in cells transfected with pcdc25A-5m3, and both H8 
(adenylcyclase inhibitor) and SQ22356 significantly inhibited hormonal activation of 
chimeric GAL4-NF-YA in ZR-75 cells transfected with expression plasmids for 
GAL4-NF-YA and a pGAL4-luc reporter plasmid (Fig. 3-8B). These results suggest that 
the CCAAT sites within the Cdc25A promoter that bind NF-Y proteins are activated 
through non-genomic pathways of estrogen action. However, in cells transfected with 
pcdc25A-1 and pcdc25A-5, E2-induced activity was inhibited only12-15% in cells 
cotreated with 100 µM SQ22536. 
The E2F1 binding site at -63 is another potential E2-responsive motif in the Cdc25A 
promoter since E2F1 is induced by E2 in MCF-7 and ZR-75 cells (427), and E2 also 
induces Rb protein phosphorylation which results in derepression of E2F1. E2 induces 
transactivation in ZR-75 cells transfected with pcdc25A-5, and cotransfection with 
dominant negative expression plasmids for the E2F1 binding partner DP1 (DPΔ103-126 
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and DRΔ127-411) or E2F1 (E132) (427) significantly decreased transactivation (Fig. 
3-9A). A second E2F1 motif at -3 in the Cdc25A promoter is present in pcdc25A-4 which 
exhibited low activity (Fig. 3-2A) but is hormone inducible (approximately 2.5-fold). 
Results in Figure 3-9B show that the fold-induction of luciferase activity by E2 in cells 
transfected with pcdc25A-4 was also significantly inhibited after cotransfection of the 
dominant negative DPΔ103-126, DPΔ127-411, and E132 expression plasmids. However, 
these plasmids also significantly altered basal activity in solvent (DMSO)-treated cells. 
ChIP assay with primers targeted to the proximal region of the Cdc25A promoter (Fig. 
3-10A) confirmed that E2F1 and NF-YA were constitutively bound to the promoter and 
ER  binding is increased after treatment with E2. This is consistent with association of 
ER  which interacts with promoter bound Sp1. Results obtained using 
immunoprecipitation with TFIIB antibodies show that TFIIB binds to the GAPDH gene 
promoter but not exon 1 of CNAP1 as previously described (428), and this serves as a 
positive control for the ChIP assay. These results demonstrate that hormone-dependent 
induction of Cdc25A gene expression in ZR-75 cells requires activation of both genomic 
and non-genomic pathways of estrogen action. The multiple E2-responsive cis-elements 
identified in this study demonstrate the complexity of hormonal regulation of Cdc25A, 
and it is possible that other promoter regions and interactions between DNA-bound 
transcription factors may also be important. 
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Figure 3-7 Effects of dominant negative 4YA13m29 expression. Cells were transfected 
with the various constructs, treated with DMSO or E2, and luciferase activity determined 
as described in the Materials and Methods and the effects of 4YA13m29 (dominant 
negative NF-YA) expression were also determined. Results are expressed as mean ± SE 
for three replicate determinations for each treatment group, and significant induction by 
E2 (*) or inhibition of the induced response (**) are indicated. 
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Figure 3-8 Effect of kinase inhibitors. (A) Inhibition of transactivation by SQ22536. ZR-75 
cells were transfected with pcdc25A-5m3 as described in Material and Methods and treated 
with DMSO, E2, and E2 plus SQ22536. SQ22536 alone did not affect activity (data not 
shown). (B) Inhibition by H8 and SQ22536. ZR-75 cells were transfected with 
GAL4-luc/pM-NF-YA as described in Material and Methods and treated with DMSO, E2, E2 
plus H8, and E2 plus SQ22536. H8 plus SQ22536 alone did not affect activity (data not 
shown). Results in (A-B) are mean ± SE for three replicate determinations for each treatment 
group, and significant induction by E2 (*) or inhibition of the induced response (**) are 
indicated. 
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Figure 3-9 Role of E2F1 in hormone activation of Cdc25A. (A) pcdc25A-5 and (B)  
pcdc25A-4 were transfected in ZR-75 cells, treated with DMSO or 10 nM E2, cotransfected 
with dominant negative expression plasmids for E2F1 (E132) or DP1 (DP1103-126; 
DP1127-411), and luciferase activity determined as described in the Materials and Methods. 
Results are expressed as mean ± SE for three replicate determinations for each treatment group, 
and significant (P < 0.05) induction by E2 (*) and inhibition of this response (**) are indicated. 
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Figure 3-10 Transcription factor binding to the Cdc25A promoter. (A) ZR-75 cells were 
treated with DMSO (0 time) or 10 nM E2 for 30, 60, or 120 min, and the ChIP assay was 
carried out essentially as described in the Materials and Methods using antibodies to ERα, 
NF-YA, and E2F1, and non-specific IgG. Sp1 antibodies also showed consistent binding to 
the Cdc25A promoter over the 0-120 min time period (data not shown). The primers 
amplified a 225 bp sequence from -186 to +39 in the Cdc25A promoter. (B) TFIIB promoter 
interactions. (C) Control ChIP analysis showed that TFIIB specifically interacts with the 
GAPDH but not CNAP1 promoters as previously described (429). 
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3.2 PIAS3 coactivates ERα-mediated transactivation 
3.2.1 Coactivation of ERα by PIAS3 
Coactivation of ERα-dependent transactivation by PIAS3 was initially examined in 
HeLa cells cotransfected with ERα (414). Cells were transfected with pERE3, which 
contained three tandem EREs in a minimal TATA-luciferase construct, and ERα expression 
plasmid and cotransfection with PIAS3 expression plasmid induced a 2 to 3-fold 
enhancement (i.e coactivation) of E2-induced activity. In my study, coactivation of ERα by 
PIAS3 was investigated in MCF-7 cells since this will determine coactivation of ERα by 
PIAS3 in a breast cancer cell context and also facilitate studies on the role endogenous 
PIAS3 using RNA interference. The results in Figure 3-11 show that E2 induces a 2.3-fold 
incease in reporter gene activity in MCF-7 cells transfected with 2.5 ng ERα expression 
plasmid, and cotransfection with 25, 50 and 100 ng PIAS3 expression plasmid resulted in a 
3.1-, 4.8- and 24.3-fold enhancement of E2-induced luciferase activity.  
We also investigated the coactivation of ERα by endogenous PIAS3 in this cell line. 
Small inhibitory RNA of PIAS3 was transfected into MCF-7 cells and Western blot analysis 
of PIAS3 expression in MCF-7 showed that the endogenous PIAS3 protein was decreased 
after transfection of different amounts of iPIAS3. The effect of iPIAS3 on E2-induced pS2 
expression was determined by Real-Time PCR. MCF-7 cells were transfected with iNS 
(nontargeting siRNAs as a negative control) or iPIAS3 and treated with 10 nM E2. Six h after 
treatment with E2, the cells were harvested and purifed RNA was analysed by Real-Time 
PCR. The results show that when MCF-7 cells were transfected with iPIAS3, the E2 induced 
pS2 gene expression was significantly repressed (Fig. 3-12). These results indicate that 
PIAS3 is involved in the E2-dependent transactivation of pS2 gene and confirms a role for 
PIAS3 as an endogenous coactivator of ERα-dependent transactivation. 
 
3.2.2 Coactivation of ERα by PIAS3 deletion mutants 
Previous studies showed that PIAS3 can activate Smad-dependent transcription (264). It 
was also shown that PIAS3 activates Smad-dependent transactivation through its interaction 
with Smads and p300/CBP and the RING domain in PIAS3 is important for this coactivation 
and  interaction. Another group showed that in yeast two-hybrid screening assay, PIAS3 
interacts with TBP (TATA-binding protein) (325-335,430-432). Domains of PIAS3 required 
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for coactivation of ERα were investigated in MCF-7 and COS-7 cells cotransfected with ERα, 
pERE3, and wild-type or deletion mutants of PIAS3 (Fig. 3-13). Results show that multiple 
regions of PIAS3 are required for coactivation of ERα.  
The pattern of coactivation of ERα by PIAS3 deletion variants was similar but not 
identical in MCF-7 (Figure 3-13B) and COS-7 (Figure 3-13C) cells. Deletion of the 
C-terminal amino acids 274-584 (PIAS3#2, which lose the SAP domain with a LXXLL motif 
inside) resulted in loss of coactivation in both cell lines whereas the N-terminal deletion 
mutant (loss of amino acids 1-273) significantly coactivated ERα. Thus the LXXLL motif 
within the N-terminal SAP domain is not required for coactivation of ERα. PIAS3#4, which 
only contains the ring finger domain of PIAS3 coactivated ERα and PIAS3#5 containing the 
acidic and serine-rich regions in the N-terminal region (amino acids 393-584) also 
coactivated ERα in both cell lines. In contrast, PIAS3#6 which contains only the N-terminal 
serine-rich domain (amino acids 416-584) coactivate ERα in COS-7 but not MCF-7 cells. 
Thus PIAS3 coactivates ERα through multiple domains and exhibits some cell 
context-dependent effects. The role of the acidic region (393-416) of PIAS3 on coactivation 
of ERα was determined in ZR-75 breast cancer and HeLa cells (Figure 3-14) transfected with 
pERE3, ERα, wild-type PIAS3#1 or the deletion mutant PIAS3#1Δ393-416. Coactivation 
was observed in cells transfected with both PIAS3#1 and PIAS3#1Δ393-416 and although 
lower coactivation was observed in cells transfected with the latter expression plasmid, the 
results showed that this acidic region was not required for coactivation by PIAS3. 
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Figure 3-11 Enhancement of ERα-mediated transactivation by PIAS3. MCF-7 cells were 
transfected with pERE3, ERα, β-galactosidase and increasing amonts of pcDNA3.1-PIAS3 
expression plasmid. After transfection, cells were treated with DMSO or 10 nM E2 for 36 h. 
Luciferase activity was normalized with β-galactosidase activity and results are expressed as 
fold induction and compared to that observed for DMSO alone. Significant (p<0.05) 
induction by E2 (*) or coactivation by PIAS3 expression plasmids (**) is indicated.  
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Figure 3-12 Inhibition of PIAS3 expression abolishes the E2-dependent transactivation 
of the pS2 gene. (A) MCF-7 cells were tranfected with 0, 1, 2, 5, 10 nM (final concentration) 
of PIAS3 specific RNAi (iPIAS3). After 48 h transfection, cells were harvested and the total 
protein was extracted and analysed by Western blot using anti-PIAS3 antibody as described 
in the Material and Methods. (B) MCF-7 cells were transfected with 5 nM of non-specific 
(control) or PIAS3 specific RNAi. After 48 h cells were then treated with DMSO or E2 for 3 
h. Cells were harvested and the total RNA was extracted as described in the Material and 
Methods. Expression levels of pS2 mRNA was analyzed by Real-Time PCR. Results are 
expressed as fold-induction compared to that observed for DMSO alone. Significant (p<0.05) 
induction by E2 (*) or repression by inhibitory RNA (**) is indicated.    
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Figure 3-13 Multiple regions of PIAS3 are required for coactivation of ERα. (A) 
Truncation mutants of PIAS3. Coactivation of ERα by PIAS3 mutants in MCF-7 (B) and 
COS-7 (C) cells. MCF-7 or COS-7 cells were transfected with pERE3, ERα, β-galactocidase 
and various truncation mutants of PIAS3 in pCDNA3.1; wild-type PIAS3 expression plasmid 
was designated PIAS3#1. After transfection cells were treated with DMSO or 10 nM E2 for 
36 h. Results are expressed as fold induction of luciferase activity by E2 compared to that 
observed for DMSO alone. Significant (p<0.05) induction by E2 (*) and coactivation by 
PIAS3 expression plasmids (**) is indicated.  
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Figure 3-14 Role of the acidic region of PIAS3 for coactivation of ERα. ZR-75 (A) HeLa 
(B) cells were transfected with pERE3-luc, ERα, β-galactosidase and a truncation mutant 
(deletion aa 393-416) of PIAS3 (PIAS3#1 Δ393-416) in pCDNA3.1. After transfection cells 
were treated with DMSO or 10 nM E2 for 36 h. Results are expressed as the fold-induction 
of luciferase activity by E2 compared to that observed for DMSO alone. Significant (p<0.05) 
induction by E2 (*) or coactivation by PIAS3 expression plasmids (**) is indicated.  
 93
3.2.3 Coactivation of variant ERα by PIAS3 
ERα contains two major activation domains and we therefore investigated the 
coactivation activity of PIAS3 with three ERα variants and the results are summarized in 
Figure 3-15. The TAF1-ERα mutant contains three mutations in helix 12 (D538N, E542Q, 
and D545N) that block AF2-dependent interaction with coactivators and inactivates 
AF2-dependent transcriptional activation. 19C-ERα is an A/B domain deletion mutant which 
lacks AF1. The null-ERα contains mutations on AF2 and deletion of AF1 exhibits minimal 
hormone responsiveness (291,349,352,423,424). 
When HeLa cells were transfected with wild type ERα and pERE3, E2 induced a 43-fold 
increase in reporter gene activity and cotransfection with 100 ng PAIS3 expression plasmid 
significantly enhanced E2-induced luciferase activity and coactivated this response by 
530-fold. In cells transfected with 19C-ERα and pERE3, E2 induced a 3.4-fold increase in 
reporter gene activity and after cotransfection with 100 ng PAIS3 expression plasmid the 
E2-induced luciferase activity waas enhanced 3.3-fold (Fig. 3-15). E2 also induced luciferase 
activity in HeLa cells transfected with pERE3 and TAF1-ERα; cotransfection with PAIS3 also 
significantly enhanced E2-induced luciferase activity as shown in Figure 3-15. However, in 
cells cotransfected pERE3, PIASA3 and null-ERα, only minimal induction by E2 and 
coactivation by PIAS3 was observed (Fig.3-15). These data suggest that helix 12 on AF2 is 
not required for coactivation by PIAS3 when the AF1 domain of ERα is intact. However, 
when the AF1 domain of ERα is deleted (i.e. 19c-ERα), the intact AF2 function is required 
for coactivation by PIAS3, and mutations of helix 12 amino acids (i.e. null-ERα) resulted in 
loss of coactivation activity. Thus coactivation of ERα by PIAS3 is associated with multiple 
domains of ERα but is not dependent on the helix 12 region of ERα which interacts with 
LXXLL boxes present in many nuclear receptor coactivators including PIAS3. These results 
are consistent with the coactivation of ERα by PIAS3 deletion mutants in which indicate that 
the LXXLL box in PIAS3 is not essential for coactivation of ERα (Figure 3-13). 
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Figure 3-15 Coactivation of wild-type and mutant ERα by PIAS3. A. ERα mutants. The 
TAF1-ERα mutant contains three mutations on helix 12 of ERα (D542N, E546Q, and 
D549N). The null-ERα mutant is an A/B domain deletion mutant and also contains three 
mutations on helix 12. B. Transfection studies. HeLa cells were transfected with pERE3, 
various ERα mutants, β-galactosidase and PIAS3 expression plasmid. After transfection, cells 
were treated with DMSO or 10 nM E2 for 36 h. Luciferase activity was normalized with 
β-galactosidase activity and results are expressed as fold induction of luciferase activity by 
E2 and compared to that oberseved for DMSO alone. Significant (p<0.05) induction by E2 (*) 
or coactivation by PIAS3 expression plasmids (**) is indicated.  
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3.2.4 Interactions of ERα with PIAS3  
Interactions between PIAS3 and ERα were investigated in a mammalian two-hybrid 
assay. HeLa cells were transfected with expression vectors for the GAL4 DBD (pM) or the 
chimeras of DBD fused to ERα (pM-ERα) in the presence of the VP16 activation domain 
alone (VP16) or VP16 fused to the PIAS3 (VP16–PIAS3), and pGAL45 (five tandem 
GAL4 response elements linked to a luciferase reporter gene). The results (Fig.3-16 A) 
show that after transfection with pM-ERα and VP16-PIAS3, E2 significantly induced 
luciferase activity compared to the control luciferase values obtained in cells transfected 
with pM in the presence of pM-ERα and VP16. The results show that in the absence of 
ligand VP16-PIAS3 does not interact with pM-ER and transactivation is E2-dependent. 
These data confirm interactions of PIAS3 and ERα in a mammalian two-hybrid assay and 
this interaction is hormone-dependent.    
In this study, we have shown that wild-type and some variant PIAS3 constructs 
coactivate ERα-dependent transactivation. Therefore we also used the mammalian 
two-hybrid assay to investigate interactions of ERα with wild-type and variant PIAS3 in 
HeLa cells transfected with VP16-PIAS3 variants and pM-ERα. The results show that 
luciferase activity was significantly increased by E2 in cells transfected with pM-ERα and 
VP16-PIAS3 #1 and VP16-PIAS3#3 (Fig. 3-16B), but not with VP16-PIAS3#2 or 
VP16-PIAS3#4. Thus in the two-hybrid assay, interactions of ERα with PIAS3 may require 
RING finger domain of PIAS3.   
Interactions between ERα and PIAS3 were also investigated in coimmunoprecipitation 
studies. Myc-tagged full-length and deletion mutants of PIAS3 and ERα were cotransfected 
in COS-7 cells and treated with 10 nM E2. After 24 h, the cells were lysed and 
immunoprecipitated with an ERα antibody, and the presence of PAIS3 in the 
immunoprecipitate was determined by Western blotting with a monoclonal antibody against 
His-tag. The results (Fig 3-16C) show that wild type PIAS3 is coimmunoprecipitated by 
ERα antibodies whereas the acidic region - deleted PIAS3 (PIAS3 Δ393-416) was not 
coimmunoprecipitated with ERα. PIAS3 was not immunoprecipitated by ERα antibodies in 
cells transfected with either ERα or PIAS3 alone or using control rabbit IgG Ab for  
 96
 
 
A
       
VP16-PIAS3 #1
RLU
VP16
VP16-PIAS3
0    20    40   60    80  100  120  140 
pM-ERα
VP16pM-ERα
VP16-PIAS3 #1pM-ERα
VP16pM-ERα
HeLa
*
DMSO
E2
 
 
Figure 3-16 Interaction of various PIAS3 deletion mutants with ERα in a 
mammalian two-hybrid assay. A, B. Mammalian two-hybrid assays in HeLa cells. 
Hela cells were transfected with 50 ng of β-galactosidase, 125 ng of pGAL4-LUC, 150 
ng pVP16 or VP16-PIAS3 wild-type or deletion mutants, and 25 ng of pM-ERα. After 
transfection cells were treated with DMSO or 10 nM E2 for 36 h. Luciferase activity 
was normalized to β-galactosidase activity, and expressed as relative luciferase units 
(RLU). Significant (p<0.05) interactions (*) are indicated. C. Interactions of PIAS3 and 
ERα in a co-immunoprecipitation assay. Myc-tagged PAIS3 was transfected into 
COS-7 cells with or without ERα. After transfection, cells were treated with 10 nM E2 
for 24h, and cell extracts were immunoprecipitated (IP) with anti-ERα antibody; and 
precipitates were then analyzed by Western blot (WB) using anti-Myc tag and anti-ERα 
antibodies as described in the Materials and Methods. 
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Figure 3-16 continued.
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Figure 3-17 Interaction of various ERα deletion mutants with PIAS3. Hela cells were 
transfected with 50 ng of β-galactosidase, 125 ng of pGAL4-LUC, 150 ng pVP16-PIAS3 
wild-type and 25ng pM-ER deletion mutants or pM empty vector. After transfection cells 
were treated with DMSO or 10 nM E2 for 36 h. Luciferase activity was normalized to 
β-galactosidase activity, and expressed as relative luciferase units (RLU). Significant 
(p<0.05) interactions (*) induced by E2 are indicated. 
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immunoprecipitation. These data further confirm that PIAS3 interacts with ERα and in the 
coimmunoprecipitation studies, deletion of the acidic region of PIAS3 decreased 
interactions with ERα. 
We also investigated the interaction between wild type PAIS3 and ERα deletion 
mutants using a mammalian two-hybrid assay in HeLa cells. The results (Fig. 3-17) show 
that in the absence of E2 stimulation, luciferase activity was highly variable among the 
pM-ERα (variants) with high luciferase activity associated with cells transfected with 
pM-15C ERα plus VP16 and pM-15C ERα pluc VP16-PAIS3. After treatment with E2, the 
interaction associated with pM-15C ERα and VP16-PIAS3 was similar in the E2 and 
DMSO treatment groups. However, significant induction by E2 using the ERα deletion 
mutants was observed only in cells transfected with pM-11C ERα and VP16-PIAS3. These 
results suggest that in the mammalian two-hybrid assay system, E2-induced interactions 
between pM-ERα (variants) and VP-PIAS3 were minimal. 
  
3.2.5 Coactivation of ERα/Sp1 by PIAS3 
Several hormone-responsive genes in breast cancer cells are regulated through 
interactions of ERα/Sp1 with GC-rich promoter elements (333,335,407,408). We therefore 
investigated coactivation of ERα/Sp1-dependent transactivation by PIAS3. ZR-75 cells 
were transfected with ERα and PIAS3 expression plasmids as well as pSp13, which 
contains three GC-rich sites in a minimal TATA-luciferase construct. Results in Figure 3-18 
shows that E2 caused a 2.4-fold increase in reporter gene activity in ZR75 cells transfected 
with 5 ng ERα expression plasmid, and cotransfection with 25, 50 and 75 ng PIAS3 
expression plasmid resulted in a 1.3-, 1.7- and 2.1-fold enhancement of E2-induced 
luciferase activity. These data also show that PIAS3 enhanced activity in cells treated with 
DMSO indicating that PIAS3 also modulated Sp-dependent transactivation. Current studies 
are further investigating the molecular mechanism of ERα/Sp coactivation by PIAS3. 
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Figure 3-18 Coactivation of ERα/Sp1 by PIAS3.  ZR-75 cells were transfected 
with pSp13, ERα, β-galactosidase and increasing amounts of pCDNA3-PIAS3 (0, 10, 
25, 50 and 75 ng) expression plasmid. After transfection cells were treated with 
DMSO or 10 nM E2 for 36 h. Luciferase activity was normalized with β-galactosidase 
activity and results are expressed as fold induction and compared to that observed for 
DMSO alone. Significant (p<0.05) induction by E2 (*) or coactivation of ERα/Sp1 by 
PAIS3 (**) is indicated  
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CHAPTER IV 
DISCUSSION AND SUMMARY 
 
4.1 Mechanism of induction of Cdc25A by E2 in ZR-75 cells 
E2 is a mitogen in ER-positive breast cancer cell lines and induces cell proliferation 
which is accompanied by induction of multiple functional classes of genes and 
protooncogenes including those required for cell cycle progression and nucleotide 
biosynthesis (407,408). For example, treatment of MCF-7 cells with E2 significantly 
enhances G0/G1 to S-phase progression and is accompanied by induction of cyclin D1, 
E2F1, cdk activities, Rb phosphorylation, downregulation of the cdk inhibitors p21 and p27 
(422). Previous studies report that E2 also induces Cdc25A (423,424), and this is consistent 
with the observed G0/G1 to S-phase progression. This study shows that Cdc25A gene 
expression is also induced by E2 in ZR-75 cells and pcdc25A-1 and related constructs are 
hormone-responsive and inhibited by the antiestrogen ICI 182780 (Figure 3-2B). Figure 4-1 
illustrates some of the important genes/proteins involved in the E2-dependent G0/G1 → S 
phase progression and highlights those genes that are E2-responsive. The molecular 
mechanisms associated with regulation of these genes in breast cancer cells is complex and 
variable and in some case may be dependent on cell context. For example, cyclin D1 is 
regulated in MCF-7 cells through proximal GC-rich motifs which interact with ERα/Sp1 
and a CRE site which is activated through a non-genomic pathway of estrogen action 
involving activation of cAMP/PKA. In MCF-7 cells, estrogen induces an unusual 
Sp1-ERα-NFY complex bound to proximal GC-rich and CCAAT sites. Thus both Sp1 and 
NFY transcription factors are activated by ERα (ligand bound). However, the hormone 
receptor acts through protein-protein and not protein-DNA interactions. In contrast, E2F1 is 
activated by E2 in ZR-75 breast cancer cells through independent interactions of ERα/Sp1 
with GC-rich motifs and activation of NFY through non-genomic activation of cAMP/PKA 
dependent phosphorylation of NF-YA bound to CCAAT sites. These results illustrate that 
activation of E2F1 by E2 involves non-classical genomic and non-genomic pathways which 
are cell context-dependent. This study has focused on investigating the molecular 
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mechanisms of hormone-dependent activation of Cdc25A by extensive promoter analysis in 
ZR-75 cells. 
The Cdc25A promoter does not contain a consensus or non-consensus estrogen 
responsive element (ERE); however, several GC-rich sites that bind Sp1 protein are present 
in the E2-responsive proximal region of the promoter (Figure 4-2) (433). Previous studies 
in this laboratory have demonstrated that ERα/Sp1 interactions with GC-rich motifs in 
several gene promoters including cyclin D1 were required for hormone-induced 
transactivation (434). Sp1 knockdown in MCF-7 cells (335,425) inhibited E2-induced 
G0/G1 to S-phase progression in MCF-7 cells, suggesting a possible role for ERα/Sp1 
activation of Cdc25A through interaction with one or more of the proximal GC-rich sites. 
The results (Figure 3-3, 3-4, 3-5) demonstrate that this pathway contributes to hormonal 
activation of Cdc25A; however, the induction response is still observed even with 
constructs in which all three GC-rich sites are mutated (Fig. 3-3A) suggesting that other 
hormone-responsive pathways are involved in activation of Cdc25A by E2. 
The minimal E2-responsive region of the Cdc25A promoter (-151 to -12) contains 
GC-rich, CCAAT and E2F1 motifs, and a second E2F1 site at -3 is also present outside this 
minimal promoter. Previous studies showed that E2F1-Rb complexes at the -3 site were 
important for inhibition of Cdc25A by the bovine papillomavirus E2 protein in cervical 
adenocarcinoma cells (335,425). In ZR-75 cells, only minimal basal activity was observed 
in cells transfected with a construct (pcdc25A-4) containing the -3 but not -62 E2F1 site 
(Fig. 3-2A); however, pcdc25A-4 was E2-responsive (Fig. 3-9B). Both dominant negative 
DP-1/E2F1 expression plasmids decreased hormone-induced transactivation in ZR-75 cells 
transfected with pcdc25A-4 (Fig. 3-9B) and pcdc25A-5 (Fig. 3-9A) confirming a role for 
E2F1 in mediating E2-dependent induction of Cdc25A. ChIP assays confirm interaction of 
E2F1 with the Cdc25A promoter (Fig. 3-10A), suggesting that induction of Cdc25A is due, 
in part, to E2-dependent Rb phosphorylation and subsequent derepression of E2F1. Both 
NF-YA and E2F1 are constitutively bound to the Cdc25A promoter and their band 
intensities are not significantly increased after treatment with hormone. This observation is 
consistent with hormonal activation of both transcription factors through phosphorylation of  
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Figure 4-1 The genes/proteins involved in the E2-dependent G0/G1 to S pahse 
progression. 
 
 
 
Figure 4-2 Promoter region of Cdc25A gene. 
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Rb and NF-YA. Moreover, since E2 also induces E2F1 mRNA/protein expression in ZR-75 
cells (335), this pathway may also contribute to the induction response at later time points, 
but would not be apparent in this study due to the shorter duration (2 h) of the ChIP 
experiment. 
Constructs containing the two CCAAT sites were also E2-responsive, and expression 
of dominant negative NF-YA significantly blocked hormone-dependent activation (Fig. 3-6, 
3-7, 3-8). Previous studies show that NF-YA bound to CCAAT sequences in the E2F1 gene 
promoter (347,374,435,436) was also activated through non-genomic pathways of estrogen 
action that involved activation of cAMP/PKA (437). Hormonal activation of cAMP/PKA 
has previously been observed (335) and involves phosphorylation of downstream 
transcription factors including NF-YA. Results in Figure 3-6 show that E2 induced 
transactivation in cells transfected with pcdc25A-6 and pcdc25A-5m3 or 
GAL4-NF-YA/pGAL4-luc. These data coupled with the effects of cAMP/PKA inhibitors 
and dominant negative NF-YA expression, confirm that induction of Cdc25A by E2 also 
involves activation of cAMP/PKA and subsequent kinase-dependent activation of NF-YA. 
Previous studies have shown that activation of human TIMP (330,333,335,425,438,439) 
and hormone-dependent activation of E2F1 (286,287,440-442) were dependent on 
cAMP/PKA phosphorylation of NF-YA bound to CCAAT motifs. However, based on PKA 
inhibitor studies in cells transfected with pcdc25A1 and pcdc25A-5 and treated with E2, we 
conclude that the contribution of the non-genomic (cAMP/PKA) pathway of estrogen 
action was relatively small (<15%). The activation of Cdc25A by genomic and 
non-genomic pathways of estrogen action is not unprecedented since c-fos, cyclin D1, bcl-2, 
and E2F1 are also induced by E2 through both nuclear and extranuclear ER pathways in 
breast cancer cells (277,278). These genes are important for cell growth/survival and clearly 
highlight the importance of both pathways for ER-positive breast cancer cell proliferation. 
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4.2 Coactivation of E2-induced transactivation by PIAS3 
Transcriptional regulation by ligand-activated NRs is a complex process that is 
dependent on multiple factors including the structure of the receptor agonist. For 
example, NR-mediated transactivation requires specific classes of coactivators and 
other transcription-related factors that are recruited to the target gene promoter by the 
DNA-bound receptor in the chromatin environment of the nucleus. Each nuclear factor 
contributes one or more distinct activities that are required for gene activation. 
Coregulators can be classified into two main groups according to their functions. The 
first group contains factors that covalently modify histones (ie. acetylation, methylation, 
phosphorylation, ubiquitylation) and modulate promoter DNA accessibility. The second 
group includes ATP-dependent chromatin remodeling factors that also modulate 
promoter accessibility to transcription factors and to the basal transcriptional machinery. 
Steroid hormone receptors such as ERα have been extensively used as models for 
determining the mechanisms of ligand-dependent receptor-mediated transactivation, 
which requires the assembly and recruitment of a complex of nuclear coregulatory 
proteins (279).  
The initial step in transactivation is the ligand-induced binding of receptor dimers 
to their cognate HREs within promoter regions of hormone-responsive genes and this is 
accompanied by interactions with coregulatory proteins and the basal transcription 
complex. Direct interactions between the p160 coactivator proteins and AF2 domains of 
NRs through LXXLL motifs in the coactivators have been demonstrated in several 
studies (280). Once bound to the NR, p160 proteins facilitate recruitment of p300/CBP 
coregulators which exhibit intrinsic HAT activity that mediates acetylation of histones 
and there is also enhanced histone acetylation by SRCs which also possess HAT activity. 
After p300/CBP binding to the NR complex, it has been suggested that this increases 
the number of productive preinitiation complexes on the promoter (283). Furthermore, 
p300/CBP can interact with Pol II through the RNA helicase A and recruit the Pol II 
holoenzyme complex to the promoter region (443). In addition, the arginine 
methyltransferase CARM1 synergizes with p160 proteins and p300 to enhance 
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ligand-dependent transcriptional activation by NRs, possibly through its ability to 
methylate histone H3 (444,445). The next step involved is the recruitment of the 
TRAP220/SMCC/mediator complex. . The multiprotein Mediator complexes also 
known as the TRAP and DRIP complexes, are a class of NR coactivators that enhance 
transactivation through interactions with DNA-bound NRs and the RNA pol II 
transcriptional machinery and stabilize the formation of transcription PICs at the 
promoter (223). DRIP205 and DRIP150 which are two components of the DRIP/TRAP 
complex coactivate ERα-mediated transactivation in ZR-75 breast cancer cells (224). 
However, in contrast to many coactivators that act through their LXXLL motifs, 
coactivation of ERα by DRIP205 and DRIP150 does not require their LXXLL motifs 
suggesting a more complex mechanism of coactivation. NRs also facilitate recruitment 
of SWI/SNF to the promoter region. SWI/SNF catalyzes remodeling of the proximal 
promoter region in order to permit binding of the basal transcriptional machinery to the 
DNA template and facilitate the association between TBP and the TATA box. The 
steroid receptor activator (SRA), is unique among coactivators which functions as an 
RNA transcript rather than as a protein (409). SRA is selective for steroid hormone 
receptors and mediates transactivation via their N-terminal activation function. In 
addition, the E6-associated-protein (E6-AP), an ubiquitin ligase that has been identified 
as a coactivator of the progesterone receptor (PR) (409). E6-AP also coactivates the 
hormone-dependent transcriptional activities of other members of the nuclear hormone 
receptor superfamily. A large number of coactivators have been identified and these 
proteins (and mRNA) differ in their structure and function and they act through both 
LXXLL box-dependent and independent pathways. There is increasing evidence that 
coactivator function is highly varable and dependent on ligand structure, nuclear 
receptor and cell context.  
The PIAS family was originally identified as cytokine-induced inhibitors of STATs 
and they consist of five structurally related mammalian proteins, PIAS1/GBP, PIAS3, 
PIASxα, PIASxβ, and PIASy. These proteins contain several conserved domains. The 
conserved N-terminal region of PIAS proteins contains several well characterized 
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domains (Figure 3-13 A). The SAF-A/B, Acinus, PIAS (SAP) domain binds A/T-rich 
DNA and may be involved in targeting PIAS proteins to the nuclear scaffold (411). The 
SAP domain encompasses an LXXLL motif that is required for transcriptional 
repression of STAT1 by PIAS3y (411). The RING-finger-like zinc-binding domain 
(RLD) mediates the SUMO-E3-ligase activity of PIAS proteins and binds directly to 
Ubc9, the SUMO E2 enzyme (412). Most PIAS proteins also contain a PINIT motif, 
which plays a role in nuclear retention (428). The C termini of PIAS proteins are more 
diverse; however all contain an acidic domain preceded by several serines (Ser/Ac). 
Within the acidic domain, a SUMO-1 Interaction Motif (SIM) exists (410) and a serine- 
and threonine-rich region (S/T) is present in the C termini of all PIAS proteins except 
for PIASγ and the function of this region is unknown.  
PIAS proteins are not only negative regulators of cytokine signaling that inhibit the 
activity of STAT-transcription factors, these proteins also function as transcriptional 
coregulators of various important cellular pathways. It has been reported that PIAS 
proteins modulate the ligand-dependent steroid hormone-mediated transactivation 
(446-448). Depending on the receptor type, cell line and gene promoter PIAS proteins 
both enhanced and repressed steroid hormone receptor-mediated transaction (413). 
These results clearly demonstrate the highly flexible activity of PIAS proteins which 
stimulated our interest in these proteins as coactivators of ERα and ERα/Sp1 in breast 
cancer and other cancer cell lines. Both activating and repressing effects on 
transcription were observed upon expression of a distinct PIAS family member, 
indicating that PIAS proteins play a cell context-dependent dual role as activators or 
repressors of steroid hormone signaling. 
In this study, the results show that PIAS3 coactivated ERα in MCF-7 cells 
transfected with pERE3 (Fig. 3-11). Moreover, decreased endogenous PIAS3 levels by 
specific inhibitory RNA significantly suppressed the induction of pS2 gene expression 
by E2 (Fig. 3-12). This further confirms that PIAS3 functions as an endogenous 
coactivator of E2-mediated transactivation in MCF-7 cells and therefor we futher 
investigated the mechanism of this coactivation response using a series of PIAS3 
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mutant constructs in order to identify domains required for coactivation. Deletion 
analysis of PIAS3 showed that the N-terminal region of PIAS3 is not required for 
coactivation of ERα (Fig. 3-13). This indicates that coactivation of ERα by PIAS3 does 
not require the LXXLL motif suggesting that “classical” interaction with helix 12 of 
ERα is not necessary for the coactivation activity of PIAS3. The C-terminal region of 
PIAS3 includes the RING finger-like domain, the acidic region and the serine-rich 
sequences. Previous studies showed that the RING finger-like domain is required for the 
SUMO-E3 ligase activity (413) and ERα is sumoylated in the presence of 
SUMO-1(412). When PIAS3 acts as E3 ligase for ERα sumoylation it stimulates 
SUMO-1 conjugation to ERα and it has been reported that extensive sumoylation of ER 
represses hormone-induced transactivation (412). Our results indicate that the RING 
finger-like domain of PIAS3 is not required for the ERα coactivation suggesting that 
PIAS3-dependent sumoylation of ERα does not play a role in coactivation of ERα in 
these studies (Fig. 3-13). However, deletion of the acidic regionof PIAS3 resulted in a 
significant loss of coactivator activity (Fig. 3-14). Although the PIAS3#5 coactivates 
ERα-mediated transactivation, this variant does not interact with ERα in mammalian 
two-hybrid assay (Fig. 3-16B) suggesting that coactivation of ERα-mediated 
transactivation by PIAS3#5 may require recruitment of other coregulatory protein(s). 
Jimenez-Lara and coworkers (449) showed that PIAS3 modulates the transcriptional 
activation of androgen receptor through cooperative interactions with the nuclear 
receptor coactivator TIF2 . The interaction between TIF2 and PIAS3 occurs through the 
acidic region of PIAS3, which is conserved through out the PIAS family of proteins 
(450,451). TIF2 coactivates ERα through interactions with the ERα AF2 domain in a 
ligand-dependent fashion (413). Taken together, these data support the hypothesis that 
PIAS3 may coactivate ERα-mediated transactivation through TIF2.  
Unlike most coactivators which are recruited by the AF2 of ERα, PIAS3 did not 
require the critical helix 12 region of ERα AF2 for coactivation of ERα when HeLa cells 
were transfected with Taf-1ERα (Figure 3-15). PIAS3 exhibited minimal coactivation 
activity in HeLa cells transfected with pERE3 and the null-ERα mutant which is an AF1 
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deletion mutant that also contains three point mutations on helix 12 (Fig. 3-15). These 
data suggest that the AF1 of ERα is also involved in coactivation of ERα by PIAS3. 
However, when HeLa cells were transfected with pERE3 and 19C-ERα, an AF1 deletion 
mutant, PIAS3 still coactivated 19C-ER (Fig 3-15) suggesting that the AF2 of ERα is 
involved in coactivation by PIAS3 but only when AF1 of ERα is deleted. These results 
suggest that coactivation of ERα-mediated transactivation by PIAS3 is complex and 
may involve interactions with more than one region of ERα and these results are 
comparable to recents studies in this laboratory on the coactivation of ERα by DRIP205 
and DRIP 150. Coactivation of ERα by DRIP205 and DRIP150 in ZR75 breast cancer 
cells was independent of the LXXLL motifs in both proteins. DRIP150 enhanced 
transactivation in cells transfected with ERα and 19C-ERα but not TAF1-ERα and this 
profile for coactivation of wild-type/ variant ERα by DRIP150 differed from PIAS3. 
DRIP205 coactivated ERα-mediated transactivation, however, coactivation was not 
observed in cells transfected with 19C-ERα or TAF1-ERα. Thus the coactivation 
activities of PIAS3, DRIP150 and DRIP205 differed with respect to their requirements 
for different domains of ERα, however, coactivation of ERα by all three proteins was 
independent of their LXXLL motifs. 
The results from mammalian two-hybrid studies showed that the PIAS3 interacts 
with AF1 of ERα when cells treated with DMSO and E2, suggesting that the 
interactions of PIAS3 and AF1 of ERα are ligand-independent (Fig. 3-17). However, 
PIAS3 also interacts with AF2 of ERα but only when cells are stimulated with E2 (Fig. 
3-17B), suggesting that the interactions between PIAS3 and AF2 of ERα are 
ligand-dependent. Thus both AF1 and AF2 of ERα are involved in coactivation by 
PIAS3 and these regions of ERα are also required for physical interactions with PAIS3. 
Several studies have reported that SUMO-1 regulates hormone-induced 
transactivation of some nuclear receptors (412). This regulation can be achieved by 
sumoylation of either receptors or coregulators indicating that sumoylation can be an 
integral part of nuclear hormone receptor function. Moreover, a recent report showed 
that ERα-mediated transcription is stimulated by SUMO-1 expression. It has been 
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speculated that the enhanced ERα-dependent transcription by SUMO-1 may be due to 
sumoylation of the coactivator steroid receptor coactivator 1 (SRC-1) (414).  
Jimenez-Lara and co-workers identified PIAS3 as a binding partner of 
GRIP1/TIF2 (333,335,452-454) and it was also reported that PIAS3 interacts with TBP 
in a yeast two-hybrid (455). Their data suggest that the TBP interaction domain of 
PIAS1 requires the 39 amino acids from aa 453 to aa 491, which includes the acidic 
region. The localization of SUMO E3-ligase activity and TBP-binding activity to 
opposite ends of PIAS proteins suggests that these proteins might “dock” at TBP and 
sumoylate transcription factors at the promoter. Based on these studies, PIAS3 may 
have cooperative coactivation with TIF2 and/or TBP. 
ERα/Sp1-mediated transactivation has been linked to hormone activation of 
several genes involved in cell cycle progression, DNA synthesis and metabolism of 
purines and pyrimidines (456). In vitro studies show that ERα interacts with both Sp1 
and Sp3, and the C-terminal DBD of Sp1 is the major interaction site for ERα. Recently 
Kim et al used the FRET technique to investigate the interactions between ERα and Sp1 
in living MCF-7 breast cancer cells. Results from FRET analysis showed that ERα 
interacts with Sp1 in living breast cancer cells and the interactions are ligand-dependent. 
Only a few coactivators of ERα such as DRIP205, and DRIP150 have been reported as 
coactivators for ERα/Sp1 in ZR-75 breast cancer cells and research on identificaon of 
ERα/Sp1 coactivaors is in progress. The results of transfection assays in ZR-75 cells 
showed that PIAS3 enhanced E2-induced luciferase activity of pSp13 (Fig. 3-18) 
suggesting that coactivation of ERα/Sp1 by PIAS3 was also observed in ZR-75 cells 
transfected with pSp13 (Fig. 3-11). The molecular mechanisms of this response are 
currently being investigated.  
In conclusion, we have shown here that PIAS3 interacts with ERα and functions as 
a coactivator for ERα-mediated transacivation. The RING finger-like domain of PIAS3 
is important for interactions with ERα and the acidic region is critical for its 
coactivation activity. PIAS3 also functions as a coactivator for ERα/Sp1 pathway in 
ZR-75 breast cancer cells. Moreover, we have also shown that knockdown of PAIS3 in 
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MCF-7 cells results in decreased induction of pS2 by E2 demonstrating an endogenous 
role for PIAS3 in hormone-induced transactivation. The role of PIAS3 and its 
interactions with other coactivators in the induction response and the potential temporal 
effects of E2-dependent recruitment of coactivators may also be important and is 
currently being investigated.   
 
 112
REFERENCES 
 
1. American Cancer Society (2006) Cancer Facts and Figures 2006, American 
Cancer Society, Atlanta. 
2. American Cancer Society (2005) Cancer Facts and Figures 2005, American 
Cancer Society, Atlanta. 
3. Cunningham, M. P. (1997) CA Cancer J Clin 47(1), 3-4 
4. Perusinghe, N. P., Monaghan, P., O'Hare, M. J., Ashley, S., and Gusterson, B. A. 
(1992) In Vitro Cell Dev Biol 28A(2), 90-96 
5. Wiseman, B. S., and Werb, Z. (2002) Science 296(5570), 1046-1049 
6. Russo, J., Mills, M. J., Moussalli, M. J., and Russo, I. H. (1989) In Vitro Cell 
Dev Biol 25(7), 643-649 
7. Dumitrescu, R. G., and Cotarla, I. (2005) J Cell Mol Med 9(1), 208-221 
8. Harris, J. R., Lippman, M. E., Veronesi, U., and Willett, W. (1992) N Engl J 
Med 327(5), 319-328 
9. Harris, J. R., Lippman, M. E., Veronesi, U., and Willett, W. (1992) N Engl J 
Med 327(6), 390-398 
10. Harris, J. R., Lippman, M. E., Veronesi, U., and Willett, W. (1992) N Engl J 
Med 327(7), 473-480 
11. Kelsey, J. L., Gammon, M. D., and John, E. M. (1993) Epidemiol Rev 15(1), 
36-47 
12. Lambe, M., Hsieh, C., Trichopoulos, D., Ekbom, A., Pavia, M., and Adami, H. 
O. (1994) N Engl J Med 331(1), 5-9 
13. Berkey, C. S., Frazier, A. L., Gardner, J. D., and Colditz, G. A. (1999) Cancer 
85(11), 2400-2409 
14. Brinton, L. A., Schairer, C., Hoover, R. N., and Fraumeni, J. F., Jr. (1988) 
Cancer Invest 6(3), 245-254 
15. Hunter, D. J., Spiegelman, D., Adami, H. O., van den Brandt, P. A., Folsom, A. 
R., Goldbohm, R. A., Graham, S., Howe, G. R., Kushi, L. H., Marshall, J. R., 
Miller, A. B., Speizer, F. E., Willett, W., Wolk, A., and Yaun, S. S. (1997) 
Cancer Causes Control 8(1), 49-56 
16. [No authors listed] (1997) Lancet 350(9084), 1047-1059 
 113
17. Pike, M. C., Spicer, D. V., Dahmoush, L., and Press, M. F. (1993) Epidemiol 
Rev 15(1), 17-35 
18. Russo, J., Hu, Y. F., Yang, X., and Russo, I. H. (2000) J Natl Cancer Inst 
Monogr (27), 17-37 
19. Bernstein, L. (2002) J Mammary Gland Biol Neoplasia 7(1), 3-15 
20. Lipworth, L., Bailey, L. R., and Trichopoulos, D. (2000) J Natl Cancer Inst 
92(4), 302-312 
21. Collaborative Group on Hormonal Factors in Breast Cancer (2002) Lancet 
360(9328), 187-195 
22. Rebbeck, T. R. (1999) Cancer 86(11 Suppl), 2493-2501 
23. Deng, C. X., and Brodie, S. G. (2000) Bioessays 22(8), 728-737 
24. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, 
D. T., Weber, B., Lenoir, G., Chang-Claude, J., Sobol, H., Teare, M. D., 
Struewing, J., Arason, A., Scherneck, S., Peto, J., Rebbeck, T. R., Tonin, P., 
Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A., Gayther, 
S. A., Zelada-Hedman, M., and et al. (1998) Am J Hum Genet 62(3), 676-689 
25. Osorio, A., de la Hoya, M., Rodriguez-Lopez, R., Martinez-Ramirez, A., 
Cazorla, A., Granizo, J. J., Esteller, M., Rivas, C., Caldes, T., and Benitez, J. 
(2002) Int J Cancer 99(2), 305-309 
26. Eiriksdottir, G., Barkardottir, R. B., Agnarsson, B. A., Johannesdottir, G., 
Olafsdottir, K., Egilsson, V., and Ingvarsson, S. (1998) Oncogene 16(1), 21-26 
27. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994) 
Cancer Res 54(18), 4855-4878 
28. Malkin, D. (1994) Annu Rev Genet 28, 443-465 
29. Garber, J. E., Goldstein, A. M., Kantor, A. F., Dreyfus, M. G., Fraumeni, J. F., 
Jr., and Li, F. P. (1991) Cancer Res 51(22), 6094-6097 
30. Rothman, N., Wacholder, S., Caporaso, N. E., Garcia-Closas, M., Buetow, K., 
and Fraumeni, J. F., Jr. (2001) Biochim Biophys Acta 1471(2), C1-10 
31. Okobia, M. N., and Bunker, C. H. (2003) Afr J Reprod Health 7(3), 17-28 
32. Glade, M. J. (1999) Nutrition 15(6), 523-526 
33. Singletary, K. W., and Gapstur, S. M. (2001) Jama 286(17), 2143-2151 
34. Hamajima, N., Hirose, K., Tajima, K., Rohan, T., Calle, E. E. and et al. (2002) 
Br J Cancer 87(11), 1234-1245 
 114
35. Poschl, G., and Seitz, H. K. (2004) Alcohol Alcohol 39(3), 155-165 
36. Morimoto, L. M., White, E., Chen, Z., Chlebowski, R. T., Hays, J., Kuller, L., 
Lopez, A. M., Manson, J., Margolis, K. L., Muti, P. C., Stefanick, M. L., and 
McTiernan, A. (2002) Cancer Causes Control 13(8), 741-751 
37. Huang, Z., Hankinson, S. E., Colditz, G. A., Stampfer, M. J., Hunter, D. J., 
Manson, J. E., Hennekens, C. H., Rosner, B., Speizer, F. E., and Willett, W. C. 
(1997) Jama 278(17), 1407-1411 
38. Sugimura, T. (2000) Carcinogenesis 21(3), 387-395 
39. Zheng, W., Gustafson, D. R., Sinha, R., Cerhan, J. R., Moore, D., Hong, C. P., 
Anderson, K. E., Kushi, L. H., Sellers, T. A., and Folsom, A. R. (1998) J Natl 
Cancer Inst 90(22), 1724-1729 
40. Velie, E., Kulldorff, M., Schairer, C., Block, G., Albanes, D., and Schatzkin, A. 
(2000) J Natl Cancer Inst 92(10), 833-839 
41. Bartsch, H., Nair, J., and Owen, R. W. (1999) Carcinogenesis 20(12), 
2209-2218 
42. Saadatian-Elahi, M., Norat, T., Goudable, J., and Riboli, E. (2004) Int J Cancer 
111(4), 584-591 
43. Sainsbury, J. R., Anderson, T. J., and Morgan, D. A. (2000) Bmj 321(7263), 
745-750 
44. National Institutes of Health Consensus Development Panel (2001) J Natl 
Cancer Inst Monogr (30), 5-15 
45. Haffty, B. G., and Ward, B. A. (1997) Cancer J Sci Am 3(1), 2-3 
46. Bartelink, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., 
Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., Collette, L., and 
Pierart, M. (2001) N Engl J Med 345(19), 1378-1387 
47. Cold, S., Jensen, N. V., Brincker, H., and Rose, C. (1993) Eur J Cancer 29A(8), 
1146-1152 
48. Ormrod, D., Holm, K., Goa, K., and Spencer, C. (1999) Drugs Aging 15(5), 
389-416 
49. Beaton, G. T. (1896) Lancet 2, 105-107 
50. Lacassagne, A. (1936) AM J Cancer 27, 217-225 
51. Jordan, V. C. (1984) Pharmacol Rev 36(4), 245-276 
52. Jordan, V. C. (2001) Cancer Res 61(15), 5683-5687 
 115
53. Jensen, E. V., and Jordan, V. C. (2003) Clin Cancer Res 9(6), 1980-1989 
54. Jordan, V. C., and Allen, K. E. (1980) Eur J Cancer 16(2), 239-251 
55. Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., 
Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., 
Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Therasse, P., Palmer, M. 
J., and Pater, J. L. (2003) N Engl J Med 349(19), 1793-1802 
56. Hendrix, S. L., and McNeeley, S. G. (2001) Ann N Y Acad Sci 949, 243-250 
57. Mourits, M. J., De Vries, E. G., Willemse, P. H., Ten Hoor, K. A., Hollema, H., 
and Van der Zee, A. G. (2001) Obstet Gynecol 97(5 Pt 2), 855-866 
58. Bissett, D., Davis, J. A., and George, W. D. (1994) Lancet 344(8932), 1244 
59. (1998) Lancet 351(9114), 1451-1467 
60. Baum, M., Budzar, A. U., Cuzick, J., Forbes, J., Houghton, J. H., Klijn, J. G., 
and Sahmoud, T. (2002) Lancet 359(9324), 2131-2139 
61. Jordan, V. C., Phelps, E., and Lindgren, J. U. (1987) Breast Cancer Res Treat 
10(1), 31-35 
62. Gottardis, M. M., and Jordan, V. C. (1987) Cancer Res 47(15), 4020-4024 
63. McDonnell, D. P., Chang, C. Y., and Norris, J. D. (2001) Ann N Y Acad Sci 949, 
16-35 
64. Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., 
Enmark, E., Pettersson, K., Warner, M., and Gustafsson, J. A. (2001) Physiol 
Rev 81(4), 1535-1565 
65. Hu, Y.-F., Russo, I. H., and Russo, J. (2001) Estrogen and human breast cancer, 
Springer Verlag, Heidelberg 
66. Russo, J., and Russo, I. H. (1997) Role of hormones in human breast 
development: The menopausal breast, Parthenon Publishing, New York 
67. Russo, I. H., and Russo, J. (1998) J Mammary Gland Biol Neoplasia 3(1), 49-61 
68. Adlercreutz, H., Gorbach, S. L., Goldin, B. R., Woods, M. N., Dwyer, J. T., and 
Hamalainen, E. (1994) J Natl Cancer Inst 86(14), 1076-1082 
69. Roy, D., and Liehr, J. G. (1988) J Biol Chem 263(8), 3646-3651 
70. Lingle, W. L., Lutz, W. H., Ingle, J. N., Maihle, N. J., and Salisbury, J. L. (1998) 
Proc Natl Acad Sci U S A 95(6), 2950-2955 
71. Chakravarti, D., Mailander, P. C., Cavalieri, E. L., and Rogan, E. G. (2000) 
 116
Mutat Res 456(1-2), 17-32 
72. Khan, S. A., Rogers, M. A., Khurana, K. K., Meguid, M. M., and Numann, P. J. 
(1998) J Natl Cancer Inst 90(1), 37-42 
73. Moolgavkar, S. H., Day, N. E., and Stevens, R. G. (1980) J Natl Cancer Inst 
65(3), 559-569 
74. Mosselman, S., Polman, J., and Dijkema, R. (1996) FEBS Lett 392(1), 49-53 
75. Enmark, E., Pelto-Huikko, M., Grandien, K., Lagercrantz, S., Lagercrantz, J., 
Fried, G., Nordenskjold, M., and Gustafsson, J. A. (1997) J Clin Endocrinol 
Metab 82(12), 4258-4265 
76. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., 
and Gustafsson, J. A. (1997) Endocrinology 138(3), 863-870 
77. Yue, W., Santen, R. J., Wang, J. P., Li, Y., Verderame, M. F., Bocchinfuso, W. 
P., Korach, K. S., Devanesan, P., Todorovic, R., Rogan, E. G., and Cavalieri, E. 
L. (2003) J Steroid Biochem Mol Biol 86(3-5), 477-486 
78. Yang, X., Edgerton, S. M., Kosanke, S. D., Mason, T. L., Alvarez, K. M., Liu, 
N., Chatterton, R. T., Liu, B., Wang, Q., Kim, A., Murthy, S., and Thor, A. D. 
(2003) Cancer Res 63(10), 2425-2433 
79. Harvell, D. M., Strecker, T. E., Tochacek, M., Xie, B., Pennington, K. L., 
McComb, R. D., Roy, S. K., and Shull, J. D. (2000) Proc Natl Acad Sci U S A 
97(6), 2779-2784 
80. Yager, J. D. (2000) J Natl Cancer Inst Monogr (27), 67-73 
81. Jefcoate, C. R., Liehr, J. G., Santen, R. J., Sutter, T. R., Yager, J. D., Yue, W., 
Santner, S. J., Tekmal, R., Demers, L., Pauley, R., Naftolin, F., Mor, G., and 
Berstein, L. (2000) J Natl Cancer Inst Monogr (27), 95-112 
82. Hayes, C. L., Spink, D. C., Spink, B. C., Cao, J. Q., Walker, N. J., and Sutter, T. 
R. (1996) Proc Natl Acad Sci U S A 93(18), 9776-9781 
83. Devanesan, P., Todorovic, R., Zhao, J., Gross, M. L., Rogan, E. G., and 
Cavalieri, E. L. (2001) Carcinogenesis 22(3), 489-497 
84. Cavalieri, E., Frenkel, K., Liehr, J. G., Rogan, E., and Roy, D. (2000) J Natl 
Cancer Inst Monogr (27), 75-93 
85. Lavigne, J. A., Goodman, J. E., Fonong, T., Odwin, S., He, P., Roberts, D. W., 
and Yager, J. D. (2001) Cancer Res 61(20), 7488-7494 
86. Schumacher, G., and Neuhaus, P. (2001) J Cancer Res Clin Oncol 127(7), 
405-410 
 117
87. Dawling, S., Roodi, N., and Parl, F. F. (2003) Cancer Res 63(12), 3127-3132 
88. van Landeghem, A. A., Poortman, J., Nabuurs, M., and Thijssen, J. H. (1985) 
Cancer Res 45(6), 2900-2906 
89. Rogan, E. G., Badawi, A. F., Devanesan, P. D., Meza, J. L., Edney, J. A., West, 
W. W., Higginbotham, S. M., and Cavalieri, E. L. (2003) Carcinogenesis 24(4), 
697-702 
90. Healey, C. S., Dunning, A. M., Durocher, F., Teare, D., Pharoah, P. D., Luben, 
R. N., Easton, D. F., and Ponder, B. A. (2000) Carcinogenesis 21(2), 189-193 
91. Morgan, D. O. (1995) Nature 374(6518), 131-134 
92. Pines, J. (1991) Cell Growth Differ 2(6), 305-310 
93. David-Pfeuty, T., and Nouvian-Dooghe, Y. (1996) Oncogene 13(7), 1447-1460 
94. Pines, J. (1995) Adv Cancer Res 66, 181-212 
95. Darzynkiewicz, Z., Gong, J., Juan, G., Ardelt, B., and Traganos, F. (1996) 
Cytometry 25(1), 1-13 
96. Luca, F. C., Shibuya, E. K., Dohrmann, C. E., and Ruderman, J. V. (1991) Embo 
J 10(13), 4311-4320 
97. Markiewicz, D. A., McKenna, W. G., Flick, M. B., Maity, A., and Muschel, R. J. 
(1994) Int J Radiat Oncol Biol Phys 28(1), 135-144 
98. Rechsteiner, M., and Rogers, S. W. (1996) Trends Biochem Sci 21(7), 267-271 
99. Morgan, D. O. (1997) Annu. Rev. Cell Dev. Biol. 13, 261-291 
100. Murray, A. W. (2004) Cell 116, 221-234 
101. Sears, R. C. a. N., J. R. (2002) J. Biol. Chem. 277, 11617-11620 
102. Stevaux, O. a. D., J. A. (2002) Curr. Opin. Cell Biol. 14, 684-691 
103. Lipinski, M. M. a. J., T. (1999) Oncogene 18, 7873-7882 
104. Bouchard, C., Staller, P., and Eilers, M. (1998) Trends Cell Biol 8(5), 202-206 
105. Santoni-Rugiu, E., Falck, J., Mailand, N., Bartek, J., and Lukas, J. (2000) Mol 
Cell Biol 20(10), 3497-3509 
106. Bouchard, C., Thieke, K., Maier, A., Saffrich, R., Hanley-Hyde, J., Ansorge, W., 
Reed, S., Sicinski, P., Bartek, J., and Eilers, M. (1999) Embo J 18(19), 
5321-5333 
107. Perez-Roger, I., Kim, S. H., Griffiths, B., Sewing, A., and Land, H. (1999) 
 118
Embo J 18(19), 5310-5320 
108. Elend, M., and Eilers, M. (1999) Curr Biol 9(24), R936-938 
109. Beier, R., Burgin, A., Kiermaier, A., Fero, M., Karsunky, H., Saffrich, R., 
Moroy, T., Ansorge, W., Roberts, J., and Eilers, M. (2000) Embo J 19(21), 
5813-5823 
110. Bartek, J., Bartkova, J., and Lukas, J. (1996) Curr Opin Cell Biol 8(6), 805-814 
111. Sherr, C. J., and Roberts, J. M. (1999) Genes Dev 13(12), 1501-1512 
112. Pines, J. (1995) Biochem J 308 (Pt 3), 697-711 
113. Nigg, E. A. (1995) Bioessays 17(6), 471-480 
114. Pines, J., and Hunter, T. (1989) Cell 58(5), 833-846 
115. Piaggio, G., Farina, A., Perrotti, D., Manni, I., Fuschi, P., Sacchi, A., and 
Gaetano, C. (1995) Exp Cell Res 216(2), 396-402 
116. Maity, A., McKenna, W. G., and Muschel, R. J. (1995) Embo J 14(3), 603-609 
117. Fisher, R. P., and Morgan, D. O. (1994) Cell 78(4), 713-724 
118. Makela, T. P., Tassan, J. P., Nigg, E. A., Frutiger, S., Hughes, G. J., and 
Weinberg, R. A. (1994) Nature 371(6494), 254-257 
119. Devault, A., Martinez, A. M., Fesquet, D., Labbe, J. C., Morin, N., Tassan, J. P., 
Nigg, E. A., Cavadore, J. C., and Doree, M. (1995) Embo J 14(20), 5027-5036 
120. Gould, K. L., and Nurse, P. (1989) Nature 342(6245), 39-45 
121. Norbury, C., Blow, J., and Nurse, P. (1991) Embo J 10(11), 3321-3329 
122. Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M., and 
Beach, D. (1991) Cell 64(6), 1111-1122 
123. Parker, L. L., and Piwnica-Worms, H. (1992) Science 257(5078), 1955-1957 
124. Russell, P., and Nurse, P. (1986) Cell 45(1), 145-153 
125. Dunphy, W. G. (1994) Trends Cell Biol 4(6), 202-207 
126. Hoffmann, I., Clarke, P. R., Marcote, M. J., Karsenti, E., and Draetta, G. (1993) 
Embo J 12(1), 53-63 
127. Izumi, T., and Maller, J. L. (1993) Mol Biol Cell 4(12), 1337-1350 
128. Pines, J., and Hunter, T. (1991) J Cell Biol 115(1), 1-17 
129. Pines, J., and Hunter, T. (1994) Embo J 13(16), 3772-3781 
 119
130. Hagting, A., Karlsson, C., Clute, P., Jackman, M., and Pines, J. (1998) Embo J 
17(14), 4127-4138 
131. Toyoshima, F., Moriguchi, T., Wada, A., Fukuda, M., and Nishida, E. (1998) 
Embo J 17(10), 2728-2735 
132. Yang, J., Bardes, E. S., Moore, J. D., Brennan, J., Powers, M. A., and Kornbluth, 
S. (1998) Genes Dev 12(14), 2131-2143 
133. Medema, R. H., Klompmaker, R., Smits, V. A., and Rijksen, G. (1998) 
Oncogene 16(4), 431-441 
134. Smits, V. A., Klompmaker, R., Vallenius, T., Rijksen, G., Makela, T. P., and 
Medema, R. H. (2000) J Biol Chem 275(39), 30638-30643 
135. Aprelikova, O., Xiong, Y., and Liu, E. T. (1995) J Biol Chem 270(31), 
18195-18197 
136. Hitomi, M., Shu, J., Agarwal, M., Agarwal, A., and Stacey, D. W. (1998) 
Oncogene 17(8), 959-969 
137. Blangy, A., Lane, H. A., d'Herin, P., Harper, M., Kress, M., and Nigg, E. A. 
(1995) Cell 83(7), 1159-1169 
138. Peter, M., Nakagawa, J., Doree, M., Labbe, J. C., and Nigg, E. A. (1990) Cell 
61(4), 591-602 
139. Yamashiro, S., Yamakita, Y., Ishikawa, R., and Matsumura, F. (1990) Nature 
344(6267), 675-678 
140. Gottesfeld, J. M., Wolf, V. J., Dang, T., Forbes, D. J., and Hartl, P. (1994) 
Science 263(5143), 81-84 
141. Jinno, S., Suto, K., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., and 
Okayama, H. (1994) Embo J 13(7), 1549-1556 
142. Gabrielli, B. G., De Souza, C. P., Tonks, I. D., Clark, J. M., Hayward, N. K., and 
Ellem, K. A. (1996) J Cell Sci 109 (Pt 5), 1081-1093 
143. Dunphy, W. G., and Kumagai, A. (1991) Cell 67(1), 189-196 
144. Gautier, J., Solomon, M. J., Booher, R. N., Bazan, J. F., and Kirschner, M. W. 
(1991) Cell 67(1), 197-211 
145. Millar, J. B., McGowan, C. H., Lenaers, G., Jones, R., and Russell, P. (1991) 
Embo J 10(13), 4301-4309 
146. Strausfeld, U., Labbe, J. C., Fesquet, D., Cavadore, J. C., Picard, A., Sadhu, K., 
Russell, P., and Doree, M. (1991) Nature 351(6323), 242-245 
 120
147. Lee, M. S., Ogg, S., Xu, M., Parker, L. L., Donoghue, D. J., Maller, J. L., and 
Piwnica-Worms, H. (1992) Mol Biol Cell 3(1), 73-84 
148. Sebastian, B., Kakizuka, A., and Hunter, T. (1993) Proc Natl Acad Sci U S A 
90(8), 3521-3524 
149. Heald, R., McLoughlin, M., and McKeon, F. (1993) Cell 74(3), 463-474 
150. Dalal, S. N., Schweitzer, C. M., Gan, J., and DeCaprio, J. A. (1999) Mol Cell 
Biol 19(6), 4465-4479 
151. Ogg, S., Gabrielli, B., and Piwnica-Worms, H. (1994) J Biol Chem 269(48), 
30461-30469 
152. Davezac, N., Baldin, V., Gabrielli, B., Forrest, A., Theis-Febvre, N., Yashida, 
M., and Ducommun, B. (2000) Oncogene 19(18), 2179-2185 
153. Izumi, T., and Maller, J. L. (1995) Mol Biol Cell 6(2), 215-226 
154. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Nature 408(6810), 307-310 
155. Zhou, B. B., and Elledge, S. J. (2000) Nature 408(6811), 433-439 
156. Rotman, G., and Shiloh, Y. (1999) Oncogene 18(45), 6135-6144 
157. Kastan, M. B., and Lim, D. S. (2000) Nat Rev Mol Cell Biol 1(3), 179-186 
158. Shiloh, Y. (2003) Nat Rev Cancer 3(3), 155-168 
159. Bartek, J., and Lukas, J. (2003) Cancer Cell 3(5), 421-429 
160. Wahl, G. M., and Carr, A. M. (2001) Nat Cell Biol 3(12), E277-286 
161. Craig, A., Scott, M., Burch, L., Smith, G., Ball, K., and Hupp, T. (2003) EMBO 
Rep 4(8), 787-792 
162. Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F., Shifman, O., Moas, M., 
Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M. B., Katzir, E., and Oren, M. 
(2001) Genes Dev 15(9), 1067-1077 
163. Bartek, J., Lukas, C., and Lukas, J. (2004) Nat Rev Mol Cell Biol 5(10), 792-804 
164. Donzelli, M., and Draetta, G. F. (2003) EMBO Rep 4(7), 671-677 
165. Falck, J., Petrini, J. H., Williams, B. R., Lukas, J., and Bartek, J. (2002) Nat 
Genet 30(3), 290-294 
166. Pichierri, P., and Rosselli, F. (2004) Embo J 23(5), 1178-1187 
167. Osborn, A. J., Elledge, S. J., and Zou, L. (2002) Trends Cell Biol 12(11), 
509-516 
 121
168. Xu, B., Kim, S. T., Lim, D. S., and Kastan, M. B. (2002) Mol Cell Biol 22(4), 
1049-1059 
169. Nyberg, K. A., Michelson, R. J., Putnam, C. W., and Weinert, T. A. (2002) 
Annu Rev Genet 36, 617-656 
170. Uto, K., Inoue, D., Shimuta, K., Nakajo, N., and Sagata, N. (2004) Embo J 
23(16), 3386-3396 
171. Mailand, N., Podtelejnikov, A. V., Groth, A., Mann, M., Bartek, J., and Lukas, J. 
(2002) Embo J 21(21), 5911-5920 
172. Bulavin, D. V., Higashimoto, Y., Popoff, I. J., Gaarde, W. A., Basrur, V., 
Potapova, O., Appella, E., and Fornace, A. J., Jr. (2001) Nature 411(6833), 
102-107 
173. Taylor, W. R., and Stark, G. R. (2001) Oncogene 20(15), 1803-1815 
174. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. 
M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) Cell 75(4), 
817-825 
175. Zhan, Q., Antinore, M. J., Wang, X. W., Carrier, F., Smith, M. L., Harris, C. C., 
and Fornace, A. J., Jr. (1999) Oncogene 18(18), 2892-2900 
176. Wang, X. W., Zhan, Q., Coursen, J. D., Khan, M. A., Kontny, H. U., Yu, L., 
Hollander, M. C., O'Connor, P. M., Fornace, A. J., Jr., and Harris, C. C. (1999) 
Proc Natl Acad Sci U S A 96(7), 3706-3711 
177. Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagalingam, S., 
Kinzler, K. W., and Vogelstein, B. (1997) Mol Cell 1(1), 3-11 
178. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W., and Vogelstein, B. 
(1999) Nature 401(6753), 616-620 
179. Hall, M., and Peters, G. (1996) Adv Cancer Res 68, 67-108 
180. Park, M. T., and Lee, S. J. (2003) J Biochem Mol Biol 36(1), 60-65 
181. Johnson, D. G., and Walker, C. L. (1999) Annu Rev Pharmacol Toxicol 39, 
295-312 
182. Borg, A., Ferno, M., and Peterson, C. (2003) Nat Med 9(1), 16-18 
183. Spruck, C. H., Won, K. A., and Reed, S. I. (1999) Nature 401(6750), 297-300 
184. Yam, C. H., Fung, T. K., and Poon, R. Y. (2002) Cell Mol Life Sci 59(8), 
1317-1326 
185. Schlotter, C. M., Vogt, U., Bosse, U., Mersch, B., and Wassmann, K. (2003) 
 122
Breast Cancer Res 5(2), R30-36 
186. Ewen, M. E. (1994) Cancer Metastasis Rev 13(1), 45-66 
187. Sherr, C. J. (1996) Science 274(5293), 1672-1677 
188. Ruas, M., and Peters, G. (1998) Biochim Biophys Acta 1378(2), F115-177 
189. Levine, A. J. (1997) Cell 88(3), 323-331 
190. Sandal, T. (2002) Oncologist 7(1), 73-81 
191. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. 
E., Housman, D. E., and Jacks, T. (1994) Science 266(5186), 807-810 
192. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Huh, Y. O., Keating, M. J., 
and Albitar, M. (1995) Leuk Lymphoma 17(1-2), 13-18 
193. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Yang, Y., McCown, P., 
Ordonez, N., Glassman, A., Sneige, N., and Albitar, M. (1996) Breast Cancer 
Res Treat 37(2), 179-188 
194. Moller, M. B., Ino, Y., Gerdes, A. M., Skjodt, K., Louis, D. N., and Pedersen, N. 
T. (1999) Leukemia 13(3), 453-459 
195. Werner, T. (1999) Mamm Genome 10(2), 168-175 
196. Frisch, M., Frech, K., Klingenhoff, A., Cartharius, K., Liebich, I., and Werner, T. 
(2002) Genome Res 12(2), 349-354 
197. Robertson, K. D. (2002) Oncogene 21(35), 5361-5379 
198. Smale, S. T., and Kadonaga, J. T. (2003) Annu Rev Biochem 72, 449-479 
199. Breathnach, R., and Chambon, P. (1981) Annu Rev Biochem 50, 349-383 
200. Lagrange, T., Kim, T. K., Orphanides, G., Ebright, Y. W., Ebright, R. H., and 
Reinberg, D. (1996) Proc Natl Acad Sci U S A 93(20), 10620-10625 
201. Lagrange, T., Kapanidis, A. N., Tang, H., Reinberg, D., and Ebright, R. H. 
(1998) Genes Dev 12(1), 34-44 
202. Tsai, F. T., and Sigler, P. B. (2000) Embo J 19(1), 25-36 
203. Evans, R., Fairley, J. A., and Roberts, S. G. (2001) Genes Dev 15(22), 
2945-2949 
204. Smale, S. T., Jain, A., Kaufmann, J., Emami, K. H., Lo, K., and Garraway, I. P. 
(1998) Cold Spring Harb Symp Quant Biol 63, 21-31 
205. Butler, J. E., and Kadonaga, J. T. (2002) Genes Dev 16(20), 2583-2592 
 123
206. Kutach, A. K., and Kadonaga, J. T. (2000) Mol Cell Biol 20(13), 4754-4764 
207. Roeder, R. G. (1996) Trends Biochem Sci 21(9), 327-335 
208. Lee, T. I., and Young, R. A. (2000) Annu Rev Genet 34, 77-137 
209. Cosma, M. P. (2002) Mol Cell 10(2), 227-236 
210. Buratowski, S., Hahn, S., Guarente, L., and Sharp, P. A. (1989) Cell 56(4), 
549-561 
211. Wang, W., Carey, M., and Gralla, J. D. (1992) Science 255(5043), 450-453 
212. Bentley, D. (2002) Curr Opin Cell Biol 14(3), 336-342 
213. Hampsey, M. (1998) Microbiol Mol Biol Rev 62(2), 465-503 
214. Cramer, P., Bushnell, D. A., and Kornberg, R. D. (2001) Science 292(5523), 
1863-1876 
215. Park, N. J., Tsao, D. C., and Martinson, H. G. (2004) Mol Cell Biol 24(10), 
4092-4103 
216. McKenna, N. J., Lanz, R. B., and O'Malley, B. W. (1999) Endocr Rev 20(3), 
321-344 
217. Spencer, T. E., Jenster, G., Burcin, M. M., Allis, C. D., Zhou, J., Mizzen, C. A., 
McKenna, N. J., Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. 
(1997) Nature 389(6647), 194-198 
218. Chakravarti, D., LaMorte, V. J., Nelson, M. C., Nakajima, T., Schulman, I. G., 
Juguilon, H., Montminy, M., and Evans, R. M. (1996) Nature 383(6595), 
99-103 
219. Chen, D., Ma, H., Hong, H., Koh, S. S., Huang, S. M., Schurter, B. T., Aswad, 
D. W., and Stallcup, M. R. (1999) Science 284(5423), 2174-2177 
220. Yoshinaga, S. K., Peterson, C. L., Herskowitz, I., and Yamamoto, K. R. (1992) 
Science 258(5088), 1598-1604 
221. DiRenzo, J., Shang, Y., Phelan, M., Sif, S., Myers, M., Kingston, R., and Brown, 
M. (2000) Mol Cell Biol 20(20), 7541-7549 
222. Hsiao, P. W., Fryer, C. J., Trotter, K. W., Wang, W., and Archer, T. K. (2003) 
Mol Cell Biol 23(17), 6210-6220 
223. Lanz, R. B., McKenna, N. J., Onate, S. A., Albrecht, U., Wong, J., Tsai, S. Y., 
Tsai, M. J., and O'Malley, B. W. (1999) Cell 97(1), 17-27 
224. Nawaz, Z., Lonard, D. M., Smith, C. L., Lev-Lehman, E., Tsai, S. Y., Tsai, M. J., 
 124
and O'Malley, B. W. (1999) Mol Cell Biol 19(2), 1182-1189 
225. Davie, J. K., and Dent, S. Y. (2004) Curr Top Dev Biol 59, 145-163 
226. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., 
Ryan, A., Kamei, Y., Soderstrom, M., Glass, C. K., and et al. (1995) Nature 
377(6548), 397-404 
227. Zamir, I., Harding, H. P., Atkins, G. B., Horlein, A., Glass, C. K., Rosenfeld, M. 
G., and Lazar, M. A. (1996) Mol Cell Biol 16(10), 5458-5465 
228. Chen, J. D., Umesono, K., and Evans, R. M. (1996) Proc Natl Acad Sci U S A 
93(15), 7567-7571 
229. Zhou, Y., Gross, W., Hong, S. H., and Privalsky, M. L. (2001) Mol Cell 
Biochem 220(1-2), 1-13 
230. Hong, S. H., and Privalsky, M. L. (2000) Mol Cell Biol 20(17), 6612-6625 
231. Gaikwad, A., Long, D. J., 2nd, Stringer, J. L., and Jaiswal, A. K. (2001) J Biol 
Chem 276(25), 22559-22564 
232. Chinnadurai, G. (2002) Mol Cell 9(2), 213-224 
233. Zhang, Q., Piston, D. W., and Goodman, R. H. (2002) Science 295(5561), 
1895-1897 
234. Landry, J., Sutton, A., Tafrov, S. T., Heller, R. C., Stebbins, J., Pillus, L., and 
Sternglanz, R. (2000) Proc Natl Acad Sci U S A 97(11), 5807-5811 
235. Sandmeier, J. J., Celic, I., Boeke, J. D., and Smith, J. S. (2002) Genetics 160(3), 
877-889 
236. Evans, R. M. (1988) Science 240(4854), 889-895 
237. Miesfeld, R., Godowski, P. J., Maler, B. A., and Yamamoto, K. R. (1987) 
Science 236(4800), 423-427 
238. Bocquel, M. T., Kumar, V., Stricker, C., Chambon, P., and Gronemeyer, H. 
(1989) Nucleic Acids Res 17(7), 2581-2595 
239. McDonnell, D. P., and Norris, J. D. (2002) Science 296(5573), 1642-1644 
240. Glass, C. K., and Rosenfeld, M. G. (2000) Genes Dev 14(2), 121-141 
241. Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., and 
Tung, L. (1996) Mol Endocrinol 10(10), 1167-1177 
242. Reid, J., Kelly, S. M., Watt, K., Price, N. C., and McEwan, I. J. (2002) J Biol 
Chem 277(22), 20079-20086 
 125
243. Warnmark, A., Wikstrom, A., Wright, A. P., Gustafsson, J. A., and Hard, T. 
(2001) J Biol Chem 276(49), 45939-45944 
244. Hope, I. A., Mahadevan, S., and Struhl, K. (1988) Nature 333(6174), 635-640 
245. Van Hoy, M., Leuther, K. K., Kodadek, T., and Johnston, S. A. (1993) Cell 
72(4), 587-594 
246. Germain, P., Altucci, L., Bourguet, W., Rochette-Egly, C., and Gronemeyer, H. 
(2003) Pure Appl. Chem., 75, 1619–1664 
247. Weigel, N. L. (1996) Biochem J 319 (Pt 3), 657-667 
248. Hall, J. M., McDonnell, D. P., and Korach, K. S. (2002) Mol Endocrinol 16(3), 
469-486 
249. Mader, S., Chambon, P., and White, J. H. (1993) Nucleic Acids Res 21(5), 
1125-1132 
250. Luisi, B. F., Xu, W. X., Otwinowski, Z., Freedman, L. P., Yamamoto, K. R., and 
Sigler, P. B. (1991) Nature 352(6335), 497-505 
251. Lee, M. S., Kliewer, S. A., Provencal, J., Wright, P. E., and Evans, R. M. (1993) 
Science 260(5111), 1117-1121 
252. O'Malley, B. W., Tsai, S. Y., Bagchi, M., Weigel, N. L., Schrader, W. T., and 
Tsai, M. J. (1991) Recent Prog Horm Res 47, 1-24; discussion 24-26 
253. Schwabe, J. W., Neuhaus, D., and Rhodes, D. (1990) Nature 348(6300), 
458-461 
254. Hard, T., Kellenbach, E., Boelens, R., Maler, B. A., Dahlman, K., Freedman, L. 
P., Carlstedt-Duke, J., Yamamoto, K. R., Gustafsson, J. A., and Kaptein, R. 
(1990) Science 249(4965), 157-160 
255. van Tilborg, P. J., Czisch, M., Mulder, F. A., Folkers, G. E., Bonvin, A. M., Nair, 
M., Boelens, R., and Kaptein, R. (2000) Biochemistry 39(30), 8747-8757 
256. Klein-Hitpass, L., Tsai, S. Y., Weigel, N. L., Allan, G. F., Riley, D., Rodriguez, 
R., Schrader, W. T., Tsai, M. J., and O'Malley, B. W. (1990) Cell 60(2), 247-257 
257. Freedman, L. P., Yoshinaga, S. K., Vanderbilt, J. N., and Yamamoto, K. R. 
(1989) Science 245(4915), 298-301 
258. Baniahmad, C., Muller, M., Altschmied, J., and Renkawitz, R. (1991) J Mol Biol 
222(2), 155-165 
259. Picard, D., and Yamamoto, K. R. (1987) Embo J 6(11), 3333-3340 
260. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., and Moras, D. (1995) 
 126
Nature 375(6530), 377-382 
261. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, 
O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M. (1997) 
Nature 389(6652), 753-758 
262. Green, S., and Chambon, P. (1988) Trends Genet 4(11), 309-314 
263. Nagpal, S., Friant, S., Nakshatri, H., and Chambon, P. (1993) Embo J 12(6), 
2349-2360 
264. Danielian, P. S., White, R., Lees, J. A., and Parker, M. G. (1992) Embo J 11(3), 
1025-1033 
265. McInerney, E. M., Tsai, M. J., O'Malley, B. W., and Katzenellenbogen, B. S. 
(1996) Proc Natl Acad Sci U S A 93(19), 10069-10073 
266. Matkovits, T., and Christakos, S. (1995) Mol Endocrinol 9(2), 232-242 
267. Lin, K. H., Parkison, C., McPhie, P., and Cheng, S. Y. (1991) Mol Endocrinol 
5(4), 485-492 
268. Tsai, M.-J., and O'Malley, B. W. (1994) Mechanism of steroid hormone 
regulation of gene transcription, R. G. Landes Company, Austin 
269. Kumar, V., and Chambon, P. (1988) Cell 55(1), 145-156 
270. Landschulz, W. H., Johnson, P. F., and McKnight, S. L. (1988) Science 
240(4860), 1759-1764 
271. Dilworth, F. J., Fromental-Ramain, C., Yamamoto, K., and Chambon, P. (2000) 
Mol Cell 6(5), 1049-1058 
272. Bhattacharyya, N., Dey, A., Minucci, S., Zimmer, A., John, S., Hager, G., and 
Ozato, K. (1997) Mol Cell Biol 17(11), 6481-6490 
273. Driscoll, M. D., Klinge, C. M., Hilf, R., and Bambara, R. A. (1996) J Steroid 
Biochem Mol Biol 58(1), 45-61 
274. Beato, M. (1989) Cell 56(3), 335-344 
275. Rastinejad, F., Perlmann, T., Evans, R. M., and Sigler, P. B. (1995) Nature 
375(6528), 203-211 
276. Gronemeyer, H., and Moras, D. (1995) Nature 375(6528), 190-191 
277. Chen, H., Lin, R. J., Schiltz, R. L., Chakravarti, D., Nash, A., Nagy, L., 
Privalsky, M. L., Nakatani, Y., and Evans, R. M. (1997) Cell 90(3), 569-580 
278. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, 
 127
X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. (1997) 
Science 277(5328), 965-968 
279. Kraus, W. L., and Kadonaga, J. T. (1998) Genes Dev 12(3), 331-342 
280. Nakajima, T., Uchida, C., Anderson, S. F., Lee, C. G., Hurwitz, J., Parvin, J. D., 
and Montminy, M. (1997) Cell 90(6), 1107-1112 
281. Kraus, W. L., Manning, E. T., and Kadonaga, J. T. (1999) Mol Cell Biol 19(12), 
8123-8135 
282. Li, J., O'Malley, B. W., and Wong, J. (2000) Mol Cell Biol 20(6), 2031-2042 
283. Chen, D., Huang, S. M., and Stallcup, M. R. (2000) J Biol Chem 275(52), 
40810-40816 
284. Perissi, V., and Rosenfeld, M. G. (2005) Nat Rev Mol Cell Biol 6(7), 542-554 
285. Perissi, V., Aggarwal, A., Glass, C. K., Rose, D. W., and Rosenfeld, M. G. 
(2004) Cell 116(4), 511-526 
286. Metivier, R., Penot, G., Hubner, M. R., Reid, G., Brand, H., Kos, M., and 
Gannon, F. (2003) Cell 115(6), 751-763 
287. Reid, G., Hubner, M. R., Metivier, R., Brand, H., Denger, S., Manu, D., 
Beaudouin, J., Ellenberg, J., and Gannon, F. (2003) Mol Cell 11(3), 695-707 
288. Grenier, J., Trousson, A., Chauchereau, A., Amazit, L., Lamirand, A., Leclerc, 
P., Guiochon-Mantel, A., Schumacher, M., and Massaad, C. (2004) Mol 
Endocrinol 18(12), 2866-2879 
289. Li, X., Wong, J., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (2003) Mol Cell 
Biol 23(11), 3763-3773 
290. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, 
K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) 
Cell 83(6), 835-839 
291. Hall, J. M., Couse, J. F., and Korach, K. S. (2001) J Biol Chem 276(40), 
36869-36872 
292. Couse, J. F., Lindzey, J., Grandien, K., Gustafsson, J. A., and Korach, K. S. 
(1997) Endocrinology 138(11), 4613-4621 
293. Pearce, S. T., and Jordan, V. C. (2004) Crit Rev Oncol Hematol 50(1), 3-22 
294. Jensen, E. V., Block, G. E., Smith, S., Kyser, K., and DeSombre, E. R. (1971) 
Natl Cancer Inst Monogr 34, 55-70 
295. Revelli, A., Massobrio, M., and Tesarik, J. (1998) Endocr Rev 19(1), 3-17 
 128
296. Jordan, V. C. (1995) J Cell Biochem Suppl 22, 51-57 
297. DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., 
Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F., Saunders, C., 
and et al. (1994) Cancer Res 54(2), 408-414 
298. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., 
Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., 
Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) J Natl Cancer Inst 
90(18), 1371-1388 
299. Palmieri, C., Cheng, G. J., Saji, S., Zelada-Hedman, M., Warri, A., Weihua, Z., 
Van Noorden, S., Wahlstrom, T., Coombes, R. C., Warner, M., and Gustafsson, 
J. A. (2002) Endocr Relat Cancer 9(1), 1-13 
300. Pettersson, K., Grandien, K., Kuiper, G. G., and Gustafsson, J. A. (1997) Mol 
Endocrinol 11(10), 1486-1496 
301. Ogawa, S., Inoue, S., Watanabe, T., Hiroi, H., Orimo, A., Hosoi, T., Ouchi, Y., 
and Muramatsu, M. (1998) Biochem Biophys Res Commun 243(1), 122-126 
302. Mann, S., Laucirica, R., Carlson, N., Younes, P. S., Ali, N., Younes, A., Li, Y., 
and Younes, M. (2001) Hum Pathol 32(1), 113-118 
303. Jarvinen, T. A., Pelto-Huikko, M., Holli, K., and Isola, J. (2000) Am J Pathol 
156(1), 29-35 
304. Omoto, Y., Inoue, S., Ogawa, S., Toyama, T., Yamashita, H., Muramatsu, M., 
Kobayashi, S., and Iwase, H. (2001) Cancer Lett 163(2), 207-212 
305. Roger, P., Sahla, M. E., Makela, S., Gustafsson, J. A., Baldet, P., and Rochefort, 
H. (2001) Cancer Res 61(6), 2537-2541 
306. Speirs, V., Parkes, A. T., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., 
and Atkin, S. L. (1999) Cancer Res 59(3), 525-528 
307. Speirs, V., Malone, C., Walton, D. S., Kerin, M. J., and Atkin, S. L. (1999) 
Cancer Res 59(21), 5421-5424 
308. Leygue, E., Dotzlaw, H., Watson, P. H., and Murphy, L. C. (1998) Cancer Res 
58(15), 3197-3201 
309. McEwen, B. S. (1999) J Clin Endocrinol Metab 84(6), 1790-1797 
310. Rosenfeld, M. G., and Glass, C. K. (2001) J Biol Chem 276(40), 36865-36868 
311. O'Lone, R., Frith, M. C., Karlsson, E. K., and Hansen, U. (2004) Mol 
Endocrinol 18(8), 1859-1875 
 129
312. Gottlicher, M., Heck, S., and Herrlich, P. (1998) J Mol Med 76(7), 480-489 
313. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., Uht, R. 
M., and Webb, P. (2000) J Steroid Biochem Mol Biol 74(5), 311-317 
314. Tora, L., Gaub, M. P., Mader, S., Dierich, A., Bellard, M., and Chambon, P. 
(1988) Embo J 7(12), 3771-3778 
315. Shaulian, E., and Karin, M. (2002) Nat Cell Biol 4(5), E131-136 
316. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. (1995) Mol Endocrinol 
9(4), 443-456 
317. Philips, A., Chalbos, D., and Rochefort, H. (1993) J Biol Chem 268(19), 
14103-14108 
318. Webb, P., Nguyen, P., Valentine, C., Lopez, G. N., Kwok, G. R., McInerney, E., 
Katzenellenbogen, B. S., Enmark, E., Gustafsson, J. A., Nilsson, S., and 
Kushner, P. J. (1999) Mol Endocrinol 13(10), 1672-1685 
319. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., 
and Scanlan, T. S. (1997) Science 277(5331), 1508-1510 
320. Umayahara, Y., Kawamori, R., Watada, H., Imano, E., Iwama, N., Morishima, 
T., Yamasaki, Y., Kajimoto, Y., and Kamada, T. (1994) J Biol Chem 269(23), 
16433-16442 
321. Sabbah, M., Courilleau, D., Mester, J., and Redeuilh, G. (1999) Proc Natl Acad 
Sci U S A 96(20), 11217-11222 
322. Stein, B., and Yang, M. X. (1995) Mol Cell Biol 15(9), 4971-4979 
323. Faulds, M. H., Pettersson, K., Gustafsson, J. A., and Haldosen, L. A. (2001) Mol 
Endocrinol 15(11), 1929-1940 
324. Dubik, D., and Shiu, R. P. (1992) Oncogene 7(8), 1587-1594 
325. Krishnan, V., Wang, X., and Safe, S. (1994) J Biol Chem 269(22), 15912-15917 
326. Porter, W., Wang, F., Wang, W., Duan, R., and Safe, S. (1996) Mol Endocrinol 
10(11), 1371-1378 
327. Sun, G., Porter, W., and Safe, S. (1998) Mol Endocrinol 12(6), 882-890 
328. Duan, R., Porter, W., and Safe, S. (1998) Endocrinology 139(4), 1981-1990 
329. Qin, C., Singh, P., and Safe, S. (1999) Endocrinology 140(6), 2501-2508 
330. Dong, L., Wang, W., Wang, F., Stoner, M., Reed, J. C., Harigai, M., Samudio, I., 
Kladde, M. P., Vyhlidal, C., and Safe, S. (1999) J Biol Chem 274(45), 
 130
32099-32107 
331. Xie, W., Duan, R., and Safe, S. (1999) Endocrinology 140(1), 219-227 
332. Xie, W., Duan, R., Chen, I., Samudio, I., and Safe, S. (2000) Endocrinology 
141(7), 2439-2449 
333. Castro-Rivera, E., Samudio, I., and Safe, S. (2001) J Biol Chem 276(33), 
30853-30861 
334. Khan, S., Abdelrahim, M., Samudio, I., and Safe, S. (2003) Endocrinology 
144(6), 2325-2335 
335. Ngwenya, S., and Safe, S. (2003) Endocrinology 144(5), 1675-1685 
336. Salvatori, L., Pallante, P., Ravenna, L., Chinzari, P., Frati, L., Russo, M. A., and 
Petrangeli, E. (2003) Oncogene 22(31), 4875-4881 
337. Porter, W., Saville, B., Hoivik, D., and Safe, S. (1997) Mol Endocrinol 11(11), 
1569-1580 
338. Kim, K., Thu, N., Saville, B., and Safe, S. (2003) Mol Endocrinol 17(5), 
804-817 
339. Stoner, M., Wormke, M., Saville, B., Samudio, I., Qin, C., Abdelrahim, M., and 
Safe, S. (2004) Oncogene 23(5), 1052-1063 
340. Stoner, M., Wang, F., Wormke, M., Nguyen, T., Samudio, I., Vyhlidal, C., 
Marme, D., Finkenzeller, G., and Safe, S. (2000) J Biol Chem 275(30), 
22769-22779 
341. Bjornstrom, L., and Sjoberg, M. (2002) J Biol Chem 277(50), 48479-48483 
342. Nakajima, T., Kitazawa, T., Hamada, E., Hazama, H., Omata, M., and Kurachi, 
Y. (1995) Eur J Pharmacol 294(2-3), 625-635 
343. Valverde, M. A., Rojas, P., Amigo, J., Cosmelli, D., Orio, P., Bahamonde, M. I., 
Mann, G. E., Vergara, C., and Latorre, R. (1999) Science 285(5435), 1929-1931 
344. Kelly, M. J., and Wagner, E. J. (1999) Trends Endocrinol Metab 10(9), 369-374 
345. Watters, J. J., Campbell, J. S., Cunningham, M. J., Krebs, E. G., and Dorsa, D. 
M. (1997) Endocrinology 138(9), 4030-4033 
346. Improta-Brears, T., Whorton, A. R., Codazzi, F., York, J. D., Meyer, T., and 
McDonnell, D. P. (1999) Proc Natl Acad Sci U S A 96(8), 4686-4691 
347. Aronica, S. M., Kraus, W. L., and Katzenellenbogen, B. S. (1994) Proc Natl 
Acad Sci U S A 91(18), 8517-8521 
 131
348. Razandi, M., Pedram, A., Greene, G. L., and Levin, E. R. (1999) Mol 
Endocrinol 13(2), 307-319 
349. Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., 
Nola, E., and Auricchio, F. (1996) Embo J 15(6), 1292-1300 
350. Chen, Z., Yuhanna, I. S., Galcheva-Gargova, Z., Karas, R. H., Mendelsohn, M. 
E., and Shaul, P. W. (1999) J Clin Invest 103(3), 401-406 
351. Jessop, H. L., Sjoberg, M., Cheng, M. Z., Zaman, G., Wheeler-Jones, C. P., and 
Lanyon, L. E. (2001) J Bone Miner Res 16(6), 1045-1055 
352. Castoria, G., Migliaccio, A., Bilancio, A., Di Domenico, M., de Falco, A., 
Lombardi, M., Fiorentino, R., Varricchio, L., Barone, M. V., and Auricchio, F. 
(2001) Embo J 20(21), 6050-6059 
353. Marino, M., Acconcia, F., Bresciani, F., Weisz, A., and Trentalance, A. (2002) 
Mol Biol Cell 13(10), 3720-3729 
354. Michalides, R., Griekspoor, A., Balkenende, A., Verwoerd, D., Janssen, L., 
Jalink, K., Floore, A., Velds, A., van't Veer, L., and Neefjes, J. (2004) Cancer 
Cell 5(6), 597-605 
355. Pietras, R. J., and Szego, C. M. (1977) Nature 265(5589), 69-72 
356. Razandi, M., Pedram, A., Merchenthaler, I., Greene, G. L., and Levin, E. R. 
(2004) Mol Endocrinol 18(12), 2854-2865 
357. Song, R. X., Barnes, C. J., Zhang, Z., Bao, Y., Kumar, R., and Santen, R. J. 
(2004) Proc Natl Acad Sci U S A 101(7), 2076-2081 
358. Razandi, M., Alton, G., Pedram, A., Ghonshani, S., Webb, P., and Levin, E. R. 
(2003) Mol Cell Biol 23(5), 1633-1646 
359. Bjornstrom, L., and Sjoberg, M. (2005) Mol Endocrinol 19(4), 833-842 
360. Saceda, M., Lippman, M. E., Chambon, P., Lindsey, R. L., Ponglikitmongkol, 
M., Puente, M., and Martin, M. B. (1988) Mol Endocrinol 2(12), 1157-1162 
361. Eckert, R. L., Mullick, A., Rorke, E. A., and Katzenellenbogen, B. S. (1984) 
Endocrinology 114(2), 629-637 
362. Joel, P. B., Traish, A. M., and Lannigan, D. A. (1995) Mol Endocrinol 9(8), 
1041-1052 
363. Bunone, G., Briand, P. A., Miksicek, R. J., and Picard, D. (1996) Embo J 15(9), 
2174-2183 
364. Arnold, S. F., Obourn, J. D., Jaffe, H., and Notides, A. C. (1994) Mol 
 132
Endocrinol 8(9), 1208-1214 
365. Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., and 
Liao, J. K. (2000) Nature 407(6803), 538-541 
366. Rogatsky, I., Trowbridge, J. M., and Garabedian, M. J. (1999) J Biol Chem 
274(32), 22296-22302 
367. Chen, D., Pace, P. E., Coombes, R. C., and Ali, S. (1999) Mol Cell Biol 19(2), 
1002-1015 
368. Tremblay, A., Tremblay, G. B., Labrie, F., and Giguere, V. (1999) Mol Cell 3(4), 
513-519 
369. Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., 
Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. 
K., Glass, C. K., Rosenfeld, M. G., and Rose, D. W. (1998) Proc Natl Acad Sci 
U S A 95(6), 2920-2925 
370. Ali, S., Metzger, D., Bornert, J. M., and Chambon, P. (1993) Embo J 12(3), 
1153-1160 
371. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., 
Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and 
Chambon, P. (1995) Science 270(5241), 1491-1494 
372. Le Goff, P., Montano, M. M., Schodin, D. J., and Katzenellenbogen, B. S. (1994) 
J Biol Chem 269(6), 4458-4466 
373. Arnold, S. F., Obourn, J. D., Jaffe, H., and Notides, A. C. (1995) Mol 
Endocrinol 9(1), 24-33 
374. El-Tanani, M. K., and Green, C. D. (1997) Mol Endocrinol 11(7), 928-937 
375. Lazennec, G., Thomas, J. A., and Katzenellenbogen, B. S. (2001) J Steroid 
Biochem Mol Biol 77(4-5), 193-203 
376. Horigome, T., Ogata, F., Golding, T. S., and Korach, K. S. (1988) 
Endocrinology 123(5), 2540-2548 
377. El Khissiin, A., and Leclercq, G. (1999) FEBS Lett 448(1), 160-166 
378. Alarid, E. T., Bakopoulos, N., and Solodin, N. (1999) Mol Endocrinol 13(9), 
1522-1534 
379. Wijayaratne, A. L., and McDonnell, D. P. (2001) J Biol Chem 276(38), 
35684-35692 
380. Dauvois, S., Danielian, P. S., White, R., and Parker, M. G. (1992) Proc Natl 
 133
Acad Sci U S A 89(9), 4037-4041 
381. Ciechanover, A., Orian, A., and Schwartz, A. L. (2000) Bioessays 22(5), 
442-451 
382. Molinari, E., Gilman, M., and Natesan, S. (1999) Embo J 18(22), 6439-6447 
383. Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, 
H., Nakatani, Y., and Livingston, D. M. (2003) Science 300(5617), 342-344 
384. Saji, S., Okumura, N., Eguchi, H., Nakashima, S., Suzuki, A., Toi, M., Nozawa, 
Y., Saji, S., and Hayashi, S. (2001) Biochem Biophys Res Commun 281(1), 
259-265 
385. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., 
Yuan, F., Auborn, K. J., Goldberg, I. D., and Rosen, E. M. (1999) Science 
284(5418), 1354-1356 
386. Fraser, R. A., Rossignol, M., Heard, D. J., Egly, J. M., and Chambon, P. (1997) 
J Biol Chem 272(11), 7122-7126 
387. Lonard, D. M., Nawaz, Z., Smith, C. L., and O'Malley, B. W. (2000) Mol Cell 
5(6), 939-948 
388. Deroo, B. J., and Archer, T. K. (2002) J Biol Chem 277(23), 20120-20123 
389. Fan, M., Nakshatri, H., and Nephew, K. P. (2004) Mol Endocrinol 18(11), 
2603-2615 
390. Tateishi, Y., Kawabe, Y., Chiba, T., Murata, S., Ichikawa, K., Murayama, A., 
Tanaka, K., Baba, T., Kato, S., and Yanagisawa, J. (2004) Embo J 23(24), 
4813-4823 
391. Sadhu, K., Reed, S. I., Richardson, H., and Russell, P. (1990) Proc Natl Acad 
Sci U S A 87(13), 5139-5143 
392. Galaktionov, K., and Beach, D. (1991) Cell 67(6), 1181-1194 
393. Draetta, G., and Eckstein, J. (1997) Biochim Biophys Acta 1332(2), M53-63 
394. Nagata, A., Igarashi, M., Jinno, S., Suto, K., and Okayama, H. (1991) New Biol 
3(10), 959-968 
395. Hoffmann, I., Draetta, G., and Karsenti, E. (1994) Embo J 13(18), 4302-4310 
396. Galaktionov, K., Jessus, C., and Beach, D. (1995) Genes Dev 9(9), 1046-1058 
397. Gabrielli, B. G., Clark, J. M., McCormack, A. K., and Ellem, K. A. (1997) J 
Biol Chem 272(45), 28607-28614 
 134
398. Garner-Hamrick, P. A., and Fisher, C. (1998) Int J Cancer 76(5), 720-728 
399. Lammer, C., Wagerer, S., Saffrich, R., Mertens, D., Ansorge, W., and Hoffmann, 
I. (1998) J Cell Sci 111 (Pt 16), 2445-2453 
400. Blomberg, I., and Hoffmann, I. (1999) Mol Cell Biol 19(9), 6183-6194 
401. Gu, Y., Rosenblatt, J., and Morgan, D. O. (1992) Embo J 11(11), 3995-4005 
402. Kudo, Y., Yasui, W., Ue, T., Yamamoto, S., Yokozaki, H., Nikai, H., and 
Tahara, E. (1997) Jpn J Cancer Res 88(10), 947-952 
403. Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., and 
Beach, D. (1995) Science 269(5230), 1575-1577 
404. Gasparotto, D., Maestro, R., Piccinin, S., Vukosavljevic, T., Barzan, L., Sulfaro, 
S., and Boiocchi, M. (1997) Cancer Res 57(12), 2366-2368 
405. Hernandez, S., Hernandez, L., Bea, S., Cazorla, M., Fernandez, P. L., Nadal, A., 
Muntane, J., Mallofre, C., Montserrat, E., Cardesa, A., and Campo, E. (1998) 
Cancer Res 58(8), 1762-1767 
406. Cangi, M. G., Cukor, B., Soung, P., Signoretti, S., Moreira, G., Jr., Ranashinge, 
M., Cady, B., Pagano, M., and Loda, M. (2000) J Clin Invest 106(6), 753-761 
407. Wang, W., Smith, R., 3rd, and Safe, S. (1998) Arch Biochem Biophys 356(2), 
239-248 
408. Foster, J. S., Henley, D. C., Bukovsky, A., Seth, P., and Wimalasena, J. (2001) 
Mol Cell Biol 21(3), 794-810 
409. Liu, B., Gross, M., ten Hoeve, J., and Shuai, K. (2001) Proc Natl Acad Sci U S A 
98(6), 3203-3207 
410. Schmidt, D., and Muller, S. (2003) Cell Mol Life Sci 60(12), 2561-2574 
411. Duval, D., Duval, G., Kedinger, C., Poch, O., and Boeuf, H. (2003) FEBS Lett 
554(1-2), 111-118 
412. Jimenez-Lara, A. M., Heine, M. J., and Gronemeyer, H. (2002) FEBS Lett 
526(1-3), 142-146 
413. Sentis, S., Le Romancer, M., Bianchin, C., Rostan, M. C., and Corbo, L. (2005) 
Mol Endocrinol 19(11), 2671-2684 
414. Prigge, J. R., and Schmidt, E. E. (2006) J Biol Chem 281(18), 12260-12269 
415. Sapetschnig, A., Rischitor, G., Braun, H., Doll, A., Schergaut, M., Melchior, F., 
and Suske, G. (2002) Embo J 21(19), 5206-5215 
 135
416. Lee, H., Quinn, J. C., Prasanth, K. V., Swiss, V. A., Economides, K. D., 
Camacho, M. M., Spector, D. L., and Abate-Shen, C. (2006) Genes Dev 20(7), 
784-794 
417. Wu, C. L., Classon, M., Dyson, N., and Harlow, E. (1996) Mol Cell Biol 16(7), 
3698-3706 
418. Cress, W. D., Johnson, D. G., and Nevins, J. R. (1993) Mol Cell Biol 13(10), 
6314-6325 
419. Petersohn, D., and Thiel, G. (1996) Eur J Biochem 239(3), 827-834 
420. Mantovani, R., Li, X. Y., Pessara, U., Hooft van Huisjduijnen, R., Benoist, C., 
and Mathis, D. (1994) J Biol Chem 269(32), 20340-20346 
421. Saville, B., Poukka, H., Wormke, M., Janne, O. A., Palvimo, J. J., Stoner, M., 
Samudio, I., and Safe, S. (2002) J Biol Chem 277(4), 2485-2497 
422. Iavarone, A., and Massague, J. (1999) Mol Cell Biol 19(1), 916-922 
423. Safe, S. (2001) Vitam Horm 62, 231-252 
424. Safe, S., and Kim, K. (2004) Prog Nucleic Acid Res Mol Biol 77, 1-36 
425. Wang, W., Dong, L., Saville, B., and Safe, S. (1999) Mol Endocrinol 13(8), 
1373-1387 
426. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. (1993) Nature 
365(6444), 349-352 
427. Hong, J., Samudio, I., Liu, S., Abdelrahim, M., and Safe, S. (2004) 
Endocrinology 145(12), 5774-5785 
428. Kotaja, N., Aittomaki, S., Silvennoinen, O., Palvimo, J. J., and Janne, O. A. 
(2000) Mol Endocrinol 14(12), 1986-2000 
429. Long, J., Wang, G., Matsuura, I., He, D., and Liu, F. (2004) Proc Natl Acad Sci 
U S A 101(1), 99-104 
430. Petz, L. N., and Nardulli, A. M. (2000) Mol Endocrinol 14(7), 972-985 
431. Vyhlidal, C., Samudio, I., Kladde, M. P., and Safe, S. (2000) J Mol Endocrinol 
24(3), 329-338 
432. Martini, P. G., and Katzenellenbogen, B. S. (2001) Endocrinology 142(8), 
3493-3501 
433. Abdelrahim, M., Samudio, I., Smith, R., 3rd, Burghardt, R., and Safe, S. (2002) 
J Biol Chem 277(32), 28815-28822 
 136
434. Wu, L., Goodwin, E. C., Naeger, L. K., Vigo, E., Galaktionov, K., Helin, K., 
and DiMaio, D. (2000) Mol Cell Biol 20(19), 7059-7067 
435. Aronica, S. M., and Katzenellenbogen, B. S. (1991) Endocrinology 128(4), 
2045-2052 
436. Aronica, S. M., and Katzenellenbogen, B. S. (1993) Mol Endocrinol 7(6), 
743-752 
437. Zhong, Z. D., Hammani, K., Bae, W. S., and DeClerck, Y. A. (2000) J Biol 
Chem 275(24), 18602-18610 
438. Duan, R., Xie, W., Li, X., McDougal, A., and Safe, S. (2002) Biochem Biophys 
Res Commun 294(2), 384-394 
439. Duan, R., Xie, W., Burghardt, R. C., and Safe, S. (2001) J Biol Chem 276(15), 
11590-11598 
440. Olefsky, J. M. (2001) J Biol Chem 276(40), 36863-36864 
441. Acevedo, M. L., and Kraus, W. L. (2003) Mol Cell Biol 23(1), 335-348 
442. Acevedo, M. L., Lee, K. C., Stender, J. D., Katzenellenbogen, B. S., and Kraus, 
W. L. (2004) Mol Cell 13(5), 725-738 
443. Blazek, E., Mittler, G., and Meisterernst, M. (2005) Chromosoma 113(8), 
399-408 
444. Wu, Q., Burghardt, R., and Safe, S. (2004) J Biol Chem 279(51), 53602-53612 
445. Lee, J. E., Kim, K., Sacchettini, J. C., Smith, C. V., and Safe, S. (2005) J Biol 
Chem 280(10), 8819-8830 
446. Kahyo, T., Nishida, T., and Yasuda, H. (2001) Mol Cell 8(3), 713-718 
447. Hochstrasser, M. (2001) Cell 107(1), 5-8 
448. Takahashi, Y., Kahyo, T., Toh, E. A., Yasuda, H., and Kikuchi, Y. (2001) J Biol 
Chem 276(52), 48973-48977 
449. Kong, E. H., Heldring, N., Gustafsson, J. A., Treuter, E., Hubbard, R. E., and 
Pike, A. C. (2005) Proc Natl Acad Sci U S A 102(10), 3593-3598 
450. Poukka, H., Karvonen, U., Janne, O. A., and Palvimo, J. J. (2000) Proc Natl 
Acad Sci U S A 97(26), 14145-14150 
451. Le Drean, Y., Mincheneau, N., Le Goff, P., and Michel, D. (2002) 
Endocrinology 143(9), 3482-3489 
452. Stossi, F., Likhite, V. S., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. 
 137
(2006) J Biol Chem 281(24), 16272-16278 
453. Margueron, R., Licznar, A., Lazennec, G., Vignon, F., and Cavailles, V. (2003) 
J Endocrinol 179(1), 41-53 
454. Samudio, I., Vyhlidal, C., Wang, F., Stoner, M., Chen, I., Kladde, M., Barhoumi, 
R., Burghardt, R., and Safe, S. (2001) Endocrinology 142(3), 1000-1008 
455. Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., 
Gustafsson, J. A., and Safe, S. (2000) J Biol Chem 275(8), 5379-5387 
456. Kim, K., Barhoumi, R., Burghardt, R., and Safe, S. (2005) Mol Endocrinol 19(4), 
843-854 
 
 
 138
VITA 
 
 
Name:   Wan-Ru Lee 
Address:    Department of Veterinary Physiology and Pharmacology 
   4466 TAMU, College Station, TX 77843 
Email Address: graybarlee@hotmail.com 
Education:   Texas A&M University      December 2006 
Ph.D., Toxicology 
National Taiwan University      May 1996  
M.S., Agricultural Chemistry 
National Taiwan University      May 1994 
B.S., Agricultural Chemistry 
 
 
 
 
